From 7e09323ab5b029c78690f64b65e7096b3ebe6c16 Mon Sep 17 00:00:00 2001 From: maish Date: Sun, 14 Jun 2026 19:29:19 +0800 Subject: [PATCH 1/2] fix(core): thread label-only rows as row-group headers 0.6.0's row-group threading only promoted the full-width band form (a body cell spanning the value region / scope="rowgroup"). The label-only-row form -- a body row whose value columns are empty while a single leading label cell carries text ("9. Trip Cancellation | (empty) | (empty)"), pervasive in Label|Value financial/insurance schedules -- was missed: is_full_width_note geometry never sees a colspan=1 label, so the row was emitted as an orphaned is_label rule and every value beneath it lost its group identity. Such a row is now promoted to scope="rowgroup" and threaded as a bounded ancestor of the value lines under it, symmetric with the full-width band: 10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Value Plan: 100 How: - New _mark_label_only_rowgroups detects body rows with no value-bearing but exactly one non-empty label source cell, groups maximal runs of consecutive label-only rows into nested header stacks, and computes each stack's extent (down to the next stack or full-width band). Promoted only when the extent holds a real value row -- a trailing label that groups nothing is left for the is_label path, never stranded as an empty group. - The single-label-cell requirement separates a group header from a data row whose designated value columns merely happen to be empty (a "Total | n=4" summary, or a row under a header that over-promoted numeric columns to row labels): threading its cells would invent a breadcrumb and misattribute it onto the rows below. Such rows keep the is_label preservation path. - maze_pathfinder honors a stored rowgroup_extent_end for these bands, since a colspan=1 label cannot encode nesting depth the way a band's width does. Full-width bands keep their colspan-bounded extent; the two compose. - _build_rules skips rowgroup-promoted rows in label preservation so a threaded header is not also emitted as an orphan label. 106 golds updated (orphan section labels collapsed into descendants' row paths; no value dropped -- verified value multiset preserved + correctness oracle). New fixtures matrix/label-only-rowgroup and label-only-rowgroup-vs-data-row. Co-Authored-By: Claude Opus 4.8 (1M context) --- CHANGELOG.md | 30 ++ .../financial-nbsp-indented-rows.out.txt | 30 +- .../label-only-rowgroup-vs-data-row.out.txt | 5 + .../matrix/label-only-rowgroup.out.txt | 7 + .../despanned-section-headers.out.txt | 14 +- .../fintabnet/fintabnet-s0-r100.out.txt | 2 - .../fintabnet/fintabnet-s0-r1117.out.txt | 1 - .../fintabnet/fintabnet-s0-r1119.out.txt | 2 - .../fintabnet/fintabnet-s0-r1135.out.txt | 1 - .../fintabnet/fintabnet-s0-r1151.out.txt | 1 - .../fintabnet/fintabnet-s0-r1152.out.txt | 1 - .../fintabnet/fintabnet-s0-r1157.out.txt | 2 - .../fintabnet/fintabnet-s0-r1159.out.txt | 1 - .../fintabnet/fintabnet-s0-r1161.out.txt | 2 - .../fintabnet/fintabnet-s0-r1165.out.txt | 1 - .../fintabnet/fintabnet-s0-r1172.out.txt | 1 - .../fintabnet/fintabnet-s0-r1175.out.txt | 2 - .../fintabnet/fintabnet-s0-r1177.out.txt | 1 - .../fintabnet/fintabnet-s0-r1182.out.txt | 1 - .../fintabnet/fintabnet-s0-r119.out.txt | 2 - .../fintabnet/fintabnet-s0-r1282.out.txt | 2 - .../fintabnet/fintabnet-s0-r1295.out.txt | 2 - .../fintabnet/fintabnet-s0-r1338.out.txt | 1 - .../fintabnet/fintabnet-s0-r138.out.txt | 2 - .../fintabnet/fintabnet-s0-r1380.out.txt | 1 - .../fintabnet/fintabnet-s0-r1504.out.txt | 1 - .../fintabnet/fintabnet-s0-r1507.out.txt | 1 - .../fintabnet/fintabnet-s0-r1593.out.txt | 3 - .../fintabnet/fintabnet-s0-r1676.out.txt | 2 - .../fintabnet/fintabnet-s0-r186.out.txt | 2 - .../fintabnet/fintabnet-s0-r1902.out.txt | 2 - .../fintabnet/fintabnet-s0-r1923.out.txt | 1 - .../fintabnet/fintabnet-s0-r1924.out.txt | 1 - .../fintabnet/fintabnet-s0-r1927.out.txt | 2 - .../fintabnet/fintabnet-s0-r1943.out.txt | 1 - .../fintabnet/fintabnet-s0-r1953.out.txt | 1 - .../fintabnet/fintabnet-s0-r200.out.txt | 2 - .../fintabnet/fintabnet-s0-r2005.out.txt | 2 - .../fintabnet/fintabnet-s0-r2028.out.txt | 2 - .../fintabnet/fintabnet-s0-r2203.out.txt | 2 - .../fintabnet/fintabnet-s0-r224.out.txt | 2 - .../fintabnet/fintabnet-s0-r2278.out.txt | 2 - .../fintabnet/fintabnet-s0-r234.out.txt | 5 +- .../fintabnet/fintabnet-s0-r235.out.txt | 1 - .../fintabnet/fintabnet-s0-r244.out.txt | 3 - .../fintabnet/fintabnet-s0-r249.out.txt | 3 - .../fintabnet/fintabnet-s0-r2528.out.txt | 2 - .../fintabnet/fintabnet-s0-r2548.out.txt | 2 - .../fintabnet/fintabnet-s0-r2567.out.txt | 2 - .../fintabnet/fintabnet-s0-r2574.out.txt | 2 - .../fintabnet/fintabnet-s0-r2640.out.txt | 2 - .../fintabnet/fintabnet-s0-r2689.out.txt | 2 - .../fintabnet/fintabnet-s0-r2704.out.txt | 2 - .../fintabnet/fintabnet-s0-r2798.out.txt | 2 - .../fintabnet/fintabnet-s0-r28.out.txt | 1 - .../fintabnet/fintabnet-s0-r3004.out.txt | 1 - .../fintabnet/fintabnet-s0-r3009.out.txt | 1 - .../fintabnet/fintabnet-s0-r3021.out.txt | 1 - .../fintabnet/fintabnet-s0-r3054.out.txt | 3 - .../fintabnet/fintabnet-s0-r3205.out.txt | 1 - .../fintabnet/fintabnet-s0-r3214.out.txt | 1 - .../fintabnet/fintabnet-s0-r3218.out.txt | 1 - .../fintabnet/fintabnet-s0-r3277.out.txt | 2 - .../fintabnet/fintabnet-s0-r3283.out.txt | 1 - .../fintabnet/fintabnet-s0-r3284.out.txt | 1 - .../fintabnet/fintabnet-s0-r3295.out.txt | 2 - .../fintabnet/fintabnet-s0-r3307.out.txt | 1 - .../fintabnet/fintabnet-s0-r3312.out.txt | 3 - .../fintabnet/fintabnet-s0-r3317.out.txt | 2 - .../fintabnet/fintabnet-s0-r3332.out.txt | 3 - .../fintabnet/fintabnet-s0-r39.out.txt | 1 - .../fintabnet/fintabnet-s0-r392.out.txt | 2 - .../fintabnet/fintabnet-s0-r529.out.txt | 4 - .../fintabnet/fintabnet-s0-r532.out.txt | 2 - .../fintabnet/fintabnet-s0-r547.out.txt | 4 - .../fintabnet/fintabnet-s0-r559.out.txt | 4 - .../fintabnet/fintabnet-s0-r597.out.txt | 2 - .../fintabnet/fintabnet-s0-r639.out.txt | 1 - .../fintabnet/fintabnet-s0-r692.out.txt | 1 - .../fintabnet/fintabnet-s0-r718.out.txt | 3 - .../fintabnet/fintabnet-s0-r80.out.txt | 2 - .../fintabnet/fintabnet-s0-r869.out.txt | 2 - .../fintabnet/fintabnet-s1-r14.out.txt | 2 - .../pubtabnet/pubtabnet-116950.out.txt | 82 +++--- .../pubtabnet/pubtabnet-133649.out.txt | 89 +++--- .../pubtabnet/pubtabnet-153359.out.txt | 82 +++--- .../pubtabnet/pubtabnet-178810.out.txt | 60 ++-- .../pubtabnet/pubtabnet-180372.out.txt | 5 - .../pubtabnet/pubtabnet-188439.out.txt | 99 ++++--- .../pubtabnet/pubtabnet-191534.out.txt | 41 ++- .../pubtabnet/pubtabnet-203260.out.txt | 49 ++-- .../pubtabnet/pubtabnet-234815.out.txt | 33 ++- .../pubtabnet/pubtabnet-262537.out.txt | 102 ++++--- .../pubtabnet/pubtabnet-279671.out.txt | 259 +++++++++--------- .../pubtabnet/pubtabnet-284789.out.txt | 96 ++++--- .../pubtabnet/pubtabnet-357665.out.txt | 42 ++- .../pubtabnet/pubtabnet-374857.out.txt | 2 - .../pubtabnet/pubtabnet-376448.out.txt | 25 +- .../pubtabnet/pubtabnet-376872.out.txt | 103 ++++--- .../pubtabnet/pubtabnet-407741.out.txt | 144 +++++----- .../pubtabnet/pubtabnet-429350.out.txt | 129 +++++---- .../pubtabnet/pubtabnet-455801.out.txt | 144 +++++----- .../pubtabnet/pubtabnet-464722.out.txt | 100 ++++--- .../pubtabnet/pubtabnet-470864.out.txt | 66 +++-- .../pubtabnet/pubtabnet-509257.out.txt | 164 ++++++----- .../pubtabnet/pubtabnet-65384.out.txt | 80 +++--- .../pubtabnet/pubtabnet-81395.out.txt | 15 +- .../pubtabnet/pubtabnet-83651.out.txt | 9 +- .../pubtabnet/pubtabnet-87275.out.txt | 84 +++--- src/table2rules/_core.py | 148 ++++++++++ src/table2rules/maze_pathfinder.py | 9 +- .../matrix/label-only-rowgroup-vs-data-row.md | 20 ++ tests/fixtures/matrix/label-only-rowgroup.md | 27 ++ 113 files changed, 1285 insertions(+), 1250 deletions(-) create mode 100644 benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt create mode 100644 benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt create mode 100644 tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md create mode 100644 tests/fixtures/matrix/label-only-rowgroup.md diff --git a/CHANGELOG.md b/CHANGELOG.md index dacf19e..5cae9ed 100644 --- a/CHANGELOG.md +++ b/CHANGELOG.md @@ -5,6 +5,36 @@ All notable changes to `table2rules` are documented here. Dates are in ## [Unreleased] +### Fixed + +- **Label-only rows are now threaded as row-group headers.** 0.6.0's row-group + threading only handled the *full-width band* form (a cell spanning the value + region / `scope="rowgroup"`). The **label-only-row** form — a body row whose + value columns are empty while a single leading label cell carries text + (`9. Trip Cancellation | (empty) | (empty)`), pervasive in `Label | Value` + financial/insurance schedules — was missed: it was emitted as an orphaned + `is_label` rule and the values beneath it lost their group identity. Such a + row is now promoted to a row-group ancestor and threaded into every value line + under it, until the next label-only row at the same level: + + ``` + 10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Value Plan: 100 + ``` + + Detection stays geometric and additive to the existing band path: + - A row with no value-bearing `` but exactly **one** non-empty label + source cell is a group header. Consecutive label-only rows nest in order + (a title followed by a description), and the two forms compose — a + full-width section band and a label-only group nest consistently. + - The **single-label-cell** requirement separates a group header from a data + row whose designated value columns merely happen to be empty: a summary row + spreading several values across its label cells (`Total | n=4`, or a row + under a header that over-promoted numeric columns to row labels) keeps the + `is_label` preservation path, so its cells are never invented into a + breadcrumb and misattributed onto the rows below. + - A trailing label-only row with no value rows beneath it stays a label + (parity with the full-width-note guard) — no empty group is created. + ## [0.6.0] — 2026-06-11 ### Added diff --git a/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt b/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt index fa9d61c..a9b1619 100644 --- a/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt +++ b/benchmarks/gold/rules/fixtures/matrix/financial-nbsp-indented-rows.out.txt @@ -1,16 +1,14 @@ -Current assets: -Cash and equivalents | 2024: 4,210 -Cash and equivalents | 2023: 3,850 -Accounts receivable | 2024: 12,400 -Accounts receivable | 2023: 11,200 -Inventory | 2024: 8,900 -Inventory | 2023: 9,100 -Total current assets | 2024: 25,510 -Total current assets | 2023: 24,150 -Non-current assets: -Property, plant & equipment | 2024: 42,100 -Property, plant & equipment | 2023: 38,900 -Goodwill | 2024: 18,200 -Goodwill | 2023: 18,200 -Total non-current assets | 2024: 60,300 -Total non-current assets | 2023: 57,100 \ No newline at end of file +Current assets: > Cash and equivalents | 2024: 4,210 +Current assets: > Cash and equivalents | 2023: 3,850 +Current assets: > Accounts receivable | 2024: 12,400 +Current assets: > Accounts receivable | 2023: 11,200 +Current assets: > Inventory | 2024: 8,900 +Current assets: > Inventory | 2023: 9,100 +Current assets: > Total current assets | 2024: 25,510 +Current assets: > Total current assets | 2023: 24,150 +Non-current assets: > Property, plant & equipment | 2024: 42,100 +Non-current assets: > Property, plant & equipment | 2023: 38,900 +Non-current assets: > Goodwill | 2024: 18,200 +Non-current assets: > Goodwill | 2023: 18,200 +Non-current assets: > Total non-current assets | 2024: 60,300 +Non-current assets: > Total non-current assets | 2023: 57,100 \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt new file mode 100644 index 0000000..4bb1d66 --- /dev/null +++ b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup-vs-data-row.out.txt @@ -0,0 +1,5 @@ +Region X > Asia > Japan | A: 10 +Region X > Asia > Japan | B: 20 +Region X > Asia > Korea | A: 30 +Region X > Asia > Korea | B: 40 +Total > n=4 \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt new file mode 100644 index 0000000..f5678b4 --- /dev/null +++ b/benchmarks/gold/rules/fixtures/matrix/label-only-rowgroup.out.txt @@ -0,0 +1,7 @@ +9. Trip Cancellation > If the trip is cancelled | Maximum limit (S$) > Value Plan: 5,000 +9. Trip Cancellation > If the trip is cancelled | Maximum limit (S$) > Economy Plan: 10,000 +10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Value Plan: 100 +10. Travel Delay > If the departure is delayed > 1. Adult insured person | Maximum limit (S$) > Economy Plan: 150 +10. Travel Delay > If the departure is delayed > 2. Child insured person | Maximum limit (S$) > Value Plan: 50 +10. Travel Delay > If the departure is delayed > 2. Child insured person | Maximum limit (S$) > Economy Plan: 75 +11. Trip Postponement \ No newline at end of file diff --git a/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt b/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt index 40f4539..0537eea 100644 --- a/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt +++ b/benchmarks/gold/rules/fixtures/relational/despanned-section-headers.out.txt @@ -1,9 +1,7 @@ -1. Accidental death and permanent disability -Each adult insured person under 70 | Sum Insured: S$250,000 -Each child insured person | Sum Insured: S$100,000 -2. Public transport double indemnity -Each adult insured person under 70 | Sum Insured: S$500,000 -Each child insured person | Sum Insured: S$200,000 +1. Accidental death and permanent disability > Each adult insured person under 70 | Sum Insured: S$250,000 +1. Accidental death and permanent disability > Each child insured person | Sum Insured: S$100,000 +2. Public transport double indemnity > Each adult insured person under 70 | Sum Insured: S$500,000 +2. Public transport double indemnity > Each child insured person | Sum Insured: S$200,000 3. COVID-19 coverage extension -Each adult insured person under 70 | Sum Insured: S$50,000 -Each child insured person | Sum Insured: S$20,000 \ No newline at end of file +2. Public transport double indemnity > Each adult insured person under 70 | Sum Insured: S$50,000 +2. Public transport double indemnity > Each child insured person | Sum Insured: S$20,000 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt index 3ac5ef9..60fd956 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r100.out.txt @@ -1,4 +1,3 @@ -2014 2014 > Fourth Quarter | NYSECommon Stock > High: $83.90 2014 > Fourth Quarter | NYSECommon Stock > Low: $52.32 2014 > Fourth Quarter | OSECommon Stock (1) > High: 638.00 @@ -15,7 +14,6 @@ 2014 > First Quarter | NYSECommon Stock > Low: $45.95 2014 > First Quarter | OSECommon Stock (1) > High: 332.60 2014 > First Quarter | OSECommon Stock (1) > Low: 284.20 -2013 2013 > Fourth Quarter | NYSECommon Stock > High: $47.66 2013 > Fourth Quarter | NYSECommon Stock > Low: $35.97 2013 > Fourth Quarter | OSECommon Stock (1) > High: 292.60 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt index 4c1e9ea..7933a38 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1117.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2014 > $: $148,909 Operating expenses: > Research and development | Year Ended December 31, > 2014 > % ofrevenue: 25.5% Operating expenses: > Research and development | Year Ended December 31, > 2013 > $: $98,587 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt index 89b06a7..0402dd9 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1119.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2015 > $: $744,877 Revenue > Product | Year Ended December 31, > 2015 > % ofrevenue: 88.9% Revenue > Product | Year Ended December 31, > 2014 > $: $531,543 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2014 > $: 584,106 Revenue > Total revenue | Year Ended December 31, > 2014 > % ofrevenue: 100.0 Revenue > Total revenue | Change in > $: 253,485 Revenue > Total revenue | Change in > %: 43.4 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2015 > $: 263,585 Cost of revenue > Product | Year Ended December 31, > 2015 > % ofrevenue: 31.5 Cost of revenue > Product | Year Ended December 31, > 2014 > $: 174,004 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt index 1820050..fa8ac6c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1135.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2015 > $: $209,448 Operating expenses: > Research and development | Year Ended December 31, > 2015 > % ofrevenue: 25.0% Operating expenses: > Research and development | Year Ended December 31, > 2014 > $: $148,909 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt index de19f94..575fcd0 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1151.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 Operating expenses: > Research and development | Year Ended December 31, > 2017 > % ofRevenue: 21.2% Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt index 9b147c8..32cf2e6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1152.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 Operating expenses: > Research and development | Year Ended December 31, > 2016 > % ofRevenue: 24.2% Operating expenses: > Research and development | Year Ended December 31, > 2015 > $: $209,448 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt index 6f2adec..ff5e404 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1157.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2016 > $: $991,337 Revenue > Product | Year Ended December 31, > 2016 > % ofRevenue: 87.8% Revenue > Product | Year Ended December 31, > 2015 > $: $744,877 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2015 > $: 837,591 Revenue > Total revenue | Year Ended December 31, > 2015 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 291,576 Revenue > Total revenue | Change in > %: 34.8 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2016 > $: 369,768 Cost of revenue > Product | Year Ended December 31, > 2016 > % ofRevenue: 32.8 Cost of revenue > Product | Year Ended December 31, > 2015 > $: 263,585 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt index a4e2675..f3e21fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1159.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > % ofRevenue: (0.2)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2016 > $: $(3,136) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt index 478a145..b658d4b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1161.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2017 > $: $1,432,810 Revenue > Product | Year Ended December 31, > 2017 > % ofRevenue: 87.0% Revenue > Product | Year Ended December 31, > 2016 > $: $991,337 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2016 > $: 1,129,167 Revenue > Total revenue | Year Ended December 31, > 2016 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 517,019 Revenue > Total revenue | Change in > %: 45.8 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2017 > $: 538,035 Cost of revenue > Product | Year Ended December 31, > 2017 > % ofRevenue: 32.7 Cost of revenue > Product | Year Ended December 31, > 2016 > $: 369,768 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt index de19f94..575fcd0 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1165.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 Operating expenses: > Research and development | Year Ended December 31, > 2017 > % ofRevenue: 21.2% Operating expenses: > Research and development | Year Ended December 31, > 2016 > $: $273,581 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt index a4e2675..f3e21fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1172.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > % ofRevenue: (0.2)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2016 > $: $(3,136) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt index b6dfa72..810c2ee 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1175.out.txt @@ -1,4 +1,3 @@ -Revenue Revenue > Product | Year Ended December 31, > 2018 > $: $1,841,100 Revenue > Product | Year Ended December 31, > 2018 > % ofRevenue: 85.6% Revenue > Product | Year Ended December 31, > 2017 > $: $1,432,810 @@ -17,7 +16,6 @@ Revenue > Total revenue | Year Ended December 31, > 2017 > $: 1,646,186 Revenue > Total revenue | Year Ended December 31, > 2017 > % ofRevenue: 100.0 Revenue > Total revenue | Change in > $: 505,183 Revenue > Total revenue | Change in > %: 30.7 -Cost of revenue Cost of revenue > Product | Year Ended December 31, > 2018 > $: 720,584 Cost of revenue > Product | Year Ended December 31, > 2018 > % ofRevenue: 33.5 Cost of revenue > Product | Year Ended December 31, > 2017 > $: 538,035 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt index 3041524..ed936fa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1177.out.txt @@ -1,4 +1,3 @@ -Other income (expense), net: Other income (expense), net: > Interest expense | Year Ended December 31, > 2018 > $: $(2,701) Other income (expense), net: > Interest expense | Year Ended December 31, > 2018 > % ofRevenue: (0.1)% Other income (expense), net: > Interest expense | Year Ended December 31, > 2017 > $: $(2,780) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt index 0b46365..4ce7d3e 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1182.out.txt @@ -1,4 +1,3 @@ -Operating expenses: Operating expenses: > Research and development | Year Ended December 31, > 2018 > $: $442,468 Operating expenses: > Research and development | Year Ended December 31, > 2018 > % ofRevenue: 20.6% Operating expenses: > Research and development | Year Ended December 31, > 2017 > $: $349,594 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt index c2185ba..b4998d3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r119.out.txt @@ -1,4 +1,3 @@ -2012 2012 > Fourth Quarter | NYSE Common Stock > High: $36.18 2012 > Fourth Quarter | NYSE Common Stock > Low: $30.26 2012 > Fourth Quarter | OSE Common Stock (1) > High: 202.50 @@ -15,7 +14,6 @@ 2012 > First Quarter | NYSE Common Stock > Low: 25.40 2012 > First Quarter | OSE Common Stock (1) > High: 183.70 2012 > First Quarter | OSE Common Stock (1) > Low: 149.30 -2011 2011 > Fourth Quarter | NYSE Common Stock > High: $30.99 2011 > Fourth Quarter | NYSE Common Stock > Low: $18.70 2011 > Fourth Quarter | OSE Common Stock (1) > High: 168.00 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt index 3a6e9b1..a098afc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1282.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2012 Balance as of December 31, 2012 > Goodwill | Vascular North America > (Dollars in thousands): $407,090 Balance as of December 31, 2012 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): $167,942 Balance as of December 31, 2012 > Goodwill | Surgical North America > (Dollars in thousands): $245,794 @@ -34,7 +33,6 @@ Balance as of December 31, 2012 > Translation adjustment | EMEA > (Dollars in th Balance as of December 31, 2012 > Translation adjustment | Asia > (Dollars in thousands): (8,917) Balance as of December 31, 2012 > Translation adjustment | All Other > (Dollars in thousands): (82) Balance as of December 31, 2012 > Translation adjustment | Total > (Dollars in thousands): (7,533) -Balance as of December 31, 2013 Balance as of December 31, 2013 > Goodwill | Vascular North America > (Dollars in thousands): 459,696 Balance as of December 31, 2013 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): 167,195 Balance as of December 31, 2013 > Goodwill | Surgical North America > (Dollars in thousands): 250,506 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt index e688882..08373ba 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1295.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2013 Balance as of December 31, 2013 > Goodwill | Vascular North America > (Dollars in thousands): $459,696 Balance as of December 31, 2013 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): $167,195 Balance as of December 31, 2013 > Goodwill | Surgical North America > (Dollars in thousands): $250,506 @@ -33,7 +32,6 @@ Balance as of December 31, 2013 > Translation adjustment | EMEA > (Dollars in th Balance as of December 31, 2013 > Translation adjustment | Asia > (Dollars in thousands): (8,220) Balance as of December 31, 2013 > Translation adjustment | All Other > (Dollars in thousands): (3,753) Balance as of December 31, 2013 > Translation adjustment | Total > (Dollars in thousands): (47,042) -Balance as of December 31, 2014 Balance as of December 31, 2014 > Goodwill | Vascular North America > (Dollars in thousands): 459,696 Balance as of December 31, 2014 > Goodwill | Anesthesia/Respiratory North America > (Dollars in thousands): 166,514 Balance as of December 31, 2014 > Goodwill | Surgical North America > (Dollars in thousands): 250,912 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt index 5577b8a..2fd6c2c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1338.out.txt @@ -26,7 +26,6 @@ Average interest rate | Year of Maturity > 2010 > (Dollars in thousands): — Average interest rate | Year of Maturity > 2011 > (Dollars in thousands): 5.6% Average interest rate | Thereafter > (Dollars in thousands): — Average interest rate | Total > (Dollars in thousands): 5.0% -Amount subject to swaps: Amount subject to swaps: > Variable to fixed | Year of Maturity > 2008 > (Dollars in thousands): $59,200 Amount subject to swaps: > Average rate to be received | Year of Maturity > 2008 > (Dollars in thousands): 4.8% Amount subject to swaps: > Average rate to be paid | Year of Maturity > 2008 > (Dollars in thousands): 5.6% \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt index a403722..7e038e7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r138.out.txt @@ -1,4 +1,3 @@ -2009 2009 > Fourth Quarter | NYSE Common Stock > High: $26.89 2009 > Fourth Quarter | NYSE Common Stock > Low: $19.75 2009 > Fourth Quarter | OSE Common Stock(1) > High: 156.30 @@ -15,7 +14,6 @@ 2009 > First Quarter | NYSE Common Stock > Low: 5.50 2009 > First Quarter | OSE Common Stock(1) > High: 106.50 2009 > First Quarter | OSE Common Stock(1) > Low: 38.70 -2008 2008 > Fourth Quarter | NYSE Common Stock > High: $21.26 2008 > Fourth Quarter | NYSE Common Stock > Low: $6.64 2008 > Fourth Quarter | OSE Common Stock(1) > High: 133.50 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt index 6aa71a6..be6f958 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1380.out.txt @@ -1,4 +1,3 @@ -Balance as of December 31, 2015 Balance as of December 31, 2015 > Goodwill | Vascular North America > (Dollars in thousands): $485,986 Balance as of December 31, 2015 > Goodwill | Interventional North America > (Dollars in thousands): $84,615 Balance as of December 31, 2015 > Goodwill | Anesthesia North America > (Dollars in thousands): $225,653 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt index 4aa2452..bfe1a9c 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1504.out.txt @@ -1,4 +1,3 @@ -Mainline CASM: Mainline CASM: > Aircraft fuel and related taxes | 2013 > (In cents): 4.94 Mainline CASM: > Aircraft fuel and related taxes | 2012 > (In cents): 5.05 Mainline CASM: > Aircraft fuel and related taxes | Percent Increase (Decrease): (2.2) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt index 86ad95c..5fe09af 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1507.out.txt @@ -1,4 +1,3 @@ -Mainline CASM: Mainline CASM: > Aircraft fuel and related taxes | 2012 > (In cents): 5.05 Mainline CASM: > Aircraft fuel and related taxes | 2011 > (In cents): 4.77 Mainline CASM: > Aircraft fuel and related taxes | Percent Increase (Decrease): 5.9 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt index 8522d39..5cd725e 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1593.out.txt @@ -1,5 +1,3 @@ -Components of net periodic benefit cost: -Defined benefit plans: Defined benefit plans: > Service cost | Pension Benefits > 2014: $3 Defined benefit plans: > Service cost | Pension Benefits > 2013: $3 Defined benefit plans: > Service cost | Pension Benefits > 2012: $341 @@ -30,7 +28,6 @@ Defined benefit plans: > Settlements | Pension Benefits > 2012: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2014: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2013: — Defined benefit plans: > Settlements | Retiree Medical and Other Benefits > 2012: — -Amortization of: Amortization of: > Prior service cost (1) | Pension Benefits > 2014: 28 Amortization of: > Prior service cost (1) | Pension Benefits > 2013: 28 Amortization of: > Prior service cost (1) | Pension Benefits > 2012: 10 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt index 107c426..44d2536 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1676.out.txt @@ -1,4 +1,3 @@ -Defined benefit plans: Defined benefit plans: > Service cost | Pension Benefits > 2015: $2 Defined benefit plans: > Service cost | Pension Benefits > 2014: $3 Defined benefit plans: > Service cost | Pension Benefits > 2013: $3 @@ -29,7 +28,6 @@ Defined benefit plans: > Settlements | Pension Benefits > 2013: (1) Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2015: — Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2014: — Defined benefit plans: > Settlements | Retiree Medical and OtherPostretirement Benefits > 2013: — -Amortization of: Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2015: 28 Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2014: 28 Amortization of: > Prior service cost (benefit) (1) | Pension Benefits > 2013: 28 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt index 424bbf3..7ae5765 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r186.out.txt @@ -1,4 +1,3 @@ -Fixed rate debt: Fixed rate debt: > Senior notes | Interest Rate: 2.65% to 7.50% Fixed rate debt: > Senior notes | Maturities Through: 2020 - 2028 Fixed rate debt: > Senior notes | As of December 31, > 2018: $1,724,194 @@ -13,7 +12,6 @@ Fixed rate debt: > Unsecured term loans | As of December 31, > 2018: 2,148,351 Fixed rate debt: > Unsecured term loans | As of December 31, > 2017: 333,351 Fixed rate debt: > Total fixed rate debt | As of December 31, > 2018: 4,542,982 Fixed rate debt: > Total fixed rate debt | As of December 31, > 2017: 2,199,710 -Variable rate debt (1) : Variable rate debt (1) : > Unsecured revolving credit facilities (2) | Interest Rate: 3.54% to 3.61% Variable rate debt (1) : > Unsecured revolving credit facilities (2) | Maturities Through: 2020 - 2022 Variable rate debt (1) : > Unsecured revolving credit facilities (2) | As of December 31, > 2018: 795,000 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt index ed25303..0a05b36 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1902.out.txt @@ -2,7 +2,6 @@ (dollars in millions) | Years Ended December 31, > 2015: Percentageof Total Net Sales (dollars in millions) | Years Ended December 31, > 2014: Net Sales (dollars in millions) | Years Ended December 31, > 2014: Percentageof Total Net Sales -Corporate: Corporate: > Medium/Large | Years Ended December 31, > 2015: $5,758.2 Corporate: > Medium/Large | Years Ended December 31, > 2015: 44.3% Corporate: > Medium/Large | Years Ended December 31, > 2014: $5,485.4 @@ -15,7 +14,6 @@ Corporate: > Total Corporate | Years Ended December 31, > 2015: 6,816.4 Corporate: > Total Corporate | Years Ended December 31, > 2015: 52.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 6,475.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 53.6 -Public: Public: > Government | Years Ended December 31, > 2015: 1,675.9 Public: > Government | Years Ended December 31, > 2015: 12.9 Public: > Government | Years Ended December 31, > 2014: 1,449.4 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt index ad77799..b9989fc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1923.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate | Years Ended December 31, > 2014 > Dollars inMillions: $439.8 Segments: (1) > Corporate | Years Ended December 31, > 2014 > OperatingMargin: 6.8% Segments: (1) > Corporate | Years Ended December 31, > 2013 > Dollars inMillions: $363.3 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt index ece3527..108d4b5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1924.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate | Years Ended December 31, > 2015 > Dollars inMillions: $470.1 Segments: (1) > Corporate | Years Ended December 31, > 2015 > OperatingMargin: 6.9% Segments: (1) > Corporate | Years Ended December 31, > 2014 > Dollars inMillions: $439.8 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt index 992342f..6adffa1 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1927.out.txt @@ -2,7 +2,6 @@ (dollars in millions) | Years Ended December 31, > 2014: Percentageof Total Net sales (dollars in millions) | Years Ended December 31, > 2013: Net Sales (dollars in millions) | Years Ended December 31, > 2013: Percentageof Total Net Sales -Corporate: Corporate: > Medium / Large | Years Ended December 31, > 2014: $5,485.4 Corporate: > Medium / Large | Years Ended December 31, > 2014: 45.4% Corporate: > Medium / Large | Years Ended December 31, > 2013: $5,052.7 @@ -15,7 +14,6 @@ Corporate: > Total Corporate | Years Ended December 31, > 2014: 6,475.5 Corporate: > Total Corporate | Years Ended December 31, > 2014: 53.6 Corporate: > Total Corporate | Years Ended December 31, > 2013: 5,960.1 Corporate: > Total Corporate | Years Ended December 31, > 2013: 55.3 -Public: Public: > Government | Years Ended December 31, > 2014: 1,449.4 Public: > Government | Years Ended December 31, > 2014: 12.0 Public: > Government | Years Ended December 31, > 2013: 1,250.6 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt index 8045437..5cc3035 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1943.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2016 > Dollars inMillions: $453.6 Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2016 > OperatingMargin: 7.7% Segments: (1) > Corporate (2)(3)(4) | Years Ended December 31, > 2015 > Dollars inMillions: $432.5 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt index 5bb8622..73501b6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r1953.out.txt @@ -1,4 +1,3 @@ -Segments: (1) Segments: (1) > Corporate (2) | Years Ended December 31, > 2017 > Dollars inMillions: $487.0 Segments: (1) > Corporate (2) | Years Ended December 31, > 2017 > OperatingMargin: 7.7% Segments: (1) > Corporate (2) | Years Ended December 31, > 2016 > Dollars inMillions: $453.6 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt index d60398d..965d940 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r200.out.txt @@ -1,4 +1,3 @@ -2011 2011 > Fourth Quarter | NYSE Common Stock > High: $30.99 2011 > Fourth Quarter | NYSE Common Stock > Low: $18.70 2011 > Fourth Quarter | OSE Common Stock (1) > High: 168.00 @@ -15,7 +14,6 @@ 2011 > First Quarter | NYSE Common Stock > Low: 40.26 2011 > First Quarter | OSE Common Stock (1) > High: 293.10 2011 > First Quarter | OSE Common Stock (1) > Low: 226.30 -2010 2010 > Fourth Quarter | NYSE Common Stock > High: $47.83 2010 > Fourth Quarter | NYSE Common Stock > Low: $30.87 2010 > Fourth Quarter | OSE Common Stock (1) > High: 284.70 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt index a97414e..e9eb698 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2005.out.txt @@ -1,4 +1,3 @@ -Composite Luxury (2) Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > 2008: 69.2% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: -1.9% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: pts. @@ -13,7 +12,6 @@ Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > 200 Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > Change vs. 2007: -0.1% Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > 2008: $225.87 Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > Change vs. 2007: -0.1% -Total Worldwide (3) Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > 2008: 70.4% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: -2.3% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2007: pts. diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt index 2d62039..f59a8a5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2028.out.txt @@ -1,4 +1,3 @@ -Composite Luxury (2) Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > 2010: 66.1% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: 5.9% Composite Luxury (2) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: pts. @@ -13,7 +12,6 @@ Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > 201 Composite Luxury (2) > RevPAR | Comparable Company-Operated Properties (1) > Change vs. 2009: 10.2% Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > 2010: $193.17 Composite Luxury (2) > RevPAR | Comparable Systemwide Properties (1) > Change vs. 2009: 10.2% -Total Worldwide (3) Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > 2010: 68.7% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: 4.1% Total Worldwide (3) > Occupancy | Comparable Company-Operated Properties (1) > Change vs. 2009: pts. diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt index f143505..6f3f9e3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2203.out.txt @@ -1,4 +1,3 @@ -Derivatives designated as hedging contracts Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Balance sheet location: Other current assets/(Other current liabilities) Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Asset derivatives December 31, > 2014 > Fair value: $309 Derivatives designated as hedging contracts > Natural gas and crude derivative contracts | Asset derivatives December 31, > 2013 > Fair value: $18 @@ -31,7 +30,6 @@ Derivatives designated as hedging contracts > Total | Asset derivatives December Derivatives designated as hedging contracts > Total | Asset derivatives December 31, > 2013 > Fair value: 335 Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2014 > Fair value: (87) Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2013 > Fair value: (179) -Derivatives not designated as hedging contracts Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Balance sheet location: Other current assets/(Other current liabilities) Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Asset derivatives December 31, > 2014 > Fair value: 73 Derivatives not designated as hedging contracts > Natural gas, crude and NGL derivative contracts | Asset derivatives December 31, > 2013 > Fair value: 4 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt index fe359fb..cca08be 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r224.out.txt @@ -4,7 +4,6 @@ (Millions of dollars) | Non-U.S.Pension Benefits: 2016 (Millions of dollars) | Other PostretirementBenefits: 2017 (Millions of dollars) | Other PostretirementBenefits: 2016 -Change in benefit obligation: Change in benefit obligation: > Benefit obligation, beginning of year | U.S. Pension Benefits: $16,218 Change in benefit obligation: > Benefit obligation, beginning of year | U.S. Pension Benefits: $15,792 Change in benefit obligation: > Benefit obligation, beginning of year | Non-U.S.Pension Benefits: $4,472 @@ -75,7 +74,6 @@ Change in benefit obligation: > Accumulated benefit obligation, end of year | U. Change in benefit obligation: > Accumulated benefit obligation, end of year | U.S. Pension Benefits: $16,034 Change in benefit obligation: > Accumulated benefit obligation, end of year | Non-U.S.Pension Benefits: $4,335 Change in benefit obligation: > Accumulated benefit obligation, end of year | Non-U.S.Pension Benefits: $4,163 -Weighted-average assumptions used todetermine benefit obligation: Weighted-average assumptions used todetermine benefit obligation: > Discount rate | U.S. Pension Benefits: 3.5% Weighted-average assumptions used todetermine benefit obligation: > Discount rate | U.S. Pension Benefits: 4.0% Weighted-average assumptions used todetermine benefit obligation: > Discount rate | Non-U.S.Pension Benefits: 2.4% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt index 051051d..9f0bfc6 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2278.out.txt @@ -1,4 +1,3 @@ -Derivatives designated as hedging contracts Derivatives designated as hedging contracts > Energy commodity derivative contracts | Balance sheetlocation: Current Derivatives designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2010 > Fair value: $20.1 Derivatives designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2009 > Fair value: $19.1 @@ -27,7 +26,6 @@ Derivatives designated as hedging contracts > Total | Asset derivatives December Derivatives designated as hedging contracts > Total | Asset derivatives December 31, > 2009 > Fair value: 312.4 Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2010 > Fair value: (448.1) Derivatives designated as hedging contracts > Total | Liability derivatives December 31, > 2009 > Fair value: (740.4) -Derivatives not designated as hedging contracts Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Balance sheetlocation: Current Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2010 > Fair value: 3.9 Derivatives not designated as hedging contracts > Energy commodity derivative contracts | Asset derivatives December 31, > 2009 > Fair value: 1.7 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt index 2776eec..b9fd11b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r234.out.txt @@ -29,7 +29,4 @@ Per share goodwill impairment 4 | Twelve Months Ended December 31, > 2016: $0.98 Adjusted profit per share | Three Months Ended December 31, > 2017: $2.16 Adjusted profit per share | Three Months Ended December 31, > 2016: $0.83 Adjusted profit per share | Twelve Months Ended December 31, > 2017: $6.88 -Adjusted profit per share | Twelve Months Ended December 31, > 2016: $3.42 -2 At statutory tax rates prior to consideration of U.S. tax reform. -3 Net of U.S. federal tax at 35 percent. -4 Includes a $17 million tax benefit. \ No newline at end of file +Adjusted profit per share | Twelve Months Ended December 31, > 2016: $3.42 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt index 8c1343c..d6f86f9 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r235.out.txt @@ -4,7 +4,6 @@ (Millions of dollars) | Non-U.S.Pension Benefits: 2016 (Millions of dollars) | Other PostretirementBenefits: 2017 (Millions of dollars) | Other PostretirementBenefits: 2016 -Change in plan assets: Change in plan assets: > Fair value of plan assets, beginning of year | U.S. Pension Benefits: $11,354 Change in plan assets: > Fair value of plan assets, beginning of year | U.S. Pension Benefits: $11,440 Change in plan assets: > Fair value of plan assets, beginning of year | Non-U.S.Pension Benefits: $3,887 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt index d8ef7fb..94243da 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r244.out.txt @@ -7,7 +7,6 @@ (Millions of dollars) | Other Postretirement Benefits: 2017 (Millions of dollars) | Other Postretirement Benefits: 2016 (Millions of dollars) | Other Postretirement Benefits: 2015 -Components of net periodic benefit cost: Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $115 Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $119 Components of net periodic benefit cost: > Service cost | U.S. Pension Benefits: $181 @@ -71,7 +70,6 @@ Components of net periodic benefit cost: > Total cost (benefit) included in oper Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $163 Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $160 Components of net periodic benefit cost: > Total cost (benefit) included in operating profit | Other Postretirement Benefits: $(362) -Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Current year prior service cost (credit) | U.S. Pension Benefits: $— @@ -108,7 +106,6 @@ Other changes in plan assets and benefit obligations recognized in other compreh Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $109 Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $35 Other changes in plan assets and benefit obligations recognized in other comprehensive income (pre-tax): > Total recognized in net periodic cost and other comprehensive income | Other Postretirement Benefits: $(292) -Weighted-average assumptions used to determine net cost: Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 4.2% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 4.5% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits: 3.8% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt index b607eed..9a5e79a 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r249.out.txt @@ -1,4 +1,3 @@ -Weighted-average assumptions used to determine benefit obligations, end of year: Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2018: 4.2% Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2017: 3.5% Weighted-average assumptions used to determine benefit obligations, end of year: > Discount rate | U.S. Pension Benefits > 2016: 4.0% @@ -17,7 +16,6 @@ Weighted-average assumptions used to determine benefit obligations, end of year: Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2018: 4.0% Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2017: 4.0% Weighted-average assumptions used to determine benefit obligations, end of year: > Rate of compensation increase | Other Postretirement Benefits > 2016: 4.0% -Weighted-average assumptions used to determine net cost: Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2018: 3.7% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2017: 4.2% Weighted-average assumptions used to determine net cost: > Discount rate used to measure service cost | U.S. Pension Benefits > 2016: 4.5% @@ -54,7 +52,6 @@ Weighted-average assumptions used to determine net cost: > Rate of compensation Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2018: 4.0% Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2017: 4.0% Weighted-average assumptions used to determine net cost: > Rate of compensation increase | Other Postretirement Benefits > 2016: 4.0% -Health care cost trend rates at year-end: Health care trend rate assumed for next year | Other Postretirement Benefits > 2018: 6.1% Health care trend rate assumed for next year | Other Postretirement Benefits > 2017: 6.1% Health care trend rate assumed for next year | Other Postretirement Benefits > 2016: 6.6% diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt index af7a0dc..07c8677 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2528.out.txt @@ -1,4 +1,3 @@ -2006 2006 > Rental income (1) | First Quarter > (In thousands, except per share data): $104,964 2006 > Rental income (1) | Second Quarter > (In thousands, except per share data): $105,533 2006 > Rental income (1) | Third Quarter > (In thousands, except per share data): $110,511 @@ -19,7 +18,6 @@ 2006 > Earnings per common share — diluted | Second Quarter > (In thousands, except per share data): $0.66 2006 > Earnings per common share — diluted | Third Quarter > (In thousands, except per share data): $0.41 2006 > Earnings per common share — diluted | Fourth Quarter > (In thousands, except per share data): $0.32 -2005 2005 > Rental income (1) | First Quarter > (In thousands, except per share data): $97,783 2005 > Rental income (1) | Second Quarter > (In thousands, except per share data): $95,762 2005 > Rental income (1) | Third Quarter > (In thousands, except per share data): $96,772 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt index 27bb5fb..85f6d34 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2548.out.txt @@ -1,4 +1,3 @@ -East East > Rental income | 2006 > (Dollars in thousands): $340,968 East > Rental income | 2005 > (Dollars in thousands): $310,063 East > Rental income | 2004 > (Dollars in thousands): $293,291 @@ -17,7 +16,6 @@ East > Total assets | 2004 > (Dollars in thousands): $1,264,135 East > Gross leasable square feet | 2006 > (Dollars in thousands): 16,195 East > Gross leasable square feet | 2005 > (Dollars in thousands): 14,941 East > Gross leasable square feet | 2004 > (Dollars in thousands): 14,482 -West West > Rental income | 2006 > (Dollars in thousands): $97,233 West > Rental income | 2005 > (Dollars in thousands): $83,485 West > Rental income | 2004 > (Dollars in thousands): $75,008 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt index 172759c..9807829 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2567.out.txt @@ -1,4 +1,3 @@ -SUPPLEMENTAL DISCLOSURES: SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2007 > (In thousands): $125,259 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2006 > (In thousands): $106,877 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2005 > (In thousands): $94,257 @@ -17,7 +16,6 @@ SUPPLEMENTAL DISCLOSURES: > Cash paid for interest, net of amounts capitalized | SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2007 > (In thousands): $1,126 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2006 > (In thousands): $5,098(1) SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2005 > (In thousands): $82 -NON-CASH INVESTING AND FINANCING TRANSACTIONS: NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2007 > (In thousands): $79,987 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2006 > (In thousands): $44,297 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Mortgage loans assumed with acquisitions | 2005 > (In thousands): $22,258 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt index 198ef85..e666a53 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2574.out.txt @@ -1,4 +1,3 @@ -East East > Rental income | 2007 > (Dollars and square feet in thousands): $363,698 East > Rental income | 2006 > (Dollars and square feet in thousands): $318,176 East > Rental income | 2005 > (Dollars and square feet in thousands): $292,688 @@ -14,7 +13,6 @@ East > Property operating income as a percent of total revenue | 2005 > (Dollars East > Gross leasable square feet | 2007 > (Dollars and square feet in thousands): 15,568 East > Gross leasable square feet | 2006 > (Dollars and square feet in thousands): 16,195 East > Gross leasable square feet | 2005 > (Dollars and square feet in thousands): 14,941 -West West > Rental income | 2007 > (Dollars and square feet in thousands): $104,800 West > Rental income | 2006 > (Dollars and square feet in thousands): $96,803 West > Rental income | 2005 > (Dollars and square feet in thousands): $83,239 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt index 65e0a15..24c146d 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2640.out.txt @@ -1,4 +1,3 @@ -2009 2009 > Revenue(1) | First Quarter > (In thousands, except per share data): $131,076 2009 > Revenue(1) | Second Quarter > (In thousands, except per share data): $130,338 2009 > Revenue(1) | Third Quarter > (In thousands, except per share data): $130,992 @@ -27,7 +26,6 @@ 2009 > Earnings per common share—diluted | Second Quarter > (In thousands, except per share data): $0.48 2009 > Earnings per common share—diluted | Third Quarter > (In thousands, except per share data): $0.45 2009 > Earnings per common share—diluted | Fourth Quarter > (In thousands, except per share data): $0.52 -2008 2008 > Revenue(1) | First Quarter > (In thousands, except per share data): $126,242 2008 > Revenue(1) | Second Quarter > (In thousands, except per share data): $128,712 2008 > Revenue(1) | Third Quarter > (In thousands, except per share data): $131,707 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt index 2e9b8b2..b030ff8 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2689.out.txt @@ -1,4 +1,3 @@ -2010 2010 > Revenue(1) | First Quarter > (In thousands, except per share data): $138,324 2010 > Revenue(1) | Second Quarter > (In thousands, except per share data): $133,689 2010 > Revenue(1) | Third Quarter > (In thousands, except per share data): $133,913 @@ -27,7 +26,6 @@ 2010 > Earnings per common share—diluted(2) | Second Quarter > (In thousands, except per share data): $0.50 2010 > Earnings per common share—diluted(2) | Third Quarter > (In thousands, except per share data): $0.48 2010 > Earnings per common share—diluted(2) | Fourth Quarter > (In thousands, except per share data): $0.53 -2009 2009 > Revenue(1) | First Quarter > (In thousands, except per share data): $131,031 2009 > Revenue(1) | Second Quarter > (In thousands, except per share data): $130,225 2009 > Revenue(1) | Third Quarter > (In thousands, except per share data): $130,841 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt index 1347a29..02e609b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2704.out.txt @@ -1,4 +1,3 @@ -SUPPLEMENTAL DISCLOSURES: SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2010 > (In thousands): $108,167 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2009 > (In thousands): $114,330 SUPPLEMENTAL DISCLOSURES: > Total interest costs incurred | 2008 > (In thousands): $104,464 @@ -14,7 +13,6 @@ SUPPLEMENTAL DISCLOSURES: > Cash paid for interest, net of amounts capitalized | SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2010 > (In thousands): $255 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2009 > (In thousands): $324 SUPPLEMENTAL DISCLOSURES: > Cash paid for income taxes | 2008 > (In thousands): $444 -NON-CASH INVESTING AND FINANCING TRANSACTIONS: NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2010 > (In thousands): $8,832 NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2009 > (In thousands): $— NON-CASH INVESTING AND FINANCING TRANSACTIONS: > Extinguishment of deferred ground rent liability | 2008 > (In thousands): $— diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt index df6186a..c1e6efc 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r2798.out.txt @@ -1,4 +1,3 @@ -2005 2005 > Rental income (1) | First Quarter > (In thousands, except per share data): $98,306 2005 > Rental income (1) | Second Quarter > (In thousands, except per share data): $96,175 2005 > Rental income (1) | Third Quarter > (In thousands, except per share data): $97,233 @@ -19,7 +18,6 @@ 2005 > Earnings per common share — diluted | Second Quarter > (In thousands, except per share data): $0.41 2005 > Earnings per common share — diluted | Third Quarter > (In thousands, except per share data): $0.52 2005 > Earnings per common share — diluted | Fourth Quarter > (In thousands, except per share data): $0.61 -2004 2004 > Rental income (1) | First Quarter > (In thousands, except per share data): $89,388 2004 > Rental income (1) | Second Quarter > (In thousands, except per share data): $93,243 2004 > Rental income (1) | Third Quarter > (In thousands, except per share data): $93,459 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt index b588ab4..c5060c3 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r28.out.txt @@ -7,7 +7,6 @@ Beginning cash and cash equivalents | One Year Change > $: $(112,818) Beginning cash and cash equivalents | One Year Change > %: -24% Beginning cash and cash equivalents | Two Year Change > $: $202,128 Beginning cash and cash equivalents | Two Year Change > %: 127% -Cash provided from (used in): Cash provided from (used in): > Operating activities | Year Ended > December 31, 2014: 1,138,670 Cash provided from (used in): > Operating activities | Year Ended > December 31, 2015: 1,373,468 Cash provided from (used in): > Operating activities | One Year Change > $: 234,798 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt index dfbe828..fd22d1b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3004.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2005 | Treasury > Stock: $(199,482) Balance at October 31, 2005 | Deferred > Stock > Compensation: $(1,475) Balance at October 31, 2005 | Accumulated Other > Comprehensive > Income (Loss): $(16,001) Balance at October 31, 2005 | Total: $1,210,637 -Components of comprehensive income: Components of comprehensive income: > Net income | Retained > Earnings: 24,742 Components of comprehensive income: > Net income | Accumulated Other > Comprehensive > Income (Loss): 24,742 Components of comprehensive income: > Net income | Total: 24,742 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt index 3a2b551..50ed47b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3009.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2004 | Treasury > Stock: $(175,762) Balance at October 31, 2004 | Deferred > Stock > Compensation: $(2,732) Balance at October 31, 2004 | Accumulated Other > Comprehensive > Income (Loss): $(645) Balance at October 31, 2004 | Total: $1,258,455 -Components of comprehensive loss Components of comprehensive loss > Net loss | Retained > Earnings: (17,114) Components of comprehensive loss > Net loss | Accumulated Other > Comprehensive > Income (Loss): (17,114) Components of comprehensive loss > Net loss | Total: (17,114) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt index 7d6a857..47b8ac7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3021.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2003 | Treasury > Stock: $(20,733) Balance at October 31, 2003 | Deferred > Stock > Compensation: $(7,170) Balance at October 31, 2003 | Accumulated Other > Comprehensive > Income (Loss): $9,353 Balance at October 31, 2003 | Total: $1,426,069 -Components of comprehensive income: Components of comprehensive income: > Net income | Retained > Earnings: 75,084 Components of comprehensive income: > Net income | Accumulated Other > Comprehensive > Income (Loss): 75,084 Components of comprehensive income: > Net income | Total: 75,084 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt index f86ee4b..4c2b611 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3054.out.txt @@ -1,5 +1,3 @@ -Balance at October 31, 2009 -Classified as current assets: Classified as current assets: > Non-interest bearing cash (U.S. and International) | Cost > (in thousands): $40,390 Classified as current assets: > Non-interest bearing cash (U.S. and International) | Gross Unrealized Gains > (in thousands): $— Classified as current assets: > Non-interest bearing cash (U.S. and International) | Gross Unrealized Losses Less Than 12 Months > (in thousands): $— @@ -25,7 +23,6 @@ Gross Unrealized Gains > (in thousands): 2,827 Gross Unrealized Losses Less Than 12 Months > (in thousands): (80) Gross Unrealized Losses 12 Months or Longer > (in thousands): — Estimated Fair Value > (in thousands): 1,168,326 -Classified as non-current assets: Classified as non-current assets: > Strategic investments | Cost > (in thousands): 8,002 Classified as non-current assets: > Strategic investments | Gross Unrealized Gains > (in thousands): 1,796 Classified as non-current assets: > Strategic investments | Gross Unrealized Losses Less Than 12 Months > (in thousands): — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt index b888b28..802ed26 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3205.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2003 | Treasury > Stock: $(20,733) Balance at October 31, 2003 | Deferred > Stock > Compensation: $(7,170) Balance at October 31, 2003 | Accumulated Other > Comprehensive > Income (Loss): $9,353 Balance at October 31, 2003 | Total: $1,433,410 -Components of comprehensive income: Components of comprehensive income: > Net income | Common Stock > Shares: — Components of comprehensive income: > Net income | Common Stock > Amount: — Components of comprehensive income: > Net income | Capital in Excess > of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt index eb49406..d3fc767 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3214.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2002 | Treasury > Stock: $(116,499) Balance at October 31, 2002 | Deferred Stock > Compensation: $(8,858) Balance at October 31, 2002 | Accumulated Other Comprehensive > Income (Loss): $(146) Balance at October 31, 2002 | Total: $1,113,481 -Components of comprehensive income: Components of comprehensive income: > Net income | Common Stock > Shares: — Components of comprehensive income: > Net income | Common Stock > Amount: — Components of comprehensive income: > Net income | Capital in Excess of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt index ff02a91..a2ef4f8 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3218.out.txt @@ -6,7 +6,6 @@ Balance at October 31, 2004 | Treasury > Stock: $(175,762) Balance at October 31, 2004 | Deferred > Stock > Compensation: $(2,732) Balance at October 31, 2004 | Accumulated Other > Comprehensive > Income (Loss): $(645) Balance at October 31, 2004 | Total: $1,265,049 -Components of comprehensive income: Components of comprehensive income: > Net loss | Common Stock > Shares: — Components of comprehensive income: > Net loss | Common Stock > Amount: — Components of comprehensive income: > Net loss | Capital in Excess > of Par > Value: — diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt index 2e7755a..cdfbc65 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3277.out.txt @@ -1,11 +1,9 @@ -Nonvested balance — Nonvested balance — > As of January 1 | 2013 > Number of Awards: 3,261,562 Nonvested balance — > As of January 1 | 2013 > Weighted Average Grant Date Fair Value: $85.17 Nonvested balance — > As of January 1 | 2012 > Number of Awards: 4,858,972 Nonvested balance — > As of January 1 | 2012 > Weighted Average Grant Date Fair Value: $73.02 Nonvested balance — > As of January 1 | 2011 > Number of Awards: 4,812,657 Nonvested balance — > As of January 1 | 2011 > Weighted Average Grant Date Fair Value: $68.75 -Granted Granted > Annual | 2013 > Number of Awards: 946,774 Granted > Annual | 2013 > Weighted Average Grant Date Fair Value: 101.57 Granted > Annual | 2012 > Number of Awards: 968,522 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt index a3588f4..a23f343 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3283.out.txt @@ -4,7 +4,6 @@ (Millions) | Qualified and Non-qualified Pension Benefits > International: 2014 (Millions) | Postretirement > Benefits: 2015 (Millions) | Postretirement > Benefits: 2014 -Amounts recognized in accumulated other comprehensive income as of Dec. 31, Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > United States: $— Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > United States: $— Amounts recognized in accumulated other comprehensive income as of Dec. 31, > Net transition obligation (asset) | Qualified and Non-qualified Pension Benefits > International: $(2) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt index b0b97dc..9692f4b 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3284.out.txt @@ -1,4 +1,3 @@ -Undistributed balance — Undistributed balance — > As of January 1 | 2015 > Number of Awards: 1,099,752 Undistributed balance — > As of January 1 | 2015 > Weighted Average Grant Date Fair Value: $102.65 Undistributed balance — > As of January 1 | 2014 > Number of Awards: 895,635 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt index 3576a9a..ad7d18a 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3295.out.txt @@ -1,11 +1,9 @@ -Nonvested balance — Nonvested balance — > As of January 1 | 2015 > Number of Awards: 2,817,786 Nonvested balance — > As of January 1 | 2015 > Weighted Average Grant Date Fair Value: $104.41 Nonvested balance — > As of January 1 | 2014 > Number of Awards: 3,105,361 Nonvested balance — > As of January 1 | 2014 > Weighted Average Grant Date Fair Value: $92.31 Nonvested balance — > As of January 1 | 2013 > Number of Awards: 3,261,562 Nonvested balance — > As of January 1 | 2013 > Weighted Average Grant Date Fair Value: $85.17 -Granted Granted > Annual | 2015 > Number of Awards: 671,204 Granted > Annual | 2015 > Weighted Average Grant Date Fair Value: 165.86 Granted > Annual | 2014 > Number of Awards: 798,615 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt index 0b1d6c8..89a9198 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3307.out.txt @@ -6,7 +6,6 @@ (Dollars in millions) | 2014 > Oper.: Income (Dollars in millions) | 2015 vs 2014 % change > Net: Sales (Dollars in millions) | 2015 vs 2014 % change > Oper.: Income -Business Segments Business Segments > Industrial | 2015 > Net: $10,328 Business Segments > Industrial | 2015 > % of: 34.1% Business Segments > Industrial | 2015 > Oper.: $2,263 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt index 4cefdf7..7951ca7 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3312.out.txt @@ -1,11 +1,9 @@ -Under option — Under option — > January 1 | 2015 > Number of Options: 39,235,557 Under option — > January 1 | 2015 > Weighted Average Exercise Price: $90.38 Under option — > January 1 | 2014 > Number of Options: 43,938,778 Under option — > January 1 | 2014 > Weighted Average Exercise Price: $83.84 Under option — > January 1 | 2013 > Number of Options: 56,565,030 Under option — > January 1 | 2013 > Weighted Average Exercise Price: $80.33 -Granted: Granted: > Annual | 2015 > Number of Options: 5,529,544 Granted: > Annual | 2015 > Weighted Average Exercise Price: 165.91 Granted: > Annual | 2014 > Number of Options: 5,736,183 @@ -42,7 +40,6 @@ Granted: > December 31 | 2014 > Number of Options: 39,235,557 Granted: > December 31 | 2014 > Weighted Average Exercise Price: $90.38 Granted: > December 31 | 2013 > Number of Options: 43,938,778 Granted: > December 31 | 2013 > Weighted Average Exercise Price: $83.84 -Options exercisable Options exercisable > December 31 | 2015 > Number of Options: 27,262,062 Options exercisable > December 31 | 2015 > Weighted Average Exercise Price: $85.97 Options exercisable > December 31 | 2014 > Number of Options: 27,502,208 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt index 4510417..cedddc1 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3317.out.txt @@ -4,14 +4,12 @@ (Millions) | Qualified and Non-qualified Pension Benefits > International: 2014 (Millions) | Postretirement > Benefits: 2015 (Millions) | Postretirement > Benefits: 2014 -Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > United States: $3 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > United States: $3 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > International: $185 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Qualified and Non-qualified Pension Benefits > International: $43 Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Postretirement > Benefits: $— Amounts recognized in the Consolidated Balance Sheet as of Dec. 31, > Non-current assets | Postretirement > Benefits: $— -Accrued benefit cost Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > United States: (47) Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > United States: (46) Accrued benefit cost > Current liabilities | Qualified and Non-qualified Pension Benefits > International: (10) diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt index b461782..d80bae5 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r3332.out.txt @@ -1,11 +1,9 @@ -Under option — Under option — > January 1 | 2012 > Number of Options: 64,148,415 Under option — > January 1 | 2012 > Weighted Average Exercise Price: $77.28 Under option — > January 1 | 2011 > Number of Options: 70,335,044 Under option — > January 1 | 2011 > Weighted Average Exercise Price: $74.80 Under option — > January 1 | 2010 > Number of Options: 74,268,165 Under option — > January 1 | 2010 > Weighted Average Exercise Price: $72.39 -Granted: Granted: > Annual | 2012 > Number of Options: 5,770,190 Granted: > Annual | 2012 > Weighted Average Exercise Price: 87.91 Granted: > Annual | 2011 > Number of Options: 5,514,500 @@ -42,7 +40,6 @@ Granted: > December 31 | 2011 > Number of Options: 64,148,415 Granted: > December 31 | 2011 > Weighted Average Exercise Price: $77.28 Granted: > December 31 | 2010 > Number of Options: 70,335,044 Granted: > December 31 | 2010 > Weighted Average Exercise Price: $74.80 -Options exercisable Options exercisable > December 31 | 2012 > Number of Options: 45,207,143 Options exercisable > December 31 | 2012 > Weighted Average Exercise Price: $78.78 Options exercisable > December 31 | 2011 > Number of Options: 52,644,364 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt index 7fc9466..6983d33 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r39.out.txt @@ -43,7 +43,6 @@ Same store NOI | One Year Change > Amount%: 19,953 Same store NOI | One Year Change: 1% Same store NOI | Two Year Change > Amount%: 41,590 Same store NOI | Two Year Change: 3% -Per share data (fully diluted): Per share data (fully diluted): > Net income attributable to common stockholders | Year Ended > December 31, 2014: $1.45 Per share data (fully diluted): > Net income attributable to common stockholders | Year Ended > December 31, 2015: $2.34 Per share data (fully diluted): > Net income attributable to common stockholders | One Year Change > Amount%: $0.89 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt index e139f94..4c57bac 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r392.out.txt @@ -1,4 +1,3 @@ -Foreign exchange instruments qualifying as accounting hedges: Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Notional Principal: $351 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Fair Value: $6 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 30, 2006 > Credit Risk Amounts: $6 @@ -17,7 +16,6 @@ Foreign exchange instruments qualifying as accounting hedges: > Sold options | S Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Notional Principal: $1,087 Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Fair Value: $(5) Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 24, 2005 > Creit Risk Amounts: $— -Foreign exchange instruments other than accounting hedges: Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Notional Principal: $1,103 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Fair Value: $2 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 30, 2006 > Credit Risk Amounts: $2 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt index 09344d2..96d1933 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r529.out.txt @@ -1,4 +1,3 @@ -2005 2005 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $3,678 2005 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $3,520 2005 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $3,243 @@ -11,7 +10,6 @@ 2005 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $320 2005 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $290 2005 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $295 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.52 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.39 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.36 @@ -20,7 +18,6 @@ Earnings per common share: > Diluted | Fourth Quarter > (Tabular amounts in mill Earnings per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.37 Earnings per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.34 Earnings per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $0.35 -2004 2004 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $2,350 2004 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $2,014 2004 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,909 @@ -33,7 +30,6 @@ Earnings per common share: > Diluted | First Quarter > (Tabular amounts in milli 2004 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $61 2004 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $46 2004 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $63 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.14 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.08 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.06 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt index 6cec04e..e771cfa 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r532.out.txt @@ -1,4 +1,3 @@ -Foreign exchange instruments qualifying as accounting hedges: Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Notional Principal: $662 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Fair Value: $10 Foreign exchange instruments qualifying as accounting hedges: > Spot/Forward contracts | September 24, 2005 > Credit Risk Amounts: $10 @@ -17,7 +16,6 @@ Foreign exchange instruments qualifying as accounting hedges: > Sold options | S Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Notional Principal: $521 Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Fair Value: $(3) Foreign exchange instruments qualifying as accounting hedges: > Sold options | September 25, 2004 > Credit Risk Amounts: $— -Foreign exchange instruments other than accounting hedges: Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Notional Principal: $833 Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Fair Value: $(3) Foreign exchange instruments other than accounting hedges: > Spot/Forward contracts | September 24, 2005 > Credit Risk Amounts: $1 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt index 32ffe4a..8146e33 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r547.out.txt @@ -1,4 +1,3 @@ -2003 2003 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,715 2003 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,545 2003 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,475 @@ -11,7 +10,6 @@ 2003 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $19 2003 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $14 2003 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $(8) -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 @@ -20,7 +18,6 @@ Earnings (loss) per common share: > Diluted | Fourth Quarter > (Tabular amounts Earnings (loss) per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 Earnings (loss) per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $(0.02) -2002 2002 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,443 2002 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,429 2002 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,495 @@ -33,7 +30,6 @@ Earnings (loss) per common share: > Diluted | First Quarter > (Tabular amounts i 2002 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $32 2002 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $40 2002 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $38 -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $(0.13) Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.09 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.11 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt index 6d9733f..7a75b9d 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r559.out.txt @@ -1,4 +1,3 @@ -2004 2004 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $2,350 2004 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $2,014 2004 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,909 @@ -11,7 +10,6 @@ 2004 > Net income | Third Quarter > (Tabular amounts in millions, except per share amounts): $61 2004 > Net income | Second Quarter > (Tabular amounts in millions, except per share amounts): $46 2004 > Net income | First Quarter > (Tabular amounts in millions, except per share amounts): $63 -Earnings per common share: Earnings per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.28 Earnings per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.16 Earnings per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.13 @@ -20,7 +18,6 @@ Earnings per common share: > Diluted | Fourth Quarter > (Tabular amounts in mill Earnings per common share: > Diluted | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.16 Earnings per common share: > Diluted | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings per common share: > Diluted | First Quarter > (Tabular amounts in millions, except per share amounts): $0.17 -2003 2003 > Net sales | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $1,715 2003 > Net sales | Third Quarter > (Tabular amounts in millions, except per share amounts): $1,545 2003 > Net sales | Second Quarter > (Tabular amounts in millions, except per share amounts): $1,475 @@ -33,7 +30,6 @@ Earnings per common share: > Diluted | First Quarter > (Tabular amounts in milli 2003 > Net income (loss) | Third Quarter > (Tabular amounts in millions, except per share amounts): $19 2003 > Net income (loss) | Second Quarter > (Tabular amounts in millions, except per share amounts): $14 2003 > Net income (loss) | First Quarter > (Tabular amounts in millions, except per share amounts): $(8) -Earnings (loss) per common share: Earnings (loss) per common share: > Basic | Fourth Quarter > (Tabular amounts in millions, except per share amounts): $0.12 Earnings (loss) per common share: > Basic | Third Quarter > (Tabular amounts in millions, except per share amounts): $0.05 Earnings (loss) per common share: > Basic | Second Quarter > (Tabular amounts in millions, except per share amounts): $0.04 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt index 619c73a..4aa8588 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r597.out.txt @@ -1,4 +1,3 @@ -(in millions) (in millions) > Long-term debt (1) | Total: $27,922 (in millions) > Long-term debt (1) | Payments Due > 2016: $2,405 (in millions) > Long-term debt (1) | Payments Due > 2017-2018: $5,097 @@ -24,7 +23,6 @@ (in millions) > Operating leases (5) | Payments Due > 2017-2018: 207 (in millions) > Operating leases (5) | Payments Due > 2019-2020: 103 (in millions) > Operating leases (5) | Payments Due > 2021 andThereafter: 195 -Purchase obligations (6) : Purchase obligations (6) : > Inventory and production costs | Total: 5,094 Purchase obligations (6) : > Inventory and production costs | Payments Due > 2016: 2,007 Purchase obligations (6) : > Inventory and production costs | Payments Due > 2017-2018: 1,586 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt index 5bd9432..dd78511 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r639.out.txt @@ -14,7 +14,6 @@ Operating leases (3) > 849 | Payments Due: 179 Operating leases (3) > 849 | Payments Due: 219 Operating leases (3) > 849 | Payments Due: 95 Operating leases (3) > 849 | Payments Due: 356 -Purchase obligations (4) : Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 2,696 Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 1,255 Purchase obligations (4) : > Inventory and production costs > 5,040 | Payments Due: 687 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt index 0bc4562..b5c0d70 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r692.out.txt @@ -14,7 +14,6 @@ Operating leases (3) > 772 | Payments Due: 147 Operating leases (3) > 772 | Payments Due: 176 Operating leases (3) > 772 | Payments Due: 95 Operating leases (3) > 772 | Payments Due: 354 -Purchase obligations (4) : Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 2,492 Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 1,165 Purchase obligations (4) : > Inventory and production costs > 4,217 | Payments Due: 406 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt index 70bebcc..0fb11eb 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r718.out.txt @@ -1,4 +1,3 @@ -Period Ended: Period Ended: > Net sales (b)(d) | Successor > December 30,2017(52 weeks) > (in millions, except per share data): $26,232 Period Ended: > Net sales (b)(d) | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): $26,487 Period Ended: > Net sales (b)(d) | Successor > January 3,2016(53 weeks) > (in millions, except per share data): $18,338 @@ -20,7 +19,6 @@ Period Ended: > Income/(loss) from continuing operations attributable to common Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Successor > February 8 - December 29,2013(29 weeks) > (in millions, except per share data): (1,118) Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Predecessor(H. J. Heinz Company) > April 29 - June 7,2013(6 weeks) > (in millions, except per share data): (194) Period Ended: > Income/(loss) from continuing operations attributable to common shareholders (b) | Predecessor(H. J. Heinz Company) > April 28,2013(52 weeks) > (in millions, except per share data): 1,088 -Income/(loss) from continuing operations per common share (b) : Income/(loss) from continuing operations per common share (b) : > Basic | Successor > December 30,2017(52 weeks) > (in millions, except per share data): 9.03 Income/(loss) from continuing operations per common share (b) : > Basic | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): 2.84 Income/(loss) from continuing operations per common share (b) : > Basic | Successor > January 3,2016(53 weeks) > (in millions, except per share data): (0.34) @@ -35,7 +33,6 @@ Income/(loss) from continuing operations per common share (b) : > Diluted | Succ Income/(loss) from continuing operations per common share (b) : > Diluted | Successor > February 8 - December 29,2013(29 weeks) > (in millions, except per share data): (2.97) Income/(loss) from continuing operations per common share (b) : > Diluted | Predecessor(H. J. Heinz Company) > April 29 - June 7,2013(6 weeks) > (in millions, except per share data): (0.60) Income/(loss) from continuing operations per common share (b) : > Diluted | Predecessor(H. J. Heinz Company) > April 28,2013(52 weeks) > (in millions, except per share data): 3.37 -As of: As of: > Total assets (d) | Successor > December 30,2017(52 weeks) > (in millions, except per share data): 120,232 As of: > Total assets (d) | Successor > December 31,2016(52 weeks) (a) > (in millions, except per share data): 120,480 As of: > Total assets (d) | Successor > January 3,2016(53 weeks) > (in millions, except per share data): 122,973 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt index 932c73a..43b09ce 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r80.out.txt @@ -1,4 +1,3 @@ -2013 2013 > Fourth Quarter | NYSECommon Stock > High: $47.66 2013 > Fourth Quarter | NYSECommon Stock > Low: $35.97 2013 > Fourth Quarter | OSECommon Stock (1) > High: 292.60 @@ -15,7 +14,6 @@ 2013 > First Quarter | NYSECommon Stock > Low: 31.72 2013 > First Quarter | OSECommon Stock (1) > High: 213.50 2013 > First Quarter | OSECommon Stock (1) > Low: 184.10 -2012 2012 > Fourth Quarter | NYSECommon Stock > High: $36.18 2012 > Fourth Quarter | NYSECommon Stock > Low: $30.26 2012 > Fourth Quarter | OSECommon Stock (1) > High: 202.50 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt index cc2f9e6..cdfdd49 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s0-r869.out.txt @@ -1,4 +1,3 @@ -2015 2015 > First Quarter | Class A > High: $60.70 2015 > First Quarter | Class A > Low: $52.45 2015 > First Quarter | Class A Special > High: $60.19 @@ -15,7 +14,6 @@ 2015 > FourthQuarter (a) | Class A > Low: $55.39 2015 > FourthQuarter (a) | Class A Special > High: $63.48 2015 > FourthQuarter (a) | Class A Special > Low: $56.88 -2014 2014 > First Quarter | Class A > High: $55.28 2014 > First Quarter | Class A > Low: $49.00 2014 > First Quarter | Class A Special > High: $53.10 diff --git a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt index 4f9dbf1..158e850 100644 --- a/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt +++ b/benchmarks/gold/rules/realworld/fintabnet/fintabnet-s1-r14.out.txt @@ -22,7 +22,6 @@ Rate of compensation increase | Pension Plans > 2016: 2.94% Rate of compensation increase | Postretirement Benefit Plans > 2018: 3.25% Rate of compensation increase | Postretirement Benefit Plans > 2017: 3.25% Rate of compensation increase | Postretirement Benefit Plans > 2016: 3.25% -Health care cost trend Health care cost trend > Initial | Postretirement Benefit Plans > 2018: 6.50% Health care cost trend > Initial | Postretirement Benefit Plans > 2017: 6.75% Health care cost trend > Initial | Postretirement Benefit Plans > 2016: 7.00% @@ -83,7 +82,6 @@ Health care cost trend > Rate of compensation increase | Pension Plans > 2016: 3 Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2018: 3.25% Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2017: 3.25% Health care cost trend > Rate of compensation increase | Postretirement Benefit Plans > 2016: 3.50% -Health care cost trend Health care cost trend > Initial | Postretirement Benefit Plans > 2018: 6.75% Health care cost trend > Initial | Postretirement Benefit Plans > 2017: 7.00% Health care cost trend > Initial | Postretirement Benefit Plans > 2016: 7.50% diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt index cc9c5bf..e1ef663 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-116950.out.txt @@ -1,42 +1,40 @@ -Hypertensives -Malay | Male > M: 28 -Malay | Male > T: 14 -Malay | Female > M: 36 -Malay | Female > T: 26 -Chinese | Male > M: 10 -Chinese | Male > T: 10 -Chinese | Female > M: 28 -Chinese | Female > T: 20 -Indian | Male > M: 1 -Indian | Male > T: 3 -Indian | Female > M: 9 -Indian | Female > T: 17 -Total | Male > M: 39 -Total | Male > T: 27 -Total | Female > M: 73 -Total | Female > T: 63 -Normotensives -Malay | Male > M: 25 -Malay | Male > T: 5 -Malay | Female > M: 48 -Malay | Female > T: 12 -Chinese | Male > M: 4 -Chinese | Male > T: 4 -Chinese | Female > M: 28 -Chinese | Female > T: 8 -Indian | Male > M: 7 -Indian | Male > T: 1 -Indian | Female > M: 24 -Indian | Female > T: 8 -Total | Male > M: 36 -Total | Male > T: 10 -Total | Female > M: 100 -Total | Female > T: 28 -χ 2 value | Male > M: 3.836 -χ 2 value | Male > T: 3.836 -χ 2 value | Female > M: 20.828 -χ 2 value | Female > T: 20.828 -P * value | Male > M: 0.140 -P * value | Male > T: 0.140 -P * value | Female > M: 0.001 -P * value | Female > T: 0.001 \ No newline at end of file +Hypertensives > Malay | Male > M: 28 +Hypertensives > Malay | Male > T: 14 +Hypertensives > Malay | Female > M: 36 +Hypertensives > Malay | Female > T: 26 +Hypertensives > Chinese | Male > M: 10 +Hypertensives > Chinese | Male > T: 10 +Hypertensives > Chinese | Female > M: 28 +Hypertensives > Chinese | Female > T: 20 +Hypertensives > Indian | Male > M: 1 +Hypertensives > Indian | Male > T: 3 +Hypertensives > Indian | Female > M: 9 +Hypertensives > Indian | Female > T: 17 +Hypertensives > Total | Male > M: 39 +Hypertensives > Total | Male > T: 27 +Hypertensives > Total | Female > M: 73 +Hypertensives > Total | Female > T: 63 +Normotensives > Malay | Male > M: 25 +Normotensives > Malay | Male > T: 5 +Normotensives > Malay | Female > M: 48 +Normotensives > Malay | Female > T: 12 +Normotensives > Chinese | Male > M: 4 +Normotensives > Chinese | Male > T: 4 +Normotensives > Chinese | Female > M: 28 +Normotensives > Chinese | Female > T: 8 +Normotensives > Indian | Male > M: 7 +Normotensives > Indian | Male > T: 1 +Normotensives > Indian | Female > M: 24 +Normotensives > Indian | Female > T: 8 +Normotensives > Total | Male > M: 36 +Normotensives > Total | Male > T: 10 +Normotensives > Total | Female > M: 100 +Normotensives > Total | Female > T: 28 +Normotensives > χ 2 value | Male > M: 3.836 +Normotensives > χ 2 value | Male > T: 3.836 +Normotensives > χ 2 value | Female > M: 20.828 +Normotensives > χ 2 value | Female > T: 20.828 +Normotensives > P * value | Male > M: 0.140 +Normotensives > P * value | Male > T: 0.140 +Normotensives > P * value | Female > M: 0.001 +Normotensives > P * value | Female > T: 0.001 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt index ded67d5..17952ba 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-133649.out.txt @@ -4,48 +4,47 @@ Number Graduated | Decompressed > Raw: 37 Number Graduated | %: 58.7 Number Graduated | Repeated > Raw: 12 Number Graduated | %: 27.2 -For those who completed: -Five Years to Graduate | Decompressed > Raw: 29 -Five Years to Graduate | %: 46 -Five Years to Graduate | Repeated > Raw: 8 -Five Years to Graduate | %: 18 -Six Years to Graduate | Decompressed > Raw: 4 -Six Years to Graduate | %: 6 -Six Years to Graduate | Repeated > Raw: 3 -Six Years to Graduate | %: 7 -Seven Years to Graduate | Decompressed > Raw: 3 -Seven Years to Graduate | %: 5 -Seven Years to Graduate | Repeated > Raw: 0 -Seven Years to Graduate | %: 0 -Eight Years to Graduate | Decompressed > Raw: 1 -Eight Years to Graduate | %: 2 -Eight Years to Graduate | Repeated > Raw: 0 -Eight Years to Graduate | %: 0 -Twelve Years to Graduate | Decompressed > Raw: 0 -Twelve Years to Graduate | %: 0 -Twelve Years to Graduate | Repeated > Raw: 1 -Twelve Years to Graduate | %: 2 -1 Attempt to Pass Step 1 | Decompressed > Raw: 29 -1 Attempt to Pass Step 1 | %: 46 -1 Attempt to Pass Step 1 | Repeated > Raw: 7 -1 Attempt to Pass Step 1 | %: 15.9 -2 Attempts to Pass Step 1 | Decompressed > Raw: 7 -2 Attempts to Pass Step 1 | %: 11 -2 Attempts to Pass Step 1 | Repeated > Raw: 1 -2 Attempts to Pass Step 1 | %: 2 -3 Attempts to Pass Step 1 | Decompressed > Raw: 1 -3 Attempts to Pass Step 1 | %: 2 -3 Attempts to Pass Step 1 | Repeated > Raw: 4 -3 Attempts to Pass Step 1 | %: 9 -1 Attempt to Pass Step 2 | Decompressed > Raw: 32 -1 Attempt to Pass Step 2 | %: 50.8 -1 Attempt to Pass Step 2 | Repeated > Raw: 9 -1 Attempt to Pass Step 2 | %: 20.5 -2 Attempts to Pass Step 2 | Decompressed > Raw: 3 -2 Attempts to Pass Step 2 | %: 4.8 -2 Attempts to Pass Step 2 | Repeated > Raw: 2 -2 Attempts to Pass Step 2 | %: 4.5 -3 Attempts to Pass Step 2 | Decompressed > Raw: 2 -3 Attempts to Pass Step 2 | %: 3 -3 Attempts to Pass Step 2 | Repeated > Raw: 1 -3 Attempts to Pass Step 2 | %: 2.3 \ No newline at end of file +For those who completed: > Five Years to Graduate | Decompressed > Raw: 29 +For those who completed: > Five Years to Graduate | %: 46 +For those who completed: > Five Years to Graduate | Repeated > Raw: 8 +For those who completed: > Five Years to Graduate | %: 18 +For those who completed: > Six Years to Graduate | Decompressed > Raw: 4 +For those who completed: > Six Years to Graduate | %: 6 +For those who completed: > Six Years to Graduate | Repeated > Raw: 3 +For those who completed: > Six Years to Graduate | %: 7 +For those who completed: > Seven Years to Graduate | Decompressed > Raw: 3 +For those who completed: > Seven Years to Graduate | %: 5 +For those who completed: > Seven Years to Graduate | Repeated > Raw: 0 +For those who completed: > Seven Years to Graduate | %: 0 +For those who completed: > Eight Years to Graduate | Decompressed > Raw: 1 +For those who completed: > Eight Years to Graduate | %: 2 +For those who completed: > Eight Years to Graduate | Repeated > Raw: 0 +For those who completed: > Eight Years to Graduate | %: 0 +For those who completed: > Twelve Years to Graduate | Decompressed > Raw: 0 +For those who completed: > Twelve Years to Graduate | %: 0 +For those who completed: > Twelve Years to Graduate | Repeated > Raw: 1 +For those who completed: > Twelve Years to Graduate | %: 2 +For those who completed: > 1 Attempt to Pass Step 1 | Decompressed > Raw: 29 +For those who completed: > 1 Attempt to Pass Step 1 | %: 46 +For those who completed: > 1 Attempt to Pass Step 1 | Repeated > Raw: 7 +For those who completed: > 1 Attempt to Pass Step 1 | %: 15.9 +For those who completed: > 2 Attempts to Pass Step 1 | Decompressed > Raw: 7 +For those who completed: > 2 Attempts to Pass Step 1 | %: 11 +For those who completed: > 2 Attempts to Pass Step 1 | Repeated > Raw: 1 +For those who completed: > 2 Attempts to Pass Step 1 | %: 2 +For those who completed: > 3 Attempts to Pass Step 1 | Decompressed > Raw: 1 +For those who completed: > 3 Attempts to Pass Step 1 | %: 2 +For those who completed: > 3 Attempts to Pass Step 1 | Repeated > Raw: 4 +For those who completed: > 3 Attempts to Pass Step 1 | %: 9 +For those who completed: > 1 Attempt to Pass Step 2 | Decompressed > Raw: 32 +For those who completed: > 1 Attempt to Pass Step 2 | %: 50.8 +For those who completed: > 1 Attempt to Pass Step 2 | Repeated > Raw: 9 +For those who completed: > 1 Attempt to Pass Step 2 | %: 20.5 +For those who completed: > 2 Attempts to Pass Step 2 | Decompressed > Raw: 3 +For those who completed: > 2 Attempts to Pass Step 2 | %: 4.8 +For those who completed: > 2 Attempts to Pass Step 2 | Repeated > Raw: 2 +For those who completed: > 2 Attempts to Pass Step 2 | %: 4.5 +For those who completed: > 3 Attempts to Pass Step 2 | Decompressed > Raw: 2 +For those who completed: > 3 Attempts to Pass Step 2 | %: 3 +For those who completed: > 3 Attempts to Pass Step 2 | Repeated > Raw: 1 +For those who completed: > 3 Attempts to Pass Step 2 | %: 2.3 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt index 57aeaed..9d71c76 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-153359.out.txt @@ -1,42 +1,40 @@ -Survivin levels (pg/ml) -Blood | Survivin high, erosive RA ( n = 27): 1180 ± 309 -Blood | P: <0.0001 -Blood | Survivin low, erosive RA ( n = 61): 97 ± 9 -Blood | P: 0.013 -Blood | Survivin low, non-erosive RA ( n = 42) †: 127 ± 5 -Synovial fluid | Survivin high, erosive RA ( n = 27): 1039 ± 523 -Synovial fluid | P: 0.016 -Synovial fluid | Survivin low, erosive RA ( n = 61): 132 ± 4 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 124 ± 2 -Disease duration (years) | Survivin high, erosive RA ( n = 27): 15.5 ± 2.4 -Disease duration (years) | P: n.s. -Disease duration (years) | Survivin low, erosive RA ( n = 61): 13.6 ± 1.2 -Disease duration (years) | P: 0.0002 -Disease duration (years) | Survivin low, non-erosive RA ( n = 42) †: 8.3 ± 1.4 -Age (years) | Survivin high, erosive RA ( n = 27): 58 ± 3 -Age (years) | P: n.s. -Age (years) | Survivin low, erosive RA ( n = 61): 60 ± 2 -Age (years) | P: 0.05 -Age (years) | Survivin low, non-erosive RA ( n = 42) †: 53 ± 3 -Rheumatoid factor-positive ( n ) | Survivin high, erosive RA ( n = 27): 25 -Rheumatoid factor-positive ( n ) | P: n.s. -Rheumatoid factor-positive ( n ) | Survivin low, erosive RA ( n = 61): 53 -Rheumatoid factor-positive ( n ) | P: <0.0001 -Rheumatoid factor-positive ( n ) | Survivin low, non-erosive RA ( n = 42) †: 10 -C-reactive protein (mg/l) | Survivin high, erosive RA ( n = 27): 45 ± 9 -C-reactive protein (mg/l) | P: 0.035 -C-reactive protein (mg/l) | Survivin low, erosive RA ( n = 61): 29 ± 5 -C-reactive protein (mg/l) | P: n.s. -C-reactive protein (mg/l) | Survivin low, non-erosive RA ( n = 42) †: 39 ± 7 -White blood cell count (× 10 9 /ml) -Blood | Survivin high, erosive RA ( n = 27): 8.7 ± 0.6 -Blood | P: 0.038 -Blood | Survivin low, erosive RA ( n = 61): 7.2 ± 0.3 -Blood | P: n.s. -Blood | Survivin low, non-erosive RA ( n = 42) †: 7.1 ± 0.3 -Synovial fluid | Survivin high, erosive RA ( n = 27): 10.8 ± 1.9 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, erosive RA ( n = 61): 11.2 ± 2.9 -Synovial fluid | P: n.s. -Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 13.1 ± 2.8 \ No newline at end of file +Survivin levels (pg/ml) > Blood | Survivin high, erosive RA ( n = 27): 1180 ± 309 +Survivin levels (pg/ml) > Blood | P: <0.0001 +Survivin levels (pg/ml) > Blood | Survivin low, erosive RA ( n = 61): 97 ± 9 +Survivin levels (pg/ml) > Blood | P: 0.013 +Survivin levels (pg/ml) > Blood | Survivin low, non-erosive RA ( n = 42) †: 127 ± 5 +Survivin levels (pg/ml) > Synovial fluid | Survivin high, erosive RA ( n = 27): 1039 ± 523 +Survivin levels (pg/ml) > Synovial fluid | P: 0.016 +Survivin levels (pg/ml) > Synovial fluid | Survivin low, erosive RA ( n = 61): 132 ± 4 +Survivin levels (pg/ml) > Synovial fluid | P: n.s. +Survivin levels (pg/ml) > Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 124 ± 2 +Survivin levels (pg/ml) > Disease duration (years) | Survivin high, erosive RA ( n = 27): 15.5 ± 2.4 +Survivin levels (pg/ml) > Disease duration (years) | P: n.s. +Survivin levels (pg/ml) > Disease duration (years) | Survivin low, erosive RA ( n = 61): 13.6 ± 1.2 +Survivin levels (pg/ml) > Disease duration (years) | P: 0.0002 +Survivin levels (pg/ml) > Disease duration (years) | Survivin low, non-erosive RA ( n = 42) †: 8.3 ± 1.4 +Survivin levels (pg/ml) > Age (years) | Survivin high, erosive RA ( n = 27): 58 ± 3 +Survivin levels (pg/ml) > Age (years) | P: n.s. +Survivin levels (pg/ml) > Age (years) | Survivin low, erosive RA ( n = 61): 60 ± 2 +Survivin levels (pg/ml) > Age (years) | P: 0.05 +Survivin levels (pg/ml) > Age (years) | Survivin low, non-erosive RA ( n = 42) †: 53 ± 3 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin high, erosive RA ( n = 27): 25 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | P: n.s. +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin low, erosive RA ( n = 61): 53 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | P: <0.0001 +Survivin levels (pg/ml) > Rheumatoid factor-positive ( n ) | Survivin low, non-erosive RA ( n = 42) †: 10 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin high, erosive RA ( n = 27): 45 ± 9 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | P: 0.035 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin low, erosive RA ( n = 61): 29 ± 5 +Survivin levels (pg/ml) > C-reactive protein (mg/l) | P: n.s. +Survivin levels (pg/ml) > C-reactive protein (mg/l) | Survivin low, non-erosive RA ( n = 42) †: 39 ± 7 +White blood cell count (× 10 9 /ml) > Blood | Survivin high, erosive RA ( n = 27): 8.7 ± 0.6 +White blood cell count (× 10 9 /ml) > Blood | P: 0.038 +White blood cell count (× 10 9 /ml) > Blood | Survivin low, erosive RA ( n = 61): 7.2 ± 0.3 +White blood cell count (× 10 9 /ml) > Blood | P: n.s. +White blood cell count (× 10 9 /ml) > Blood | Survivin low, non-erosive RA ( n = 42) †: 7.1 ± 0.3 +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin high, erosive RA ( n = 27): 10.8 ± 1.9 +White blood cell count (× 10 9 /ml) > Synovial fluid | P: n.s. +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin low, erosive RA ( n = 61): 11.2 ± 2.9 +White blood cell count (× 10 9 /ml) > Synovial fluid | P: n.s. +White blood cell count (× 10 9 /ml) > Synovial fluid | Survivin low, non-erosive RA ( n = 42) †: 13.1 ± 2.8 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt index ca094f3..b3130fa 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-178810.out.txt @@ -2,35 +2,31 @@ Age [mean (S.D.)] | Group I > Controls (n = 10): 40.5 (9.6) Age [mean (S.D.)] | Group II > Renal Dysfunction (n = 13): 46.5 (15.0) Age [mean (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 45.1 (11.1) Age [mean (S.D.)] | P-value: NS -Race [number (%)] -Caucasian | Group I > Controls (n = 10): 5 (50) -Caucasian | Group II > Renal Dysfunction (n = 13): 1 (8) -Caucasian | Group III > Diabetes and Renal Dysfunction (n = 7): 0 -Black | Group I > Controls (n = 10): 3 (30) -Black | Group II > Renal Dysfunction (n = 13): 12 (92) -Black | Group III > Diabetes and Renal Dysfunction (n = 7): 6 (86) -Black | P-value: 0.02 § -Other | Group I > Controls (n = 10): 2 (20) -Other | Group II > Renal Dysfunction (n = 13): 0 -Other | Group III > Diabetes and Renal Dysfunction (n = 7): 1 (14) -Sex [number (%)] -Male | Group I > Controls (n = 10): 5 (50) -Male | Group II > Renal Dysfunction (n = 13): 7 (54) -Male | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) -Male | P-value: NS -Female | Group I > Controls (n = 10): 5 (50) -Female | Group II > Renal Dysfunction (n = 13): 6 (46) -Female | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) -Weight -[mean kg (S.D.)] | Group I > Controls (n = 10): 75.0 (13.4) -[mean kg (S.D.)] | Group II > Renal Dysfunction (n = 13): 83.9 (23.1) -[mean kg (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 86.0 (25.0) -[mean kg (S.D.)] | P-value: NS -CAD [number (%)] -Yes | Group I > Controls (n = 10): 1 (10) -Yes | Group II > Renal Dysfunction (n = 13): 2 (15) -Yes | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) -Yes | P-value: NS -No | Group I > Controls (n = 10): 9 (90) -No | Group II > Renal Dysfunction (n = 13): 11 (85) -No | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) \ No newline at end of file +Race [number (%)] > Caucasian | Group I > Controls (n = 10): 5 (50) +Race [number (%)] > Caucasian | Group II > Renal Dysfunction (n = 13): 1 (8) +Race [number (%)] > Caucasian | Group III > Diabetes and Renal Dysfunction (n = 7): 0 +Race [number (%)] > Black | Group I > Controls (n = 10): 3 (30) +Race [number (%)] > Black | Group II > Renal Dysfunction (n = 13): 12 (92) +Race [number (%)] > Black | Group III > Diabetes and Renal Dysfunction (n = 7): 6 (86) +Race [number (%)] > Black | P-value: 0.02 § +Race [number (%)] > Other | Group I > Controls (n = 10): 2 (20) +Race [number (%)] > Other | Group II > Renal Dysfunction (n = 13): 0 +Race [number (%)] > Other | Group III > Diabetes and Renal Dysfunction (n = 7): 1 (14) +Sex [number (%)] > Male | Group I > Controls (n = 10): 5 (50) +Sex [number (%)] > Male | Group II > Renal Dysfunction (n = 13): 7 (54) +Sex [number (%)] > Male | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) +Sex [number (%)] > Male | P-value: NS +Sex [number (%)] > Female | Group I > Controls (n = 10): 5 (50) +Sex [number (%)] > Female | Group II > Renal Dysfunction (n = 13): 6 (46) +Sex [number (%)] > Female | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) +Weight > [mean kg (S.D.)] | Group I > Controls (n = 10): 75.0 (13.4) +Weight > [mean kg (S.D.)] | Group II > Renal Dysfunction (n = 13): 83.9 (23.1) +Weight > [mean kg (S.D.)] | Group III > Diabetes and Renal Dysfunction (n = 7): 86.0 (25.0) +Weight > [mean kg (S.D.)] | P-value: NS +CAD [number (%)] > Yes | Group I > Controls (n = 10): 1 (10) +CAD [number (%)] > Yes | Group II > Renal Dysfunction (n = 13): 2 (15) +CAD [number (%)] > Yes | Group III > Diabetes and Renal Dysfunction (n = 7): 3 (43) +CAD [number (%)] > Yes | P-value: NS +CAD [number (%)] > No | Group I > Controls (n = 10): 9 (90) +CAD [number (%)] > No | Group II > Renal Dysfunction (n = 13): 11 (85) +CAD [number (%)] > No | Group III > Diabetes and Renal Dysfunction (n = 7): 4 (57) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt index 3c87195..e977ca4 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-180372.out.txt @@ -1,4 +1,3 @@ -1998 Municipality of Bologna | resident population > N.: 2398 Municipality of Bologna | living abroad > %: 0.71 Municipality of Bologna | no fixed abode > %: 0.12 @@ -13,7 +12,6 @@ Emilia Romagna | refusals objectors > %: 0.29 Emilia Romagna | immigrated > %: 0.22 Emilia Romagna | delays > %: 0.51 Emilia Romagna | other* > %: 0.22 -1999 Municipality of Bologna | resident population > N.: 2560 Municipality of Bologna | living abroad > %: 1.09 Municipality of Bologna | no fixed abode > %: 0.43 @@ -28,7 +26,6 @@ Emilia Romagna | refusals objectors > %: 0.35 Emilia Romagna | immigrated > %: 0.22 Emilia Romagna | delays > %: 0.37 Emilia Romagna | other* > %: 0.11 -2000 Municipality of Bologna | resident population > N.: 2429 Municipality of Bologna | living abroad > %: 0,00 Municipality of Bologna | no fixed abode > %: 0.08 @@ -43,7 +40,6 @@ Emilia Romagna | refusals objectors > %: 0.20 Emilia Romagna | immigrated > %: 0.40 Emilia Romagna | delays > %: 0.50 Emilia Romagna | other* > %: 0.2 -2001 Municipality of Bologna | resident population > N.: 2619 Municipality of Bologna | living abroad > %: 0.04 Municipality of Bologna | no fixed abode > %: 0.19 @@ -58,7 +54,6 @@ Emilia Romagna | refusals objectors > %: 0.60 Emilia Romagna | immigrated > %: 0.26 Emilia Romagna | delays > %: 0.58 Emilia Romagna | other* > %: 0.25 -2002 Municipality of Bologna | resident population > N.: 2706 Municipality of Bologna | living abroad > %: 0.00 Municipality of Bologna | no fixed abode > %: 0.04 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt index 9544c37..94cd002 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-188439.out.txt @@ -1,51 +1,48 @@ -Cigarettes/day -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.46 -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.02 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.24 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.44 -Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.027 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: 0.35 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.095 -Eosinophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.19 -Eosinophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS -Eosinophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.39 -Eosinophils sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.057 -Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > rho: -0.11 -Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > p-value: NS -Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > rho: -0.44 -Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > p-value: 0.029 -CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: 0.69 -CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.002 -CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.46 -CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: 0.029 -EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: -0.79 -EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.001 -EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.02 -EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: NS -Pack-years smoking -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.48 -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.043 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.21 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS -FEV 1 post BD, %pred . -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.31 -Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: 0.15 -Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.41 -Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.046 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: -0.22 -Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: NS -IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > rho: -0.54 -IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > p-value: 0.007 -IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > rho: 0.15 -IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > p-value: NS -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.33 -CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: NS -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.18 -CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS -AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.53 -AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.02 -AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.09 -AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS \ No newline at end of file +Cigarettes/day > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.46 +Cigarettes/day > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.02 +Cigarettes/day > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.24 +Cigarettes/day > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +Cigarettes/day > Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.44 +Cigarettes/day > Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.027 +Cigarettes/day > Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: 0.35 +Cigarettes/day > Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.095 +Cigarettes/day > Eosinophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.19 +Cigarettes/day > Eosinophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS +Cigarettes/day > Eosinophils sputum, % | Asymptomatic smokers (n = 26) > rho: -0.39 +Cigarettes/day > Eosinophils sputum, % | Asymptomatic smokers (n = 26) > p-value: 0.057 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > rho: -0.11 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | COPD GOLD I-III (n = 19) > p-value: NS +Cigarettes/day > Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > rho: -0.44 +Cigarettes/day > Eosinophils sputum, 10 6 /ml | Asymptomatic smokers (n = 26) > p-value: 0.029 +Cigarettes/day > CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: 0.69 +Cigarettes/day > CD68 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.002 +Cigarettes/day > CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.46 +Cigarettes/day > CD68 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: 0.029 +Cigarettes/day > EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > rho: -0.79 +Cigarettes/day > EG2 biopsy, % pos. area | COPD GOLD I-III (n = 19) > p-value: 0.001 +Cigarettes/day > EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > rho: 0.02 +Cigarettes/day > EG2 biopsy, % pos. area | Asymptomatic smokers (n = 26) > p-value: NS +Pack-years smoking > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.48 +Pack-years smoking > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.043 +Pack-years smoking > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.21 +Pack-years smoking > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > rho: -0.31 +FEV 1 post BD, %pred . > Neutrophils sputum, % | COPD GOLD I-III (n = 19) > p-value: NS +FEV 1 post BD, %pred . > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > rho: 0.15 +FEV 1 post BD, %pred . > Neutrophils sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > Macrophages sputum, % | COPD GOLD I-III (n = 19) > rho: 0.41 +FEV 1 post BD, %pred . > Macrophages sputum, % | COPD GOLD I-III (n = 19) > p-value: 0.046 +FEV 1 post BD, %pred . > Macrophages sputum, % | Asymptomatic smokers (n = 26) > rho: -0.22 +FEV 1 post BD, %pred . > Macrophages sputum, % | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > rho: -0.54 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | COPD GOLD I-III (n = 19) > p-value: 0.007 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > rho: 0.15 +FEV 1 post BD, %pred . > IL-8 sputum, ng/ml | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.33 +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: NS +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.18 +FEV 1 post BD, %pred . > CD68 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > rho: 0.53 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | COPD GOLD I-III (n = 19) > p-value: 0.02 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > rho: 0.09 +FEV 1 post BD, %pred . > AA1 biopsy, %pos. area | Asymptomatic smokers (n = 26) > p-value: NS \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt index 65aa681..15bb6b3 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-191534.out.txt @@ -1,23 +1,18 @@ -Primary prevention (7683 with no prior CVD) -Total CVD events† | Allocated treatment > Fenofibrate: 298 -Total CVD events† | Allocated treatment > Placebo: 385 -Total CVD events† | Power to detect effect at 2 P < 0.05*: 93% -Secondary prevention (2112 with prior CVD) -Total CVD events | Allocated treatment > Fenofibrate: 229 -Total CVD events | Allocated treatment > Placebo: 288 -Total CVD events | Power to detect effect at 2 P < 0.05*: 83% -Men (6139) -Total CVD events | Allocated treatment > Fenofibrate: 392 -Total CVD events | Allocated treatment > Placebo: 503 -Total CVD events | Power to detect effect at 2 P < 0.05*: 98% -Women (3656) -Total CVD events | Allocated treatment > Fenofibrate: 133 -Total CVD events | Allocated treatment > Placebo: 171 -Total CVD events | Power to detect effect at 2 P < 0.05*: 60% -All patients (9795) -Total CVD events | Allocated treatment > Fenofibrate: 525 -Total CVD events | Allocated treatment > Placebo: 675 -Total CVD events | Power to detect effect at 2 P < 0.05*: 99% -Total CHD events | Allocated treatment > Fenofibrate: 219 -Total CHD events | Allocated treatment > Placebo: 281 -Total CHD events | Power to detect effect at 2 P < 0.05*: 80% \ No newline at end of file +Primary prevention (7683 with no prior CVD) > Total CVD events† | Allocated treatment > Fenofibrate: 298 +Primary prevention (7683 with no prior CVD) > Total CVD events† | Allocated treatment > Placebo: 385 +Primary prevention (7683 with no prior CVD) > Total CVD events† | Power to detect effect at 2 P < 0.05*: 93% +Secondary prevention (2112 with prior CVD) > Total CVD events | Allocated treatment > Fenofibrate: 229 +Secondary prevention (2112 with prior CVD) > Total CVD events | Allocated treatment > Placebo: 288 +Secondary prevention (2112 with prior CVD) > Total CVD events | Power to detect effect at 2 P < 0.05*: 83% +Men (6139) > Total CVD events | Allocated treatment > Fenofibrate: 392 +Men (6139) > Total CVD events | Allocated treatment > Placebo: 503 +Men (6139) > Total CVD events | Power to detect effect at 2 P < 0.05*: 98% +Women (3656) > Total CVD events | Allocated treatment > Fenofibrate: 133 +Women (3656) > Total CVD events | Allocated treatment > Placebo: 171 +Women (3656) > Total CVD events | Power to detect effect at 2 P < 0.05*: 60% +All patients (9795) > Total CVD events | Allocated treatment > Fenofibrate: 525 +All patients (9795) > Total CVD events | Allocated treatment > Placebo: 675 +All patients (9795) > Total CVD events | Power to detect effect at 2 P < 0.05*: 99% +All patients (9795) > Total CHD events | Allocated treatment > Fenofibrate: 219 +All patients (9795) > Total CHD events | Allocated treatment > Placebo: 281 +All patients (9795) > Total CHD events | Power to detect effect at 2 P < 0.05*: 80% \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt index b885f76..5c3bc6a 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-203260.out.txt @@ -7,28 +7,27 @@ Wheezing | P value for comparison of proportions: 0.43 Chest retractions | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) Chest retractions | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 25.8 (8/31) Chest retractions | P value for comparison of proportions: 0.33 -Feeding pattern: -Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) -Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 54.8 (17/31) -Normal feeding | P value for comparison of proportions: 0.80 -Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) -Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 41.9 (13/31) -Less than normal | P value for comparison of proportions: 0.61 -Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) -Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) -Unable to feed | P value for comparison of proportions: 1.00 -Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 20 (6/30) -Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 35.5 (11/31) -Vomiting | P value for comparison of proportions: 0.25 -Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) -Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 0 (0/31) -Tremors | P value for comparison of proportions: N/A -Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) -Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 6.5 (2/31) -Pallor | P value for comparison of proportions: 0 -Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 23.3 (7/30) -Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 19.4 (6/31) -Has had a visit to a physician | P value for comparison of proportions: 0.42 -Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 3.3 (1/30) -Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) -Has visited an emergency department or been hospitalized | P value for comparison of proportions: 1.00 \ No newline at end of file +Feeding pattern: > Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) +Feeding pattern: > Normal feeding | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 54.8 (17/31) +Feeding pattern: > Normal feeding | P value for comparison of proportions: 0.80 +Feeding pattern: > Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 50 (15/30) +Feeding pattern: > Less than normal | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 41.9 (13/31) +Feeding pattern: > Less than normal | P value for comparison of proportions: 0.61 +Feeding pattern: > Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) +Feeding pattern: > Unable to feed | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) +Feeding pattern: > Unable to feed | P value for comparison of proportions: 1.00 +Feeding pattern: > Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 20 (6/30) +Feeding pattern: > Vomiting | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 35.5 (11/31) +Feeding pattern: > Vomiting | P value for comparison of proportions: 0.25 +Feeding pattern: > Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 0 (0/31) +Feeding pattern: > Tremors | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 0 (0/31) +Feeding pattern: > Tremors | P value for comparison of proportions: N/A +Feeding pattern: > Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 13.3 (4/30) +Feeding pattern: > Pallor | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 6.5 (2/31) +Feeding pattern: > Pallor | P value for comparison of proportions: 0 +Feeding pattern: > Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 23.3 (7/30) +Feeding pattern: > Has had a visit to a physician | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 19.4 (6/31) +Feeding pattern: > Has had a visit to a physician | P value for comparison of proportions: 0.42 +Feeding pattern: > Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Racemic epinephrine: 3.3 (1/30) +Feeding pattern: > Has visited an emergency department or been hospitalized | Percentage of children with symptom at one week post-discharge phone call (absolute numbers)* > Salbutamol: 3.2 (1/31) +Feeding pattern: > Has visited an emergency department or been hospitalized | P value for comparison of proportions: 1.00 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt index 608389e..fa00331 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-234815.out.txt @@ -35,20 +35,19 @@ Coffee drinking | Formulation A: 7 (41.2%) Coffee drinking | Formulation B: 7 (41.2%) Coffee drinking | Total: 14 (41.2%) Coffee drinking | p: 1.00 Δ -Causes of renal failure -Diabetes Mellitus | Formulation A: 7 (46.7%) -Diabetes Mellitus | Formulation B: 6 (40.0%) -Diabetes Mellitus | Total: 13 (43.3%) -Diabetes Mellitus | p: 0.71 Δ -Hypertension | Formulation A: 5 (33.3%) -Hypertension | Formulation B: 4 (26.7%) -Hypertension | Total: 9 (30.0%) -Hypertension | p: 1.00 ! -Other glomerulopathies | Formulation A: 1 (6.7%) -Other glomerulopathies | Formulation B: 1 (6.7%) -Other glomerulopathies | Total: 2 (6.7%) -Other glomerulopathies | p: 1.00 ! -Cystic disease | Formulation A: 1 (6.7%) -Cystic disease | Formulation B: 3 (20.0%) -Cystic disease | Total: 4 (5.6%) -Cystic disease | p: 0.60 ! \ No newline at end of file +Causes of renal failure > Diabetes Mellitus | Formulation A: 7 (46.7%) +Causes of renal failure > Diabetes Mellitus | Formulation B: 6 (40.0%) +Causes of renal failure > Diabetes Mellitus | Total: 13 (43.3%) +Causes of renal failure > Diabetes Mellitus | p: 0.71 Δ +Causes of renal failure > Hypertension | Formulation A: 5 (33.3%) +Causes of renal failure > Hypertension | Formulation B: 4 (26.7%) +Causes of renal failure > Hypertension | Total: 9 (30.0%) +Causes of renal failure > Hypertension | p: 1.00 ! +Causes of renal failure > Other glomerulopathies | Formulation A: 1 (6.7%) +Causes of renal failure > Other glomerulopathies | Formulation B: 1 (6.7%) +Causes of renal failure > Other glomerulopathies | Total: 2 (6.7%) +Causes of renal failure > Other glomerulopathies | p: 1.00 ! +Causes of renal failure > Cystic disease | Formulation A: 1 (6.7%) +Causes of renal failure > Cystic disease | Formulation B: 3 (20.0%) +Causes of renal failure > Cystic disease | Total: 4 (5.6%) +Causes of renal failure > Cystic disease | p: 0.60 ! \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt index 8ef65a1..131ced2 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-262537.out.txt @@ -1,54 +1,48 @@ -Lactate (mg/dl) -Lornoxicam | Baseline: 25.2 ± 4.1 -Lornoxicam | Hours after the start of infusion > 24: 25.0 ± 3.9 -Lornoxicam | Hours after the start of infusion > 48: 25.9 ± 5.2 -Lornoxicam | Hours after the start of infusion > 72: 26.2 ± 3.7 -Placebo | Baseline: 26.3 ± 3.8 -Placebo | Hours after the start of infusion > 24: 26.7 ± 2.9 -Placebo | Hours after the start of infusion > 48: 27.0 ± 3.1 -Placebo | Hours after the start of infusion > 72: 26.9 ± 4.8 -Platelets (×10 9 /l) -Lornoxicam | Baseline: 192.9 ± 16.5 -Lornoxicam | Hours after the start of infusion > 24: 193.5 ± 15.0 -Lornoxicam | Hours after the start of infusion > 48: 178.1 ± 15.4 -Lornoxicam | Hours after the start of infusion > 72: 182.9 ± 15.6 -Placebo | Baseline: 188.5 ± 14.4 -Placebo | Hours after the start of infusion > 24: 190.8 ± 15.1 -Placebo | Hours after the start of infusion > 48: 188.7 ± 13.3 -Placebo | Hours after the start of infusion > 72: 190.5 ± 16.7 -Leucocytes (×10 9 /l) -Lornoxicam | Baseline: 14 ± 8.3 -Lornoxicam | Hours after the start of infusion > 24: 15.8 ± 8.3 -Lornoxicam | Hours after the start of infusion > 48: 16.0 ± 7.8 -Lornoxicam | Hours after the start of infusion > 72: 15.9 ± 6.2 -Placebo | Baseline: 13.5 ± 6.6 -Placebo | Hours after the start of infusion > 24: 14.7 ± 4.7 -Placebo | Hours after the start of infusion > 48: 15.7 ± 6.7 -Placebo | Hours after the start of infusion > 72: 14.8 ± 7.4 -Bilirubin (mg/dl) -Lornoxicam | Baseline: 0.89 ± 0.38 -Lornoxicam | Hours after the start of infusion > 24: 0.90 ± 0.45 -Lornoxicam | Hours after the start of infusion > 48: 0.93 ± 0.33 -Lornoxicam | Hours after the start of infusion > 72: 0.90 ± 0.34 -Placebo | Baseline: 0.90 ± 0.62 -Placebo | Hours after the start of infusion > 24: 0.91 ± 0.38 -Placebo | Hours after the start of infusion > 48: 0.92 ± 0.28 -Placebo | Hours after the start of infusion > 72: 0.91 ± 0.36 -Alanine aminotransferase (IU/l) -Lornoxicam | Baseline: 35.4 ± 5.5 -Lornoxicam | Hours after the start of infusion > 24: 36.0 ± 10.8 -Lornoxicam | Hours after the start of infusion > 48: 35.1 ± 8.6 -Lornoxicam | Hours after the start of infusion > 72: 36.7 ± 8.4 -Placebo | Baseline: 35.4 ± 7.4 -Placebo | Hours after the start of infusion > 24: 35.5 ± 5.2 -Placebo | Hours after the start of infusion > 48: 36.2 ± 6.0 -Placebo | Hours after the start of infusion > 72: 37.4 ± 4.9 -Creatinine (mg/dl) -Lornoxicam | Baseline: 1.13 ± 0.96 -Lornoxicam | Hours after the start of infusion > 24: 1.15 ± 0.85 -Lornoxicam | Hours after the start of infusion > 48: 1.2 ± 0.3 -Lornoxicam | Hours after the start of infusion > 72: 1.28 ± 0.8 -Placebo | Baseline: 1.01 ± 0.91 -Placebo | Hours after the start of infusion > 24: 1.1 ± 0.65 -Placebo | Hours after the start of infusion > 48: 1.08 ± 0.7 -Placebo | Hours after the start of infusion > 72: 1.1 ± 0.8 \ No newline at end of file +Lactate (mg/dl) > Lornoxicam | Baseline: 25.2 ± 4.1 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 25.0 ± 3.9 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 25.9 ± 5.2 +Lactate (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 26.2 ± 3.7 +Lactate (mg/dl) > Placebo | Baseline: 26.3 ± 3.8 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 24: 26.7 ± 2.9 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 48: 27.0 ± 3.1 +Lactate (mg/dl) > Placebo | Hours after the start of infusion > 72: 26.9 ± 4.8 +Platelets (×10 9 /l) > Lornoxicam | Baseline: 192.9 ± 16.5 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 24: 193.5 ± 15.0 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 48: 178.1 ± 15.4 +Platelets (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 72: 182.9 ± 15.6 +Platelets (×10 9 /l) > Placebo | Baseline: 188.5 ± 14.4 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 24: 190.8 ± 15.1 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 48: 188.7 ± 13.3 +Platelets (×10 9 /l) > Placebo | Hours after the start of infusion > 72: 190.5 ± 16.7 +Leucocytes (×10 9 /l) > Lornoxicam | Baseline: 14 ± 8.3 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 24: 15.8 ± 8.3 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 48: 16.0 ± 7.8 +Leucocytes (×10 9 /l) > Lornoxicam | Hours after the start of infusion > 72: 15.9 ± 6.2 +Leucocytes (×10 9 /l) > Placebo | Baseline: 13.5 ± 6.6 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 24: 14.7 ± 4.7 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 48: 15.7 ± 6.7 +Leucocytes (×10 9 /l) > Placebo | Hours after the start of infusion > 72: 14.8 ± 7.4 +Bilirubin (mg/dl) > Lornoxicam | Baseline: 0.89 ± 0.38 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 0.90 ± 0.45 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 0.93 ± 0.33 +Bilirubin (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 0.90 ± 0.34 +Bilirubin (mg/dl) > Placebo | Baseline: 0.90 ± 0.62 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 24: 0.91 ± 0.38 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 48: 0.92 ± 0.28 +Bilirubin (mg/dl) > Placebo | Hours after the start of infusion > 72: 0.91 ± 0.36 +Alanine aminotransferase (IU/l) > Lornoxicam | Baseline: 35.4 ± 5.5 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 24: 36.0 ± 10.8 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 48: 35.1 ± 8.6 +Alanine aminotransferase (IU/l) > Lornoxicam | Hours after the start of infusion > 72: 36.7 ± 8.4 +Alanine aminotransferase (IU/l) > Placebo | Baseline: 35.4 ± 7.4 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 24: 35.5 ± 5.2 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 48: 36.2 ± 6.0 +Alanine aminotransferase (IU/l) > Placebo | Hours after the start of infusion > 72: 37.4 ± 4.9 +Creatinine (mg/dl) > Lornoxicam | Baseline: 1.13 ± 0.96 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 24: 1.15 ± 0.85 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 48: 1.2 ± 0.3 +Creatinine (mg/dl) > Lornoxicam | Hours after the start of infusion > 72: 1.28 ± 0.8 +Creatinine (mg/dl) > Placebo | Baseline: 1.01 ± 0.91 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 24: 1.1 ± 0.65 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 48: 1.08 ± 0.7 +Creatinine (mg/dl) > Placebo | Hours after the start of infusion > 72: 1.1 ± 0.8 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt index 5eb06cb..e6f7dac 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-279671.out.txt @@ -1,131 +1,128 @@ -DD -α 1 = 0.005 | Radial Score Test: 0.02 -α 1 = 0.005 | DIR Score Test: 0.02 -α 1 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.005 | Tango's Test ( τ = 5): 0.02 -α 1 = 0.005 | LRS DIR Test: 0.02 -α 1 = 0.005 | LRS DD Test: 0.02 -α 1 = 0.005 | Stone's Test: 0.02 -α 1 = 0.05 | Radial Score Test: 0.02 -α 1 = 0.05 | DIR Score Test: 0.02 -α 1 = 0.05 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.05 | Tango's Test ( τ = 5): 0.03 -α 1 = 0.05 | LRS DIR Test: 0.02 -α 1 = 0.05 | LRS DD Test: 0.03 -α 1 = 0.05 | Stone's Test: 0.02 -α 1 = 0.1 | Radial Score Test: 0.02 -α 1 = 0.1 | DIR Score Test: 0.02 -α 1 = 0.1 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 1 = 0.1 | Tango's Test ( τ = 5): 0.03 -α 1 = 0.1 | LRS DIR Test: 0.02 -α 1 = 0.1 | LRS DD Test: 0.03 -α 1 = 0.1 | Stone's Test: 0.03 -α 1 = 1 | Radial Score Test: 0.05 -α 1 = 1 | DIR Score Test: 0.02 -α 1 = 1 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 1 | Cuzick and Edwards' Test ( k = 7): 0.03 -α 1 = 1 | Tango's Test ( τ = 5): 0.04 -α 1 = 1 | LRS DIR Test: 0.02 -α 1 = 1 | LRS DD Test: 0.04 -α 1 = 1 | Stone's Test: 0.05 -α 1 = 2 | Radial Score Test: 0.03 -α 1 = 2 | DIR Score Test: 0.02 -α 1 = 2 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 2 | Cuzick and Edwards' Test ( k = 7): 0.04 -α 1 = 2 | Tango's Test ( τ = 5): 0.02 -α 1 = 2 | LRS DIR Test: 0.03 -α 1 = 2 | LRS DD Test: 0.01 -α 1 = 2 | Stone's Test: 0.03 -α 1 = 10 | Radial Score Test: 0.04 -α 1 = 10 | DIR Score Test: 0.02 -α 1 = 10 | Besag and Newell's Test ( k = 7): 0.01 -α 1 = 10 | Cuzick and Edwards' Test ( k = 7): 0.05 -α 1 = 10 | Tango's Test ( τ = 5): 0.03 -α 1 = 10 | LRS DIR Test: 0.02 -α 1 = 10 | LRS DD Test: 0.03 -α 1 = 10 | Stone's Test: 0.03 -DIR -α 3 and α 4 = 0.005 | Radial Score Test: 0.03 -α 3 and α 4 = 0.005 | DIR Score Test: 0.04 -α 3 and α 4 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 -α 3 and α 4 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 3 and α 4 = 0.005 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 0.005 | LRS DIR Test: 0.04 -α 3 and α 4 = 0.005 | LRS DD Test: 0.03 -α 3 and α 4 = 0.005 | Stone's Test: 0.02 -α 3 and α 4 = 0.1 | Radial Score Test: 0.03 -α 3 and α 4 = 0.1 | DIR Score Test: 0.04 -α 3 and α 4 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 -α 3 and α 4 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 3 and α 4 = 0.1 | Tango's Test ( τ = 5): 0.02 -α 3 and α 4 = 0.1 | LRS DIR Test: 0.05 -α 3 and α 4 = 0.1 | LRS DD Test: 0.02 -α 3 and α 4 = 0.1 | Stone's Test: 0.02 -α 3 and α 4 = 0.2 | Radial Score Test: 0.03 -α 3 and α 4 = 0.2 | DIR Score Test: 0.03 -α 3 and α 4 = 0.2 | Besag and Newell's Test ( k = 7): 0.01 -α 3 and α 4 = 0.2 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 3 and α 4 = 0.2 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 0.2 | LRS DIR Test: 0.01 -α 3 and α 4 = 0.2 | LRS DD Test: 0.03 -α 3 and α 4 = 0.2 | Stone's Test: 0.02 -α 3 and α 4 = 0.5 | Radial Score Test: 0.03 -α 3 and α 4 = 0.5 | DIR Score Test: 0.00 -α 3 and α 4 = 0.5 | Besag and Newell's Test ( k = 7): 0.02 -α 3 and α 4 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 3 and α 4 = 0.5 | Tango's Test ( τ = 5): 0.02 -α 3 and α 4 = 0.5 | LRS DIR Test: 0.00 -α 3 and α 4 = 0.5 | LRS DD Test: 0.02 -α 3 and α 4 = 0.5 | Stone's Test: 0.02 -α 3 and α 4 = 1 | Radial Score Test: 0.03 -α 3 and α 4 = 1 | DIR Score Test: 0.00 -α 3 and α 4 = 1 | Besag and Newell's Test ( k = 7): 0.03 -α 3 and α 4 = 1 | Cuzick and Edwards' Test ( k = 7): 0.00 -α 3 and α 4 = 1 | Tango's Test ( τ = 5): 0.03 -α 3 and α 4 = 1 | LRS DIR Test: 0.00 -α 3 and α 4 = 1 | LRS DD Test: 0.03 -α 3 and α 4 = 1 | Stone's Test: 0.02 -α 3 and α 4 = 2 | Radial Score Test: 0.03 -α 3 and α 4 = 2 | DIR Score Test: 0.00 -α 3 and α 4 = 2 | Besag and Newell's Test ( k = 7): 0.04 -α 3 and α 4 = 2 | Cuzick and Edwards' Test ( k = 7): 0.00 -α 3 and α 4 = 2 | Tango's Test ( τ = 5): 0.04 -α 3 and α 4 = 2 | LRS DIR Test: 0.00 -α 3 and α 4 = 2 | LRS DD Test: 0.04 -α 3 and α 4 = 2 | Stone's Test: 0.03 -PKDD α 1 = 0.005 -α 2 = 0.05 | Radial Score Test: 0.03 -α 2 = 0.05 | DIR Score Test: 0.02 -α 2 = 0.05 | Besag and Newell's Test ( k = 7): 0.02 -α 2 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 -α 2 = 0.05 | Tango's Test ( τ = 5): 0.01 -α 2 = 0.05 | LRS DIR Test: 0.02 -α 2 = 0.05 | LRS DD Test: 0.02 -α 2 = 0.05 | Stone's Test: 0.01 -α 2 = 0.1 | Radial Score Test: 0.04 -α 2 = 0.1 | DIR Score Test: 0.02 -α 2 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 -α 2 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 0.1 | Tango's Test ( τ = 5): 0.01 -α 2 = 0.1 | LRS DIR Test: 0.02 -α 2 = 0.1 | LRS DD Test: 0.01 -α 2 = 0.1 | Stone's Test: 0.00 -α 2 = 0.5 | Radial Score Test: 0.03 -α 2 = 0.5 | DIR Score Test: 0.02 -α 2 = 0.5 | Besag and Newell's Test ( k = 7): 0.04 -α 2 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 0.5 | Tango's Test ( τ = 5): 0.00 -α 2 = 0.5 | LRS DIR Test: 0.02 -α 2 = 0.5 | LRS DD Test: 0.00 -α 2 = 0.5 | Stone's Test: 0.00 -α 2 = 1 | Radial Score Test: 0.01 -α 2 = 1 | DIR Score Test: 0.02 -α 2 = 1 | Besag and Newell's Test ( k = 7): 0.04 -α 2 = 1 | Cuzick and Edwards' Test ( k = 7): 0.01 -α 2 = 1 | Tango's Test ( τ = 5): 0.00 -α 2 = 1 | LRS DIR Test: 0.02 -α 2 = 1 | LRS DD Test: 0.00 -α 2 = 1 | Stone's Test: 0.00 \ No newline at end of file +DD > α 1 = 0.005 | Radial Score Test: 0.02 +DD > α 1 = 0.005 | DIR Score Test: 0.02 +DD > α 1 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.005 | Tango's Test ( τ = 5): 0.02 +DD > α 1 = 0.005 | LRS DIR Test: 0.02 +DD > α 1 = 0.005 | LRS DD Test: 0.02 +DD > α 1 = 0.005 | Stone's Test: 0.02 +DD > α 1 = 0.05 | Radial Score Test: 0.02 +DD > α 1 = 0.05 | DIR Score Test: 0.02 +DD > α 1 = 0.05 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.05 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 0.05 | LRS DIR Test: 0.02 +DD > α 1 = 0.05 | LRS DD Test: 0.03 +DD > α 1 = 0.05 | Stone's Test: 0.02 +DD > α 1 = 0.1 | Radial Score Test: 0.02 +DD > α 1 = 0.1 | DIR Score Test: 0.02 +DD > α 1 = 0.1 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 +DD > α 1 = 0.1 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 0.1 | LRS DIR Test: 0.02 +DD > α 1 = 0.1 | LRS DD Test: 0.03 +DD > α 1 = 0.1 | Stone's Test: 0.03 +DD > α 1 = 1 | Radial Score Test: 0.05 +DD > α 1 = 1 | DIR Score Test: 0.02 +DD > α 1 = 1 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 1 | Cuzick and Edwards' Test ( k = 7): 0.03 +DD > α 1 = 1 | Tango's Test ( τ = 5): 0.04 +DD > α 1 = 1 | LRS DIR Test: 0.02 +DD > α 1 = 1 | LRS DD Test: 0.04 +DD > α 1 = 1 | Stone's Test: 0.05 +DD > α 1 = 2 | Radial Score Test: 0.03 +DD > α 1 = 2 | DIR Score Test: 0.02 +DD > α 1 = 2 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 2 | Cuzick and Edwards' Test ( k = 7): 0.04 +DD > α 1 = 2 | Tango's Test ( τ = 5): 0.02 +DD > α 1 = 2 | LRS DIR Test: 0.03 +DD > α 1 = 2 | LRS DD Test: 0.01 +DD > α 1 = 2 | Stone's Test: 0.03 +DD > α 1 = 10 | Radial Score Test: 0.04 +DD > α 1 = 10 | DIR Score Test: 0.02 +DD > α 1 = 10 | Besag and Newell's Test ( k = 7): 0.01 +DD > α 1 = 10 | Cuzick and Edwards' Test ( k = 7): 0.05 +DD > α 1 = 10 | Tango's Test ( τ = 5): 0.03 +DD > α 1 = 10 | LRS DIR Test: 0.02 +DD > α 1 = 10 | LRS DD Test: 0.03 +DD > α 1 = 10 | Stone's Test: 0.03 +DIR > α 3 and α 4 = 0.005 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.005 | DIR Score Test: 0.04 +DIR > α 3 and α 4 = 0.005 | Besag and Newell's Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.005 | Cuzick and Edwards' Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.005 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 0.005 | LRS DIR Test: 0.04 +DIR > α 3 and α 4 = 0.005 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 0.005 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.1 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.1 | DIR Score Test: 0.04 +DIR > α 3 and α 4 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.1 | Tango's Test ( τ = 5): 0.02 +DIR > α 3 and α 4 = 0.1 | LRS DIR Test: 0.05 +DIR > α 3 and α 4 = 0.1 | LRS DD Test: 0.02 +DIR > α 3 and α 4 = 0.1 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.2 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.2 | DIR Score Test: 0.03 +DIR > α 3 and α 4 = 0.2 | Besag and Newell's Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.2 | Cuzick and Edwards' Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.2 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 0.2 | LRS DIR Test: 0.01 +DIR > α 3 and α 4 = 0.2 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 0.2 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 0.5 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 0.5 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 0.5 | Besag and Newell's Test ( k = 7): 0.02 +DIR > α 3 and α 4 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 +DIR > α 3 and α 4 = 0.5 | Tango's Test ( τ = 5): 0.02 +DIR > α 3 and α 4 = 0.5 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 0.5 | LRS DD Test: 0.02 +DIR > α 3 and α 4 = 0.5 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 1 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 1 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 1 | Besag and Newell's Test ( k = 7): 0.03 +DIR > α 3 and α 4 = 1 | Cuzick and Edwards' Test ( k = 7): 0.00 +DIR > α 3 and α 4 = 1 | Tango's Test ( τ = 5): 0.03 +DIR > α 3 and α 4 = 1 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 1 | LRS DD Test: 0.03 +DIR > α 3 and α 4 = 1 | Stone's Test: 0.02 +DIR > α 3 and α 4 = 2 | Radial Score Test: 0.03 +DIR > α 3 and α 4 = 2 | DIR Score Test: 0.00 +DIR > α 3 and α 4 = 2 | Besag and Newell's Test ( k = 7): 0.04 +DIR > α 3 and α 4 = 2 | Cuzick and Edwards' Test ( k = 7): 0.00 +DIR > α 3 and α 4 = 2 | Tango's Test ( τ = 5): 0.04 +DIR > α 3 and α 4 = 2 | LRS DIR Test: 0.00 +DIR > α 3 and α 4 = 2 | LRS DD Test: 0.04 +DIR > α 3 and α 4 = 2 | Stone's Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.05 | Radial Score Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.05 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Besag and Newell's Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Cuzick and Edwards' Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Tango's Test ( τ = 5): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.05 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | LRS DD Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.05 | Stone's Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Radial Score Test: 0.04 +PKDD α 1 = 0.005 > α 2 = 0.1 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | Besag and Newell's Test ( k = 7): 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Tango's Test ( τ = 5): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.1 | LRS DD Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 0.1 | Stone's Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | Radial Score Test: 0.03 +PKDD α 1 = 0.005 > α 2 = 0.5 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.5 | Besag and Newell's Test ( k = 7): 0.04 +PKDD α 1 = 0.005 > α 2 = 0.5 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 0.5 | Tango's Test ( τ = 5): 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 0.5 | LRS DD Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 0.5 | Stone's Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | Radial Score Test: 0.01 +PKDD α 1 = 0.005 > α 2 = 1 | DIR Score Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 1 | Besag and Newell's Test ( k = 7): 0.04 +PKDD α 1 = 0.005 > α 2 = 1 | Cuzick and Edwards' Test ( k = 7): 0.01 +PKDD α 1 = 0.005 > α 2 = 1 | Tango's Test ( τ = 5): 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | LRS DIR Test: 0.02 +PKDD α 1 = 0.005 > α 2 = 1 | LRS DD Test: 0.00 +PKDD α 1 = 0.005 > α 2 = 1 | Stone's Test: 0.00 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt index 1045e41..d9d5f56 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-284789.out.txt @@ -1,49 +1,47 @@ -Variable 1 -Cathepsin K | Mean: 304.66 -Cathepsin K | Standard deviation: 677.607 -Variable 2 -Age (years) | Mean: 62.89 -Age (years) | Standard deviation: 11.1581 -Age (years) | n: 100 -Age (years) | Coeffficient: 0.0543 -Age (years) | Probability > | r |: 0.5915 -Rheumatoid factor (U/l) | Mean: 298.818 -Rheumatoid factor (U/l) | Standard deviation: 1136.49 -Rheumatoid factor (U/l) | n: 100 -Rheumatoid factor (U/l) | Coeffficient: 0.4761 -Rheumatoid factor (U/l) | Probability > | r |: < 0.0001 -Morning stiffness (min) | Mean: 32 -Morning stiffness (min) | Standard deviation: 38.7233 -Morning stiffness (min) | n: 100 -Morning stiffness (min) | Coeffficient: 0.1320 -Morning stiffness (min) | Probability > | r |: 0.1905 -Erythrocyte sedimentation rate (mm/hour) | Mean: 30.27 -Erythrocyte sedimentation rate (mm/hour) | Standard deviation: 20.8404 -Erythrocyte sedimentation rate (mm/hour) | n: 100 -Erythrocyte sedimentation rate (mm/hour) | Coeffficient: 0.2200 -Erythrocyte sedimentation rate (mm/hour) | Probability > | r |: 0.0279 -C-reactive protein (mg/l) | Mean: 24.96 -C-reactive protein (mg/l) | Standard deviation: 23.5032 -C-reactive protein (mg/l) | n: 100 -C-reactive protein (mg/l) | Coeffficient: 0.1121 -C-reactive protein (mg/l) | Probability > | r |: 0.2670 -Ritchie score | Mean: 11.31 -Ritchie score | Standard deviation: 10.3394 -Ritchie score | n: 100 -Ritchie score | Coeffficient: 0.1353 -Ritchie score | Probability > | r |: 0.1797 -Proximal interphalangeal score | Mean: 1.51 -Proximal interphalangeal score | Standard deviation: 2.69865 -Proximal interphalangeal score | n: 100 -Proximal interphalangeal score | Coeffficient: 0.2560 -Proximal interphalangeal score | Probability > | r |: 0.0101 -Disease activity score | Mean: 3.33283 -Disease activity score | Standard deviation: 1.43345 -Disease activity score | n: 100 -Disease activity score | Coeffficient: 0.2093 -Disease activity score | Probability > | r |: 0.0376 -Larsen score | Mean: 54.77 -Larsen score | Standard deviation: 49.3335 -Larsen score | n: 100 -Larsen score | Coeffficient: 0.2856 -Larsen score | Probability > | r |: 0.0040 \ No newline at end of file +Variable 1 > Cathepsin K | Mean: 304.66 +Variable 1 > Cathepsin K | Standard deviation: 677.607 +Variable 2 > Age (years) | Mean: 62.89 +Variable 2 > Age (years) | Standard deviation: 11.1581 +Variable 2 > Age (years) | n: 100 +Variable 2 > Age (years) | Coeffficient: 0.0543 +Variable 2 > Age (years) | Probability > | r |: 0.5915 +Variable 2 > Rheumatoid factor (U/l) | Mean: 298.818 +Variable 2 > Rheumatoid factor (U/l) | Standard deviation: 1136.49 +Variable 2 > Rheumatoid factor (U/l) | n: 100 +Variable 2 > Rheumatoid factor (U/l) | Coeffficient: 0.4761 +Variable 2 > Rheumatoid factor (U/l) | Probability > | r |: < 0.0001 +Variable 2 > Morning stiffness (min) | Mean: 32 +Variable 2 > Morning stiffness (min) | Standard deviation: 38.7233 +Variable 2 > Morning stiffness (min) | n: 100 +Variable 2 > Morning stiffness (min) | Coeffficient: 0.1320 +Variable 2 > Morning stiffness (min) | Probability > | r |: 0.1905 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Mean: 30.27 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Standard deviation: 20.8404 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | n: 100 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Coeffficient: 0.2200 +Variable 2 > Erythrocyte sedimentation rate (mm/hour) | Probability > | r |: 0.0279 +Variable 2 > C-reactive protein (mg/l) | Mean: 24.96 +Variable 2 > C-reactive protein (mg/l) | Standard deviation: 23.5032 +Variable 2 > C-reactive protein (mg/l) | n: 100 +Variable 2 > C-reactive protein (mg/l) | Coeffficient: 0.1121 +Variable 2 > C-reactive protein (mg/l) | Probability > | r |: 0.2670 +Variable 2 > Ritchie score | Mean: 11.31 +Variable 2 > Ritchie score | Standard deviation: 10.3394 +Variable 2 > Ritchie score | n: 100 +Variable 2 > Ritchie score | Coeffficient: 0.1353 +Variable 2 > Ritchie score | Probability > | r |: 0.1797 +Variable 2 > Proximal interphalangeal score | Mean: 1.51 +Variable 2 > Proximal interphalangeal score | Standard deviation: 2.69865 +Variable 2 > Proximal interphalangeal score | n: 100 +Variable 2 > Proximal interphalangeal score | Coeffficient: 0.2560 +Variable 2 > Proximal interphalangeal score | Probability > | r |: 0.0101 +Variable 2 > Disease activity score | Mean: 3.33283 +Variable 2 > Disease activity score | Standard deviation: 1.43345 +Variable 2 > Disease activity score | n: 100 +Variable 2 > Disease activity score | Coeffficient: 0.2093 +Variable 2 > Disease activity score | Probability > | r |: 0.0376 +Variable 2 > Larsen score | Mean: 54.77 +Variable 2 > Larsen score | Standard deviation: 49.3335 +Variable 2 > Larsen score | n: 100 +Variable 2 > Larsen score | Coeffficient: 0.2856 +Variable 2 > Larsen score | Probability > | r |: 0.0040 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt index d827c07..7a6057f 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-357665.out.txt @@ -2,17 +2,16 @@ Annual change in mL per pack-year to 1991: Coef Annual change in mL per pack-year to 1991: 95%CI Annual change in mL per pack-year to 1991: p value Annual change in mL per packs per day between 1991 and 2002: Coef -Quitters† -Men (n = 245) | Term: Linear -Men (n = 245) | Annual change in mL per pack-year to 1991: -0.1 -Men (n = 245) | Annual change in mL per pack-year to 1991: -0.4, 0.3 -Men (n = 245) | Annual change in mL per pack-year to 1991: 0.78 -Men (n = 245) | Annual change in mL per packs per day between 1991 and 2002: -14.3 -Women (n = 179) | Term: Linear -Women (n = 179) | Annual change in mL per pack-year to 1991: 1.5 -Women (n = 179) | Annual change in mL per pack-year to 1991: 0.3, 2.6 -Women (n = 179) | Annual change in mL per pack-year to 1991: 0.01 -Women (n = 179) | Annual change in mL per packs per day between 1991 and 2002: -6.4 +Quitters† > Men (n = 245) | Term: Linear +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: -0.1 +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: -0.4, 0.3 +Quitters† > Men (n = 245) | Annual change in mL per pack-year to 1991: 0.78 +Quitters† > Men (n = 245) | Annual change in mL per packs per day between 1991 and 2002: -14.3 +Quitters† > Women (n = 179) | Term: Linear +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 1.5 +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 0.3, 2.6 +Quitters† > Women (n = 179) | Annual change in mL per pack-year to 1991: 0.01 +Quitters† > Women (n = 179) | Annual change in mL per packs per day between 1991 and 2002: -6.4 Term: Quadratic Annual change in mL per pack-year to 1991: -0.04 Annual change in mL per pack-year to 1991: -0.08,-0.01 @@ -23,17 +22,16 @@ Annual change in mL per pack-year to 1991: 0.0004 Annual change in mL per pack-year to 1991: 0.0001,0.0006 Annual change in mL per pack-year to 1991: 0.006 Annual change in mL per packs per day between 1991 and 2002: na -Persistent smokers† -Men (n = 595) | Term: Linear -Men (n = 595) | Annual change in mL per pack-year to 1991: -0.1 -Men (n = 595) | Annual change in mL per pack-year to 1991: -0.3, 0.12 -Men (n = 595) | Annual change in mL per pack-year to 1991: 0.41 -Men (n = 595) | Annual change in mL per packs per day between 1991 and 2002: -9.0 -Women (n = 556) | Term: Linear -Women (n = 556) | Annual change in mL per pack-year to 1991: 1.4 -Women (n = 556) | Annual change in mL per pack-year to 1991: 0.5, 2.3 -Women (n = 556) | Annual change in mL per pack-year to 1991: 0.001 -Women (n = 556) | Annual change in mL per packs per day between 1991 and 2002: -11.6 +Persistent smokers† > Men (n = 595) | Term: Linear +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: -0.1 +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: -0.3, 0.12 +Persistent smokers† > Men (n = 595) | Annual change in mL per pack-year to 1991: 0.41 +Persistent smokers† > Men (n = 595) | Annual change in mL per packs per day between 1991 and 2002: -9.0 +Persistent smokers† > Women (n = 556) | Term: Linear +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 1.4 +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 0.5, 2.3 +Persistent smokers† > Women (n = 556) | Annual change in mL per pack-year to 1991: 0.001 +Persistent smokers† > Women (n = 556) | Annual change in mL per packs per day between 1991 and 2002: -11.6 Term: Quadratic Annual change in mL per pack-year to 1991: -0.06 Annual change in mL per pack-year to 1991: -0.08, -0.02 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt index 0c29c95..e57fefa 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-374857.out.txt @@ -1,4 +1,3 @@ -2001 Municipality of Bologna | 12 months > DPT > %: 98.7 Municipality of Bologna | 12 months > Polio > %: 98.5 Municipality of Bologna | 12 months > Hepatitis B > %: 97.1 @@ -14,7 +13,6 @@ Emilia Romagna | 24 months > Hepatitis B > %: 98.0 Italy | 24 months > DPT > %: 96.1 Italy | 24 months > Polio > %: 96.0 Italy | 24 months > Hepatitis B > %: 94.7 -2002 Municipality of Bologna | 12 months > DPT > %: 96.7 Municipality of Bologna | 12 months > Polio > %: 96.7 Municipality of Bologna | 12 months > Hepatitis B > %: 95.9 diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt index 2b382ae..24c1af8 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376448.out.txt @@ -26,16 +26,15 @@ UF coefficient (ml/mmHg/h) | Low-flux HD: 13 UF coefficient (ml/mmHg/h) | Low-flux HD: 18 UF coefficient (ml/mmHg/h) | Online HDF: 65 UF coefficient (ml/mmHg/h) | Online HDF: 59 -In vitro clearance: # -Urea | Low-flux HD: 260 -Urea | Low-flux HD: 251 -Urea | Online HDF: 268 -Urea | Online HDF: 276 -Phosphate | Low-flux HD: 198 -Phosphate | Low-flux HD: 193 -Phosphate | Online HDF: 229 -Phosphate | Online HDF: 239 -Vit B12 | Low-flux HD: 111 -Vit B12 | Low-flux HD: 118 -Vit B12 | Online HDF: 158 -Vit B12 | Online HDF: 175 \ No newline at end of file +In vitro clearance: # > Urea | Low-flux HD: 260 +In vitro clearance: # > Urea | Low-flux HD: 251 +In vitro clearance: # > Urea | Online HDF: 268 +In vitro clearance: # > Urea | Online HDF: 276 +In vitro clearance: # > Phosphate | Low-flux HD: 198 +In vitro clearance: # > Phosphate | Low-flux HD: 193 +In vitro clearance: # > Phosphate | Online HDF: 229 +In vitro clearance: # > Phosphate | Online HDF: 239 +In vitro clearance: # > Vit B12 | Low-flux HD: 111 +In vitro clearance: # > Vit B12 | Low-flux HD: 118 +In vitro clearance: # > Vit B12 | Online HDF: 158 +In vitro clearance: # > Vit B12 | Online HDF: 175 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt index a32c267..db0c647 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-376872.out.txt @@ -1,52 +1,51 @@ -Adjusted for -Sex | Cognition at 7 > OR†: 1.42 -Sex | Cognition at 7 > (95% CI): (1.36 to 1.49) -Sex | Cognition at 9 > OR†: 1.50 -Sex | Cognition at 9 > (95% CI): (1.43 to 1.57) -Sex | Cognition at 11 > OR†: 1.55 -Sex | Cognition at 11 > (95% CI): (1.47 to 1.62) -Sex, Marital status at birth | Cognition at 7 > OR†: 1.42 -Sex, Marital status at birth | Cognition at 7 > (95% CI): (1.35 to 1.48) -Sex, Marital status at birth | Cognition at 9 > OR†: 1.49 -Sex, Marital status at birth | Cognition at 9 > (95% CI): (1.42 to 1.56) -Sex, Marital status at birth | Cognition at 11 > OR†: 1.54 -Sex, Marital status at birth | Cognition at 11 > (95% CI): (1.47 to 1.62) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > OR†: 1.34 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > (95% CI): (1.27 to 1.41) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > OR†: 1.42 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > (95% CI): (1.35 to 1.49) -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > OR†: 1.48 -Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > (95% CI): (1.40 to 1.56) -Sex, Height & Weight at 1st medical exam | Cognition at 7 > OR†: 1.40 -Sex, Height & Weight at 1st medical exam | Cognition at 7 > (95% CI): (1.34 to 1.47) -Sex, Height & Weight at 1st medical exam | Cognition at 9 > OR†: 1.48 -Sex, Height & Weight at 1st medical exam | Cognition at 9 > (95% CI): (1.41 to 1.55) -Sex, Height & Weight at 1st medical exam | Cognition at 11 > OR†: 1.53 -Sex, Height & Weight at 1st medical exam | Cognition at 11 > (95% CI): (1.46 to 1.61) -Sex, Rutter B behavioral score | Cognition at 7 > OR†: 1.36 -Sex, Rutter B behavioral score | Cognition at 7 > (95% CI): (1.29 to 1.42) -Sex, Rutter B behavioral score | Cognition at 9 > OR†: 1.43 -Sex, Rutter B behavioral score | Cognition at 9 > (95% CI): (1.36 to 1.51) -Sex, Rutter B behavioral score | Cognition at 11 > OR†: 1.50 -Sex, Rutter B behavioral score | Cognition at 11 > (95% CI): (1.42 to 1.58) -Sex, All early life factors‡ | Cognition at 7 > OR†: 1.29 -Sex, All early life factors‡ | Cognition at 7 > (95% CI): (1.22 to 1.36) -Sex, All early life factors‡ | Cognition at 9 > OR†: 1.37 -Sex, All early life factors‡ | Cognition at 9 > (95% CI): (1.30 to 1.45) -Sex, All early life factors‡ | Cognition at 11 > OR†: 1.43 -Sex, All early life factors‡ | Cognition at 11 > (95% CI): (1.36 to 1.52) -Sex, Cognition at 7 | Cognition at 7 > (95% CI): - -Sex, Cognition at 7 | Cognition at 9 > OR†: 1.36 -Sex, Cognition at 7 | Cognition at 9 > (95% CI): (1.27 to 1.46) -Sex, Cognition at 7 | Cognition at 11 > OR†: 1.46 -Sex, Cognition at 7 | Cognition at 11 > (95% CI): (1.37 to 1.57) -Sex, Cognition at 9 | Cognition at 7 > OR†: 1.14 -Sex, Cognition at 9 | Cognition at 7 > (95% CI): (1.06 to 1.22) -Sex, Cognition at 9 | Cognition at 9 > (95% CI): - -Sex, Cognition at 9 | Cognition at 11 > OR†: 1.44 -Sex, Cognition at 9 | Cognition at 11 > (95% CI): (1.30 to 1.59) -Sex, Cognition at 11 | Cognition at 7 > OR†: 1.08 -Sex, Cognition at 11 | Cognition at 7 > (95% CI): (1.01 to 1.15) -Sex, Cognition at 11 | Cognition at 9 > OR†: 1.09 -Sex, Cognition at 11 | Cognition at 9 > (95% CI): (0.98 to 1.20) -Sex, Cognition at 11 | Cognition at 11 > (95% CI): - \ No newline at end of file +Adjusted for > Sex | Cognition at 7 > OR†: 1.42 +Adjusted for > Sex | Cognition at 7 > (95% CI): (1.36 to 1.49) +Adjusted for > Sex | Cognition at 9 > OR†: 1.50 +Adjusted for > Sex | Cognition at 9 > (95% CI): (1.43 to 1.57) +Adjusted for > Sex | Cognition at 11 > OR†: 1.55 +Adjusted for > Sex | Cognition at 11 > (95% CI): (1.47 to 1.62) +Adjusted for > Sex, Marital status at birth | Cognition at 7 > OR†: 1.42 +Adjusted for > Sex, Marital status at birth | Cognition at 7 > (95% CI): (1.35 to 1.48) +Adjusted for > Sex, Marital status at birth | Cognition at 9 > OR†: 1.49 +Adjusted for > Sex, Marital status at birth | Cognition at 9 > (95% CI): (1.42 to 1.56) +Adjusted for > Sex, Marital status at birth | Cognition at 11 > OR†: 1.54 +Adjusted for > Sex, Marital status at birth | Cognition at 11 > (95% CI): (1.47 to 1.62) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > OR†: 1.34 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 7 > (95% CI): (1.27 to 1.41) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > OR†: 1.42 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 9 > (95% CI): (1.35 to 1.49) +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > OR†: 1.48 +Adjusted for > Sex, Father's occupation at birth & in 1962, Number of children | Cognition at 11 > (95% CI): (1.40 to 1.56) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 7 > OR†: 1.40 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 7 > (95% CI): (1.34 to 1.47) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 9 > OR†: 1.48 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 9 > (95% CI): (1.41 to 1.55) +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 11 > OR†: 1.53 +Adjusted for > Sex, Height & Weight at 1st medical exam | Cognition at 11 > (95% CI): (1.46 to 1.61) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 7 > OR†: 1.36 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 7 > (95% CI): (1.29 to 1.42) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 9 > OR†: 1.43 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 9 > (95% CI): (1.36 to 1.51) +Adjusted for > Sex, Rutter B behavioral score | Cognition at 11 > OR†: 1.50 +Adjusted for > Sex, Rutter B behavioral score | Cognition at 11 > (95% CI): (1.42 to 1.58) +Adjusted for > Sex, All early life factors‡ | Cognition at 7 > OR†: 1.29 +Adjusted for > Sex, All early life factors‡ | Cognition at 7 > (95% CI): (1.22 to 1.36) +Adjusted for > Sex, All early life factors‡ | Cognition at 9 > OR†: 1.37 +Adjusted for > Sex, All early life factors‡ | Cognition at 9 > (95% CI): (1.30 to 1.45) +Adjusted for > Sex, All early life factors‡ | Cognition at 11 > OR†: 1.43 +Adjusted for > Sex, All early life factors‡ | Cognition at 11 > (95% CI): (1.36 to 1.52) +Adjusted for > Sex, Cognition at 7 | Cognition at 7 > (95% CI): - +Adjusted for > Sex, Cognition at 7 | Cognition at 9 > OR†: 1.36 +Adjusted for > Sex, Cognition at 7 | Cognition at 9 > (95% CI): (1.27 to 1.46) +Adjusted for > Sex, Cognition at 7 | Cognition at 11 > OR†: 1.46 +Adjusted for > Sex, Cognition at 7 | Cognition at 11 > (95% CI): (1.37 to 1.57) +Adjusted for > Sex, Cognition at 9 | Cognition at 7 > OR†: 1.14 +Adjusted for > Sex, Cognition at 9 | Cognition at 7 > (95% CI): (1.06 to 1.22) +Adjusted for > Sex, Cognition at 9 | Cognition at 9 > (95% CI): - +Adjusted for > Sex, Cognition at 9 | Cognition at 11 > OR†: 1.44 +Adjusted for > Sex, Cognition at 9 | Cognition at 11 > (95% CI): (1.30 to 1.59) +Adjusted for > Sex, Cognition at 11 | Cognition at 7 > OR†: 1.08 +Adjusted for > Sex, Cognition at 11 | Cognition at 7 > (95% CI): (1.01 to 1.15) +Adjusted for > Sex, Cognition at 11 | Cognition at 9 > OR†: 1.09 +Adjusted for > Sex, Cognition at 11 | Cognition at 9 > (95% CI): (0.98 to 1.20) +Adjusted for > Sex, Cognition at 11 | Cognition at 11 > (95% CI): - \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt index bf8289d..4cbb03e 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-407741.out.txt @@ -1,74 +1,70 @@ -24 months -vaccine against -pertussis | 1998 > BO > %: 95.7 -pertussis | 1998 > ER > %: 96.8 -pertussis | 1999 > BO > %: 94.2 -pertussis | 1999 > ER > %: 96.1 -pertussis | 2000 > BO > %: 95.1 -pertussis | 2000 > ER > %: 96.7 -pertussis | 2001 > BO > %: 94.9 -pertussis | 2001 > ER > %: 96.8 -pertussis | 2002 > BO > %: 94.8 -pertussis | 2002 > ER > %: 96.8 -H. influenzae | 1998 > BO > %: 41.8 -H. influenzae | 1998 > ER > %: 50.6 -H. influenzae | 1999 > BO > %: 45.0 -H. influenzae | 1999 > ER > %: 66.8 -H. influenzae | 2000 > BO > %: 65.9 -H. influenzae | 2000 > ER > %: 81.0 -H. influenzae | 2001 > BO > %: 86.9 -H. influenzae | 2001 > ER > %: 90.6 -H. influenzae | 2002 > BO > %: 93.3 -H. influenzae | 2002 > ER > %: 95.2 -measles | 1998 > BO > %: 79.3 -measles | 1998 > ER > %: 88.2 -measles | 1999 > BO > %: 82.4 -measles | 1999 > ER > %: 89.1 -measles | 2000 > BO > %: 83.5 -measles | 2000 > ER > %: 90.4 -measles | 2001 > BO > %: 86.4 -measles | 2001 > ER > %: 90.7 -measles | 2002 > BO > %: 90.2 -measles | 2002 > ER > %: 92.3 -mumps | 1998 > BO > %: - -mumps | 1998 > ER > %: - -mumps | 1999 > BO > %: 78.8 -mumps | 1999 > ER > %: 84.2 -mumps | 2000 > BO > %: 83.3 -mumps | 2000 > ER > %: 89.4 -mumps | 2001 > BO > %: 85.1 -mumps | 2001 > ER > %: 90.1 -mumps | 2002 > BO > %: 88.8 -mumps | 2002 > ER > %: 91.7 -rubella | 1998 > BO > %: 77.2* -rubella | 1998 > ER > %: 85.2* -rubella | 1999 > BO > %: 78.6 -rubella | 1999 > ER > %: 88.0 -rubella | 2000 > BO > %: 83.4 -rubella | 2000 > ER > %: 89.4 -rubella | 2001 > BO > %: 85.6 -rubella | 2001 > ER > %: 90.1 -rubella | 2002 > BO > %: 88.8 -rubella | 2002 > ER > %: 91.7 -13 years -vaccine against -measles | 1998 > BO > %: 75.1 -measles | 1998 > ER > %: 83.8 -measles | 1999 > BO > %: 72.5 -measles | 1999 > ER > %: 89.1 -measles | 2000 > BO > %: 85.8 -measles | 2000 > ER > %: 84.9 -measles | 2001 > BO > %: 90.1 -measles | 2001 > ER > %: 87.4 -measles | 2002 > BO > %: 92.6 -measles | 2002 > ER > %: 91.3 -rubella | 1998 > BO > %: 84.7* -rubella | 1998 > ER > %: 85.2* -rubella | 1999 > BO > %: 49.9 -rubella | 1999 > ER > %: 60.8 -rubella | 2000 > BO > %: 72.6 -rubella | 2000 > ER > %: 66.3 -rubella | 2001 > BO > %: 76.1 -rubella | 2001 > ER > %: 73.4 -rubella | 2002 > BO > %: 84.2 -rubella | 2002 > ER > %: 80.6 \ No newline at end of file +24 months > vaccine against > pertussis | 1998 > BO > %: 95.7 +24 months > vaccine against > pertussis | 1998 > ER > %: 96.8 +24 months > vaccine against > pertussis | 1999 > BO > %: 94.2 +24 months > vaccine against > pertussis | 1999 > ER > %: 96.1 +24 months > vaccine against > pertussis | 2000 > BO > %: 95.1 +24 months > vaccine against > pertussis | 2000 > ER > %: 96.7 +24 months > vaccine against > pertussis | 2001 > BO > %: 94.9 +24 months > vaccine against > pertussis | 2001 > ER > %: 96.8 +24 months > vaccine against > pertussis | 2002 > BO > %: 94.8 +24 months > vaccine against > pertussis | 2002 > ER > %: 96.8 +24 months > vaccine against > H. influenzae | 1998 > BO > %: 41.8 +24 months > vaccine against > H. influenzae | 1998 > ER > %: 50.6 +24 months > vaccine against > H. influenzae | 1999 > BO > %: 45.0 +24 months > vaccine against > H. influenzae | 1999 > ER > %: 66.8 +24 months > vaccine against > H. influenzae | 2000 > BO > %: 65.9 +24 months > vaccine against > H. influenzae | 2000 > ER > %: 81.0 +24 months > vaccine against > H. influenzae | 2001 > BO > %: 86.9 +24 months > vaccine against > H. influenzae | 2001 > ER > %: 90.6 +24 months > vaccine against > H. influenzae | 2002 > BO > %: 93.3 +24 months > vaccine against > H. influenzae | 2002 > ER > %: 95.2 +24 months > vaccine against > measles | 1998 > BO > %: 79.3 +24 months > vaccine against > measles | 1998 > ER > %: 88.2 +24 months > vaccine against > measles | 1999 > BO > %: 82.4 +24 months > vaccine against > measles | 1999 > ER > %: 89.1 +24 months > vaccine against > measles | 2000 > BO > %: 83.5 +24 months > vaccine against > measles | 2000 > ER > %: 90.4 +24 months > vaccine against > measles | 2001 > BO > %: 86.4 +24 months > vaccine against > measles | 2001 > ER > %: 90.7 +24 months > vaccine against > measles | 2002 > BO > %: 90.2 +24 months > vaccine against > measles | 2002 > ER > %: 92.3 +24 months > vaccine against > mumps | 1998 > BO > %: - +24 months > vaccine against > mumps | 1998 > ER > %: - +24 months > vaccine against > mumps | 1999 > BO > %: 78.8 +24 months > vaccine against > mumps | 1999 > ER > %: 84.2 +24 months > vaccine against > mumps | 2000 > BO > %: 83.3 +24 months > vaccine against > mumps | 2000 > ER > %: 89.4 +24 months > vaccine against > mumps | 2001 > BO > %: 85.1 +24 months > vaccine against > mumps | 2001 > ER > %: 90.1 +24 months > vaccine against > mumps | 2002 > BO > %: 88.8 +24 months > vaccine against > mumps | 2002 > ER > %: 91.7 +24 months > vaccine against > rubella | 1998 > BO > %: 77.2* +24 months > vaccine against > rubella | 1998 > ER > %: 85.2* +24 months > vaccine against > rubella | 1999 > BO > %: 78.6 +24 months > vaccine against > rubella | 1999 > ER > %: 88.0 +24 months > vaccine against > rubella | 2000 > BO > %: 83.4 +24 months > vaccine against > rubella | 2000 > ER > %: 89.4 +24 months > vaccine against > rubella | 2001 > BO > %: 85.6 +24 months > vaccine against > rubella | 2001 > ER > %: 90.1 +24 months > vaccine against > rubella | 2002 > BO > %: 88.8 +24 months > vaccine against > rubella | 2002 > ER > %: 91.7 +13 years > vaccine against > measles | 1998 > BO > %: 75.1 +13 years > vaccine against > measles | 1998 > ER > %: 83.8 +13 years > vaccine against > measles | 1999 > BO > %: 72.5 +13 years > vaccine against > measles | 1999 > ER > %: 89.1 +13 years > vaccine against > measles | 2000 > BO > %: 85.8 +13 years > vaccine against > measles | 2000 > ER > %: 84.9 +13 years > vaccine against > measles | 2001 > BO > %: 90.1 +13 years > vaccine against > measles | 2001 > ER > %: 87.4 +13 years > vaccine against > measles | 2002 > BO > %: 92.6 +13 years > vaccine against > measles | 2002 > ER > %: 91.3 +13 years > vaccine against > rubella | 1998 > BO > %: 84.7* +13 years > vaccine against > rubella | 1998 > ER > %: 85.2* +13 years > vaccine against > rubella | 1999 > BO > %: 49.9 +13 years > vaccine against > rubella | 1999 > ER > %: 60.8 +13 years > vaccine against > rubella | 2000 > BO > %: 72.6 +13 years > vaccine against > rubella | 2000 > ER > %: 66.3 +13 years > vaccine against > rubella | 2001 > BO > %: 76.1 +13 years > vaccine against > rubella | 2001 > ER > %: 73.4 +13 years > vaccine against > rubella | 2002 > BO > %: 84.2 +13 years > vaccine against > rubella | 2002 > ER > %: 80.6 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt index 4d6af73..c001fd5 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-429350.out.txt @@ -1,66 +1,63 @@ -Asthma -No | Case (n = 158) > n: 96 -No | Case (n = 158) > %: 60.7 -No | Control (n = 171) > n: 126 -No | Control (n = 171) > %: 73.6 -No | p-value: 0.007 -Father | Case (n = 158) > n: 12 -Father | Case (n = 158) > %: 7.6 -Father | Control (n = 171) > n: 7 -Father | Control (n = 171) > %: 4.1 -Mother | Case (n = 158) > n: 12 -Mother | Case (n = 158) > %: 7.6 -Mother | Control (n = 171) > n: 7 -Mother | Control (n = 171) > %: 4.1 -More than one in the family | Case (n = 158) > n: 18 -More than one in the family | Case (n = 158) > %: 11.4 -More than one in the family | Control (n = 171) > n: 5 -More than one in the family | Control (n = 171) > %: 2.9 -Sibling | Case (n = 158) > n: 20 -Sibling | Case (n = 158) > %: 12.6 -Sibling | Control (n = 171) > n: 26 -Sibling | Control (n = 171) > %: 15.2 -Allergic rhinitis -No | Case (n = 158) > n: 67 -No | Case (n = 158) > %: 42.4 -No | Control (n = 171) > n: 91 -No | Control (n = 171) > %: 53.2 -No | p-value: 0.10 -Father | Case (n = 158) > n: 16 -Father | Case (n = 158) > %: 10.1 -Father | Control (n = 171) > n: 20 -Father | Control (n = 171) > %: 11.7 -Mother | Case (n = 158) > n: 29 -Mother | Case (n = 158) > %: 18.4 -Mother | Control (n = 171) > n: 17 -Mother | Control (n = 171) > %: 9.9 -More than one in the family | Case (n = 158) > n: 34 -More than one in the family | Case (n = 158) > %: 21.5 -More than one in the family | Control (n = 171) > n: 28 -More than one in the family | Control (n = 171) > %: 16.3 -Sibling | Case (n = 158) > n: 12 -Sibling | Case (n = 158) > %: 7.6 -Sibling | Control (n = 171) > n: 15 -Sibling | Control (n = 171) > %: 8.8 -Eczema as a Child -No | Case (n = 158) > n: 80 -No | Case (n = 158) > %: 50.6 -No | Control (n = 171) > n: 87 -No | Control (n = 171) > %: 50.8 -No | p-value: 0.97 -Father | Case (n = 158) > n: 8 -Father | Case (n = 158) > %: 5.0 -Father | Control (n = 171) > n: 6 -Father | Control (n = 171) > %: 2.9 -Mother | Case (n = 158) > n: 15 -Mother | Case (n = 158) > %: 9.5 -Mother | Control (n = 171) > n: 17 -Mother | Control (n = 171) > %: 9.9 -More than one in the family | Case (n = 158) > n: 22 -More than one in the family | Case (n = 158) > %: 13.9 -More than one in the family | Control (n = 171) > n: 25 -More than one in the family | Control (n = 171) > %: 14.6 -Sibling | Case (n = 158) > n: 33 -Sibling | Case (n = 158) > %: 20.8 -Sibling | Control (n = 171) > n: 36 -Sibling | Control (n = 171) > %: 21.0 \ No newline at end of file +Asthma > No | Case (n = 158) > n: 96 +Asthma > No | Case (n = 158) > %: 60.7 +Asthma > No | Control (n = 171) > n: 126 +Asthma > No | Control (n = 171) > %: 73.6 +Asthma > No | p-value: 0.007 +Asthma > Father | Case (n = 158) > n: 12 +Asthma > Father | Case (n = 158) > %: 7.6 +Asthma > Father | Control (n = 171) > n: 7 +Asthma > Father | Control (n = 171) > %: 4.1 +Asthma > Mother | Case (n = 158) > n: 12 +Asthma > Mother | Case (n = 158) > %: 7.6 +Asthma > Mother | Control (n = 171) > n: 7 +Asthma > Mother | Control (n = 171) > %: 4.1 +Asthma > More than one in the family | Case (n = 158) > n: 18 +Asthma > More than one in the family | Case (n = 158) > %: 11.4 +Asthma > More than one in the family | Control (n = 171) > n: 5 +Asthma > More than one in the family | Control (n = 171) > %: 2.9 +Asthma > Sibling | Case (n = 158) > n: 20 +Asthma > Sibling | Case (n = 158) > %: 12.6 +Asthma > Sibling | Control (n = 171) > n: 26 +Asthma > Sibling | Control (n = 171) > %: 15.2 +Allergic rhinitis > No | Case (n = 158) > n: 67 +Allergic rhinitis > No | Case (n = 158) > %: 42.4 +Allergic rhinitis > No | Control (n = 171) > n: 91 +Allergic rhinitis > No | Control (n = 171) > %: 53.2 +Allergic rhinitis > No | p-value: 0.10 +Allergic rhinitis > Father | Case (n = 158) > n: 16 +Allergic rhinitis > Father | Case (n = 158) > %: 10.1 +Allergic rhinitis > Father | Control (n = 171) > n: 20 +Allergic rhinitis > Father | Control (n = 171) > %: 11.7 +Allergic rhinitis > Mother | Case (n = 158) > n: 29 +Allergic rhinitis > Mother | Case (n = 158) > %: 18.4 +Allergic rhinitis > Mother | Control (n = 171) > n: 17 +Allergic rhinitis > Mother | Control (n = 171) > %: 9.9 +Allergic rhinitis > More than one in the family | Case (n = 158) > n: 34 +Allergic rhinitis > More than one in the family | Case (n = 158) > %: 21.5 +Allergic rhinitis > More than one in the family | Control (n = 171) > n: 28 +Allergic rhinitis > More than one in the family | Control (n = 171) > %: 16.3 +Allergic rhinitis > Sibling | Case (n = 158) > n: 12 +Allergic rhinitis > Sibling | Case (n = 158) > %: 7.6 +Allergic rhinitis > Sibling | Control (n = 171) > n: 15 +Allergic rhinitis > Sibling | Control (n = 171) > %: 8.8 +Eczema as a Child > No | Case (n = 158) > n: 80 +Eczema as a Child > No | Case (n = 158) > %: 50.6 +Eczema as a Child > No | Control (n = 171) > n: 87 +Eczema as a Child > No | Control (n = 171) > %: 50.8 +Eczema as a Child > No | p-value: 0.97 +Eczema as a Child > Father | Case (n = 158) > n: 8 +Eczema as a Child > Father | Case (n = 158) > %: 5.0 +Eczema as a Child > Father | Control (n = 171) > n: 6 +Eczema as a Child > Father | Control (n = 171) > %: 2.9 +Eczema as a Child > Mother | Case (n = 158) > n: 15 +Eczema as a Child > Mother | Case (n = 158) > %: 9.5 +Eczema as a Child > Mother | Control (n = 171) > n: 17 +Eczema as a Child > Mother | Control (n = 171) > %: 9.9 +Eczema as a Child > More than one in the family | Case (n = 158) > n: 22 +Eczema as a Child > More than one in the family | Case (n = 158) > %: 13.9 +Eczema as a Child > More than one in the family | Control (n = 171) > n: 25 +Eczema as a Child > More than one in the family | Control (n = 171) > %: 14.6 +Eczema as a Child > Sibling | Case (n = 158) > n: 33 +Eczema as a Child > Sibling | Case (n = 158) > %: 20.8 +Eczema as a Child > Sibling | Control (n = 171) > n: 36 +Eczema as a Child > Sibling | Control (n = 171) > %: 21.0 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt index 3b53051..9696e13 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-455801.out.txt @@ -1,73 +1,71 @@ -Knows someone with tuberculosis -Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 305 -Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 63.0 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 179 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.0 -Yes | Crude OR: 1.00 -Yes | 95% CI: - -Yes | P value: - -No | Total delay in treatment > Unacceptable (> 60 days) > N: 375 -No | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 -No | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 -No | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 -No | Crude OR: 0.93 -No | 95% CI: 0.72 – 1.19 -No | P value: 0.5782 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 680 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 415 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - -Recent contact with someone with tuberculosis | P value: 0.8554 -< 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 151 -< 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 63.4 -< 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 87 -< 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.6 -< 1 year | Crude OR: 1.00 -< 1 year | 95% CI: - -< 1 year | P value: - -≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 128 -≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 61.8 -≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 79 -≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.2 -≥ 1 year | Crude OR: 0.93 -≥ 1 year | 95% CI: 0.63 – 1.37 -≥ 1 year | P value: 0.7263 -Not known | Total delay in treatment > Unacceptable (> 60 days) > N: 375 -Not known | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 -Not known | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 -Not known | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 -Not known | Crude OR: 0.91 -Not known | 95% CI: 0.67 – 1.24 -Not known | P value: 0.5769 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 654 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 402 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - -Household contact with a case of tuberculosis -Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 104 -Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 62.7 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 62 -Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.3 -Yes | Crude OR: 1.00 -Yes | 95% CI: - -Yes | P value: - -No | Total delay in treatment > Unacceptable (> 60 days) > N: 198 -No | Total delay in treatment > Unacceptable (> 60 days) > %: 63.1 -No | Total delay in treatment > Acceptable (≤ 60 days) > N: 116 -No | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.9 -No | Crude OR: 1.01 -No | 95% CI: 0.68 – 1.50 -No | P value: 0.9301 -Total | Total delay in treatment > Unacceptable (> 60 days) > N: 302 -Total | Total delay in treatment > Unacceptable (> 60 days) > %: - -Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 178 -Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - -Total | Crude OR: - -Total | 95% CI: - -Total | P value: - \ No newline at end of file +Knows someone with tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 305 +Knows someone with tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 63.0 +Knows someone with tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 179 +Knows someone with tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.0 +Knows someone with tuberculosis > Yes | Crude OR: 1.00 +Knows someone with tuberculosis > Yes | 95% CI: - +Knows someone with tuberculosis > Yes | P value: - +Knows someone with tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > N: 375 +Knows someone with tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 +Knows someone with tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 +Knows someone with tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 +Knows someone with tuberculosis > No | Crude OR: 0.93 +Knows someone with tuberculosis > No | 95% CI: 0.72 – 1.19 +Knows someone with tuberculosis > No | P value: 0.5782 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 680 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 415 +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Knows someone with tuberculosis > Total | Crude OR: - +Knows someone with tuberculosis > Total | 95% CI: - +Knows someone with tuberculosis > Total | P value: - +Knows someone with tuberculosis > Recent contact with someone with tuberculosis | P value: 0.8554 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 151 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 63.4 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 87 +Knows someone with tuberculosis > < 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.6 +Knows someone with tuberculosis > < 1 year | Crude OR: 1.00 +Knows someone with tuberculosis > < 1 year | 95% CI: - +Knows someone with tuberculosis > < 1 year | P value: - +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > N: 128 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Unacceptable (> 60 days) > %: 61.8 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > N: 79 +Knows someone with tuberculosis > ≥ 1 year | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.2 +Knows someone with tuberculosis > ≥ 1 year | Crude OR: 0.93 +Knows someone with tuberculosis > ≥ 1 year | 95% CI: 0.63 – 1.37 +Knows someone with tuberculosis > ≥ 1 year | P value: 0.7263 +Knows someone with tuberculosis > Not known | Total delay in treatment > Unacceptable (> 60 days) > N: 375 +Knows someone with tuberculosis > Not known | Total delay in treatment > Unacceptable (> 60 days) > %: 61.4 +Knows someone with tuberculosis > Not known | Total delay in treatment > Acceptable (≤ 60 days) > N: 236 +Knows someone with tuberculosis > Not known | Total delay in treatment > Acceptable (≤ 60 days) > %: 38.6 +Knows someone with tuberculosis > Not known | Crude OR: 0.91 +Knows someone with tuberculosis > Not known | 95% CI: 0.67 – 1.24 +Knows someone with tuberculosis > Not known | P value: 0.5769 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 654 +Knows someone with tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 402 +Knows someone with tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Knows someone with tuberculosis > Total | Crude OR: - +Knows someone with tuberculosis > Total | 95% CI: - +Knows someone with tuberculosis > Total | P value: - +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > N: 104 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Unacceptable (> 60 days) > %: 62.7 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > N: 62 +Household contact with a case of tuberculosis > Yes | Total delay in treatment > Acceptable (≤ 60 days) > %: 37.3 +Household contact with a case of tuberculosis > Yes | Crude OR: 1.00 +Household contact with a case of tuberculosis > Yes | 95% CI: - +Household contact with a case of tuberculosis > Yes | P value: - +Household contact with a case of tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > N: 198 +Household contact with a case of tuberculosis > No | Total delay in treatment > Unacceptable (> 60 days) > %: 63.1 +Household contact with a case of tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > N: 116 +Household contact with a case of tuberculosis > No | Total delay in treatment > Acceptable (≤ 60 days) > %: 36.9 +Household contact with a case of tuberculosis > No | Crude OR: 1.01 +Household contact with a case of tuberculosis > No | 95% CI: 0.68 – 1.50 +Household contact with a case of tuberculosis > No | P value: 0.9301 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > N: 302 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Unacceptable (> 60 days) > %: - +Household contact with a case of tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > N: 178 +Household contact with a case of tuberculosis > Total | Total delay in treatment > Acceptable (≤ 60 days) > %: - +Household contact with a case of tuberculosis > Total | Crude OR: - +Household contact with a case of tuberculosis > Total | 95% CI: - +Household contact with a case of tuberculosis > Total | P value: - \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt index bce8fa9..0972bab 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-464722.out.txt @@ -1,52 +1,48 @@ -Fibroblasts -Total > OA | Nucleotides sequenced: 18489 -Total > OA | Number of mutations > Initial: 38 -Total > OA | Number of mutations > Published polymorphisms removed: 20 -Total > OA | Total mutational burden (mutations/kbp) > Initial: 2.055 -Total > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.082 -Total > RA | Nucleotides sequenced: 30503 -Total > RA | Number of mutations > Initial: 101 -Total > RA | Number of mutations > Published polymorphisms removed: 65 -Total > RA | Total mutational burden (mutations/kbp) > Initial: 3.311 -Total > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.131 -Total > RA | OA vs RA a > Initial: ρ = 0.01 -Total > RA | OA vs RA a > Published Polymorphisms removed: ρ = 6.9 × 10 -3 -Tissue -Total > OA | Nucleotides sequenced: 37145 -Total > OA | Number of mutations > Initial: 67 -Total > OA | Number of mutations > Published polymorphisms removed: 40 -Total > OA | Total mutational burden (mutations/kbp) > Initial: 1.804 -Total > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.077 -Total > RA | Nucleotides sequenced: 17663 -Total > RA | Number of mutations > Initial: 60 -Total > RA | Number of mutations > Published polymorphisms removed: 42 -Total > RA | Total mutational burden (mutations/kbp) > Initial: 3.397 -Total > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.378 -Total > RA | OA vs RA a > Initial: ρ = 4 × 10 -4 -Total > RA | OA vs RA a > Published Polymorphisms removed: ρ = 5.1 × 10 -4 -Fibroblasts -Expressed > OA | Nucleotides sequenced: 6956 -Expressed > OA | Number of mutations > Initial: 12 -Expressed > OA | Number of mutations > Published polymorphisms removed: 7 -Expressed > OA | Total mutational burden (mutations/kbp) > Initial: 1.725 -Expressed > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.006 -Expressed > RA | Nucleotides sequenced: 12394 -Expressed > RA | Number of mutations > Initial: 28 -Expressed > RA | Number of mutations > Published polymorphisms removed: 26 -Expressed > RA | Total mutational burden (mutations/kbp) > Initial: 2.259 -Expressed > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.098 -Expressed > RA | OA vs RA a > Initial: ρ = 0.5 -Expressed > RA | OA vs RA a > Published Polymorphisms removed: ρ = 0.10 -Tissue -Expressed > OA | Nucleotides sequenced: 15805 -Expressed > OA | Number of mutations > Initial: 10 -Expressed > OA | Number of mutations > Published polymorphisms removed: 10 -Expressed > OA | Total mutational burden (mutations/kbp) > Initial: 0.633 -Expressed > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 0.633 -Expressed > RA | Nucleotides sequenced: 6397 -Expressed > RA | Number of mutations > Initial: 16 -Expressed > RA | Number of mutations > Published polymorphisms removed: 14 -Expressed > RA | Total mutational burden (mutations/kbp) > Initial: 2.501 -Expressed > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.189 -Expressed > RA | OA vs RA a > Initial: ρ = 6 × 10 -4 -Expressed > RA | OA vs RA a > Published Polymorphisms removed: ρ = 2.7 × 10 -3 \ No newline at end of file +Total > Fibroblasts > OA | Nucleotides sequenced: 18489 +Total > Fibroblasts > OA | Number of mutations > Initial: 38 +Total > Fibroblasts > OA | Number of mutations > Published polymorphisms removed: 20 +Total > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Initial: 2.055 +Total > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.082 +Total > Fibroblasts > RA | Nucleotides sequenced: 30503 +Total > Fibroblasts > RA | Number of mutations > Initial: 101 +Total > Fibroblasts > RA | Number of mutations > Published polymorphisms removed: 65 +Total > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Initial: 3.311 +Total > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.131 +Total > Fibroblasts > RA | OA vs RA a > Initial: ρ = 0.01 +Total > Fibroblasts > RA | OA vs RA a > Published Polymorphisms removed: ρ = 6.9 × 10 -3 +Total > Tissue > OA | Nucleotides sequenced: 37145 +Total > Tissue > OA | Number of mutations > Initial: 67 +Total > Tissue > OA | Number of mutations > Published polymorphisms removed: 40 +Total > Tissue > OA | Total mutational burden (mutations/kbp) > Initial: 1.804 +Total > Tissue > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.077 +Total > Tissue > RA | Nucleotides sequenced: 17663 +Total > Tissue > RA | Number of mutations > Initial: 60 +Total > Tissue > RA | Number of mutations > Published polymorphisms removed: 42 +Total > Tissue > RA | Total mutational burden (mutations/kbp) > Initial: 3.397 +Total > Tissue > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.378 +Total > Tissue > RA | OA vs RA a > Initial: ρ = 4 × 10 -4 +Total > Tissue > RA | OA vs RA a > Published Polymorphisms removed: ρ = 5.1 × 10 -4 +Expressed > Fibroblasts > OA | Nucleotides sequenced: 6956 +Expressed > Fibroblasts > OA | Number of mutations > Initial: 12 +Expressed > Fibroblasts > OA | Number of mutations > Published polymorphisms removed: 7 +Expressed > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Initial: 1.725 +Expressed > Fibroblasts > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 1.006 +Expressed > Fibroblasts > RA | Nucleotides sequenced: 12394 +Expressed > Fibroblasts > RA | Number of mutations > Initial: 28 +Expressed > Fibroblasts > RA | Number of mutations > Published polymorphisms removed: 26 +Expressed > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Initial: 2.259 +Expressed > Fibroblasts > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.098 +Expressed > Fibroblasts > RA | OA vs RA a > Initial: ρ = 0.5 +Expressed > Fibroblasts > RA | OA vs RA a > Published Polymorphisms removed: ρ = 0.10 +Expressed > Tissue > OA | Nucleotides sequenced: 15805 +Expressed > Tissue > OA | Number of mutations > Initial: 10 +Expressed > Tissue > OA | Number of mutations > Published polymorphisms removed: 10 +Expressed > Tissue > OA | Total mutational burden (mutations/kbp) > Initial: 0.633 +Expressed > Tissue > OA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 0.633 +Expressed > Tissue > RA | Nucleotides sequenced: 6397 +Expressed > Tissue > RA | Number of mutations > Initial: 16 +Expressed > Tissue > RA | Number of mutations > Published polymorphisms removed: 14 +Expressed > Tissue > RA | Total mutational burden (mutations/kbp) > Initial: 2.501 +Expressed > Tissue > RA | Total mutational burden (mutations/kbp) > Published polymorphisms removed: 2.189 +Expressed > Tissue > RA | OA vs RA a > Initial: ρ = 6 × 10 -4 +Expressed > Tissue > RA | OA vs RA a > Published Polymorphisms removed: ρ = 2.7 × 10 -3 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt index c55a7fc..c7895e1 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-470864.out.txt @@ -1,34 +1,32 @@ -Increase, mm 2 -Medial | Total: 36.8 ± 70.7 -Medial | P: <0.001 -Medial | Crude analysis > Men: 38.3 ± 62.6 -Medial | Crude analysis > Women: 35.7 ± 76.1 -Medial | Crude analysis > P a: 0.85 -Medial | Adjusted analysis > Men: 70.8 ± 12.3 -Medial | Adjusted analysis > Women: 13.5 ± 9.6 -Medial | Adjusted analysis > P b: 0.002 -Lateral | Total: 19.1 ± 60.1 -Lateral | P: 0.004 -Lateral | Crude analysis > Men: 16.5 ± 83.9 -Lateral | Crude analysis > Women: 20.4 ± 45.1 -Lateral | Crude analysis > P a: 0.77 -Lateral | Adjusted analysis > Men: 17.2 ± 13.3 -Lateral | Adjusted analysis > Women: 20.1 ± 8.5 -Lateral | Adjusted analysis > P b: 0.87 -Change % -Medial | Total: 2.2 ± 6.9 -Medial | P: <0.001 -Medial | Crude analysis > Men: 1.6 ± 2.8 -Medial | Crude analysis > Women: 2.6 ± 8.7 -Medial | Crude analysis > P a: 0.49 -Medial | Adjusted analysis > Men: 5.4 ± 1.1 -Medial | Adjusted analysis > Women: 0.004 ± 0.9 -Medial | Adjusted analysis > P b: 0.001 -Lateral | Total: 1.5 ± 4.3 -Lateral | P: 0.004 -Lateral | Crude analysis > Men: 1.3 ± 5.8 -Lateral | Crude analysis > Women: 1.6 ± 3.4 -Lateral | Crude analysis > P a: 0.79 -Lateral | Adjusted analysis > Men: 1.6 ± 0.9 -Lateral | Adjusted analysis > Women: 1.5 ± 0.6 -Lateral | Adjusted analysis > P b: 0.95 \ No newline at end of file +Increase, mm 2 > Medial | Total: 36.8 ± 70.7 +Increase, mm 2 > Medial | P: <0.001 +Increase, mm 2 > Medial | Crude analysis > Men: 38.3 ± 62.6 +Increase, mm 2 > Medial | Crude analysis > Women: 35.7 ± 76.1 +Increase, mm 2 > Medial | Crude analysis > P a: 0.85 +Increase, mm 2 > Medial | Adjusted analysis > Men: 70.8 ± 12.3 +Increase, mm 2 > Medial | Adjusted analysis > Women: 13.5 ± 9.6 +Increase, mm 2 > Medial | Adjusted analysis > P b: 0.002 +Increase, mm 2 > Lateral | Total: 19.1 ± 60.1 +Increase, mm 2 > Lateral | P: 0.004 +Increase, mm 2 > Lateral | Crude analysis > Men: 16.5 ± 83.9 +Increase, mm 2 > Lateral | Crude analysis > Women: 20.4 ± 45.1 +Increase, mm 2 > Lateral | Crude analysis > P a: 0.77 +Increase, mm 2 > Lateral | Adjusted analysis > Men: 17.2 ± 13.3 +Increase, mm 2 > Lateral | Adjusted analysis > Women: 20.1 ± 8.5 +Increase, mm 2 > Lateral | Adjusted analysis > P b: 0.87 +Change % > Medial | Total: 2.2 ± 6.9 +Change % > Medial | P: <0.001 +Change % > Medial | Crude analysis > Men: 1.6 ± 2.8 +Change % > Medial | Crude analysis > Women: 2.6 ± 8.7 +Change % > Medial | Crude analysis > P a: 0.49 +Change % > Medial | Adjusted analysis > Men: 5.4 ± 1.1 +Change % > Medial | Adjusted analysis > Women: 0.004 ± 0.9 +Change % > Medial | Adjusted analysis > P b: 0.001 +Change % > Lateral | Total: 1.5 ± 4.3 +Change % > Lateral | P: 0.004 +Change % > Lateral | Crude analysis > Men: 1.3 ± 5.8 +Change % > Lateral | Crude analysis > Women: 1.6 ± 3.4 +Change % > Lateral | Crude analysis > P a: 0.79 +Change % > Lateral | Adjusted analysis > Men: 1.6 ± 0.9 +Change % > Lateral | Adjusted analysis > Women: 1.5 ± 0.6 +Change % > Lateral | Adjusted analysis > P b: 0.95 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt index 965d7f3..0d2eeda 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-509257.out.txt @@ -22,86 +22,84 @@ Number of deliveries (live and stillbirths) (mean ± SEM) | WELL-HART ( n = 105) Number of deliveries (live and stillbirths) (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 4.1 ± 0.5 Number of deliveries (live and stillbirths) (mean ± SEM) | P *: 0.47 Number of deliveries (live and stillbirths) (mean ± SEM) | P †: 0.0001 -Race, n (%) -White, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 34 (59.7) -White, non-latina | EPAT ( n = 127) > ET ( n = 70): 40 (57.1) -White, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 12 (32.4) -White, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -White, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 14 (41.2) -Black, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 6 (10.5) -Black, non-latina | EPAT ( n = 127) > ET ( n = 70): 10 (14.3) -Black, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 4 (10.8) -Black, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 10 (29.4) -Black, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 5 (14.7) -Latina | EPAT ( n = 127) > Placebo ( n = 57): 10 (17.5) -Latina | EPAT ( n = 127) > ET ( n = 70): 13 (18.6) -Latina | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) -Latina | WELL-HART ( n = 105) > ET ( n = 34): 9 (26.5) -Latina | WELL-HART ( n = 105) > EPT ( n = 34): 11 (32.4) -Asian or Pacific Islander | EPAT ( n = 127) > Placebo ( n = 57): 7 (12.3) -Asian or Pacific Islander | EPAT ( n = 127) > ET ( n = 70): 7 (10.0) -Asian or Pacific Islander | P: 0.91 -Asian or Pacific Islander | WELL-HART ( n = 105) > Placebo ( n = 37): 1 (2.7) -Asian or Pacific Islander | WELL-HART ( n = 105) > ET ( n = 34): 8 (23.5) -Asian or Pacific Islander | WELL-HART ( n = 105) > EPT ( n = 34): 4 (11.8) -Asian or Pacific Islander | P *: 0.01 ‡ -Asian or Pacific Islander | P †: 0.0005 -Education, n (%) -High school graduate or less | EPAT ( n = 127) > Placebo ( n = 57): 8 (14.0) -High school graduate or less | EPAT ( n = 127) > ET ( n = 70): 9 (12.9) -High school graduate or less | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) -High school graduate or less | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) -High school graduate or less | WELL-HART ( n = 105) > EPT ( n = 34): 15 (44.1) -Trade or business school/some college | EPAT ( n = 127) > Placebo ( n = 57): 29 (50.9) -Trade or business school/some college | EPAT ( n = 127) > ET ( n = 70): 33 (48.6) -Trade or business school/some college | WELL-HART ( n = 105) > Placebo ( n = 37): 11 (29.7) -Trade or business school/some college | WELL-HART ( n = 105) > ET ( n = 34): 12 (35.3) -Trade or business school/some college | WELL-HART ( n = 105) > EPT ( n = 34): 13 (38.2) -Bachelor's degree or more | EPAT ( n = 127) > Placebo ( n = 57): 20 (35.1) -Bachelor's degree or more | EPAT ( n = 127) > ET ( n = 70): 27 (38.6) -Bachelor's degree or more | P: 0.92 -Bachelor's degree or more | WELL-HART ( n = 105) > Placebo ( n = 37): 6 (16.2) -Bachelor's degree or more | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -Bachelor's degree or more | WELL-HART ( n = 105) > EPT ( n = 34): 6 (17.7) -Bachelor's degree or more | P *: 0.90 -Bachelor's degree or more | P †: 0.0001 -Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > Placebo ( n = 57): 9 (15.8) -Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > ET ( n = 70): 6 (8.6) -Family history of breast cancer (first-degree relative), n (%) | P: 0.21 -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 2 (5.4) -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) -Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 3 (8.8) -Family history of breast cancer (first-degree relative), n (%) | P *: 0.14 ‡ -Family history of breast cancer (first-degree relative), n (%) | P †: 0.91 -Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 12.7 ± 0.2 -Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 12.6 ± 0.2 -Age at menarche, years (mean ± SEM) | P: 0.86 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 12.7 ± 0.3 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 12.8 ± 0.3 -Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 0.3 -Age at menarche, years (mean ± SEM) | P *: 0.32 -Age at menarche, years (mean ± SEM) | P †: 0.21 -Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > Placebo ( n = 57): 36 (63.2) -Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > ET ( n = 70): 42 (60.0) -Ever used postmenopausal hormones, n (%) | P: 0.72 -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 13 (35.1) -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) -Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 21 (61.8) -Ever used postmenopausal hormones, n (%) | P *: 0.08 -Ever used postmenopausal hormones, n (%) | P †: 0.02 -BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 28.7 ± 0.7 -BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 28.7 ± 0.7 -BMI, kg/m 2 (mean ± SEM) | P: 0.96 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 30.8 ± 1.0 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 31.4 ± 1.0 -BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 30.2 ± 1.1 -BMI, kg/m 2 (mean ± SEM) | P *: 0.73 -BMI, kg/m 2 (mean ± SEM) | P †: 0.007 -Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 17.8 ± 2.3 -Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 22.3 ± 1.9 -Mammographic density at baseline, % (mean ± SEM) | P: 0.13 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 7.9 ± 1.8 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 10.8 ± 2.1 -Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 2.3 -Mammographic density at baseline, % (mean ± SEM) | P *: 0.19 -Mammographic density at baseline, % (mean ± SEM) | P †: 0.0001 \ No newline at end of file +Race, n (%) > White, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 34 (59.7) +Race, n (%) > White, non-latina | EPAT ( n = 127) > ET ( n = 70): 40 (57.1) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 12 (32.4) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Race, n (%) > White, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 14 (41.2) +Race, n (%) > Black, non-latina | EPAT ( n = 127) > Placebo ( n = 57): 6 (10.5) +Race, n (%) > Black, non-latina | EPAT ( n = 127) > ET ( n = 70): 10 (14.3) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > Placebo ( n = 37): 4 (10.8) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > ET ( n = 34): 10 (29.4) +Race, n (%) > Black, non-latina | WELL-HART ( n = 105) > EPT ( n = 34): 5 (14.7) +Race, n (%) > Latina | EPAT ( n = 127) > Placebo ( n = 57): 10 (17.5) +Race, n (%) > Latina | EPAT ( n = 127) > ET ( n = 70): 13 (18.6) +Race, n (%) > Latina | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) +Race, n (%) > Latina | WELL-HART ( n = 105) > ET ( n = 34): 9 (26.5) +Race, n (%) > Latina | WELL-HART ( n = 105) > EPT ( n = 34): 11 (32.4) +Race, n (%) > Asian or Pacific Islander | EPAT ( n = 127) > Placebo ( n = 57): 7 (12.3) +Race, n (%) > Asian or Pacific Islander | EPAT ( n = 127) > ET ( n = 70): 7 (10.0) +Race, n (%) > Asian or Pacific Islander | P: 0.91 +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > Placebo ( n = 37): 1 (2.7) +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > ET ( n = 34): 8 (23.5) +Race, n (%) > Asian or Pacific Islander | WELL-HART ( n = 105) > EPT ( n = 34): 4 (11.8) +Race, n (%) > Asian or Pacific Islander | P *: 0.01 ‡ +Race, n (%) > Asian or Pacific Islander | P †: 0.0005 +Education, n (%) > High school graduate or less | EPAT ( n = 127) > Placebo ( n = 57): 8 (14.0) +Education, n (%) > High school graduate or less | EPAT ( n = 127) > ET ( n = 70): 9 (12.9) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > Placebo ( n = 37): 20 (54.1) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) +Education, n (%) > High school graduate or less | WELL-HART ( n = 105) > EPT ( n = 34): 15 (44.1) +Education, n (%) > Trade or business school/some college | EPAT ( n = 127) > Placebo ( n = 57): 29 (50.9) +Education, n (%) > Trade or business school/some college | EPAT ( n = 127) > ET ( n = 70): 33 (48.6) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > Placebo ( n = 37): 11 (29.7) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > ET ( n = 34): 12 (35.3) +Education, n (%) > Trade or business school/some college | WELL-HART ( n = 105) > EPT ( n = 34): 13 (38.2) +Education, n (%) > Bachelor's degree or more | EPAT ( n = 127) > Placebo ( n = 57): 20 (35.1) +Education, n (%) > Bachelor's degree or more | EPAT ( n = 127) > ET ( n = 70): 27 (38.6) +Education, n (%) > Bachelor's degree or more | P: 0.92 +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > Placebo ( n = 37): 6 (16.2) +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Education, n (%) > Bachelor's degree or more | WELL-HART ( n = 105) > EPT ( n = 34): 6 (17.7) +Education, n (%) > Bachelor's degree or more | P *: 0.90 +Education, n (%) > Bachelor's degree or more | P †: 0.0001 +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > Placebo ( n = 57): 9 (15.8) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | EPAT ( n = 127) > ET ( n = 70): 6 (8.6) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P: 0.21 +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 2 (5.4) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > ET ( n = 34): 7 (20.6) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 3 (8.8) +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P *: 0.14 ‡ +Education, n (%) > Family history of breast cancer (first-degree relative), n (%) | P †: 0.91 +Education, n (%) > Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 12.7 ± 0.2 +Education, n (%) > Age at menarche, years (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 12.6 ± 0.2 +Education, n (%) > Age at menarche, years (mean ± SEM) | P: 0.86 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 12.7 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 12.8 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 0.3 +Education, n (%) > Age at menarche, years (mean ± SEM) | P *: 0.32 +Education, n (%) > Age at menarche, years (mean ± SEM) | P †: 0.21 +Education, n (%) > Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > Placebo ( n = 57): 36 (63.2) +Education, n (%) > Ever used postmenopausal hormones, n (%) | EPAT ( n = 127) > ET ( n = 70): 42 (60.0) +Education, n (%) > Ever used postmenopausal hormones, n (%) | P: 0.72 +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > Placebo ( n = 37): 13 (35.1) +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > ET ( n = 34): 15 (44.1) +Education, n (%) > Ever used postmenopausal hormones, n (%) | WELL-HART ( n = 105) > EPT ( n = 34): 21 (61.8) +Education, n (%) > Ever used postmenopausal hormones, n (%) | P *: 0.08 +Education, n (%) > Ever used postmenopausal hormones, n (%) | P †: 0.02 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 28.7 ± 0.7 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 28.7 ± 0.7 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P: 0.96 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 30.8 ± 1.0 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 31.4 ± 1.0 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 30.2 ± 1.1 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P *: 0.73 +Education, n (%) > BMI, kg/m 2 (mean ± SEM) | P †: 0.007 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > Placebo ( n = 57): 17.8 ± 2.3 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | EPAT ( n = 127) > ET ( n = 70): 22.3 ± 1.9 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P: 0.13 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > Placebo ( n = 37): 7.9 ± 1.8 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > ET ( n = 34): 10.8 ± 2.1 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | WELL-HART ( n = 105) > EPT ( n = 34): 13.3 ± 2.3 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P *: 0.19 +Education, n (%) > Mammographic density at baseline, % (mean ± SEM) | P †: 0.0001 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt index a2b2125..cb9dae1 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-65384.out.txt @@ -1,41 +1,39 @@ -CYP17 -C | Estimated allele frequency (%): 42.46 -C | Nonfounder statistic > Recessive model: - 1.01 -C | Nonfounder statistic > Dominant model: - 1.52 -C | Nonfounder statistic > Additive model: - 1.85 -C | Founder statistic > Recessive model: 0.40 -C | Founder statistic > Dominant model: 1.08 -C | Founder statistic > Additive model: 1.01 -P | Nonfounder statistic > Recessive model: 0.16 -P | Nonfounder statistic > Dominant model: 0.06 -P | Nonfounder statistic > Additive model: 0.03 -P | Founder statistic > Recessive model: 0.34 -P | Founder statistic > Dominant model: 0.14 -P | Founder statistic > Additive model: 0.16 -CYP19 -(TTTA) ≥10 | Estimated allele frequency (%): 33.71 -(TTTA) ≥10 | Nonfounder statistic > Recessive model: - 1.24 -(TTTA) ≥10 | Nonfounder statistic > Dominant model: 1.26 -(TTTA) ≥10 | Nonfounder statistic > Additive model: 0.32 -(TTTA) ≥10 | Founder statistic > Recessive model: - 0.32 -(TTTA) ≥10 | Founder statistic > Dominant model: 1.66 -(TTTA) ≥10 | Founder statistic > Additive model: 1.13 -P | Nonfounder statistic > Recessive model: 0.11 -P | Nonfounder statistic > Dominant model: 0.10 -P | Nonfounder statistic > Additive model: 0.38 -P | Founder statistic > Recessive model: 0.37 -P | Founder statistic > Dominant model: 0.05 -P | Founder statistic > Additive model: 0.13 -(TTTA) 11 | Estimated allele frequency (%): 28.78 -(TTTA) 11 | Nonfounder statistic > Recessive model: - 1.09 -(TTTA) 11 | Nonfounder statistic > Dominant model: 1.83 -(TTTA) 11 | Nonfounder statistic > Additive model: 0.97 -(TTTA) 11 | Founder statistic > Recessive model: - 1.50 -(TTTA) 11 | Founder statistic > Dominant model: 1.96 -(TTTA) 11 | Founder statistic > Additive model: 0.89 -P | Nonfounder statistic > Recessive model: 0.14 -P | Nonfounder statistic > Dominant model: 0.03 -P | Nonfounder statistic > Additive model: 0.17 -P | Founder statistic > Recessive model: 0.07 -P | Founder statistic > Dominant model: 0.03 -P | Founder statistic > Additive model: 0.19 \ No newline at end of file +CYP17 > C | Estimated allele frequency (%): 42.46 +CYP17 > C | Nonfounder statistic > Recessive model: - 1.01 +CYP17 > C | Nonfounder statistic > Dominant model: - 1.52 +CYP17 > C | Nonfounder statistic > Additive model: - 1.85 +CYP17 > C | Founder statistic > Recessive model: 0.40 +CYP17 > C | Founder statistic > Dominant model: 1.08 +CYP17 > C | Founder statistic > Additive model: 1.01 +CYP17 > P | Nonfounder statistic > Recessive model: 0.16 +CYP17 > P | Nonfounder statistic > Dominant model: 0.06 +CYP17 > P | Nonfounder statistic > Additive model: 0.03 +CYP17 > P | Founder statistic > Recessive model: 0.34 +CYP17 > P | Founder statistic > Dominant model: 0.14 +CYP17 > P | Founder statistic > Additive model: 0.16 +CYP19 > (TTTA) ≥10 | Estimated allele frequency (%): 33.71 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Recessive model: - 1.24 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Dominant model: 1.26 +CYP19 > (TTTA) ≥10 | Nonfounder statistic > Additive model: 0.32 +CYP19 > (TTTA) ≥10 | Founder statistic > Recessive model: - 0.32 +CYP19 > (TTTA) ≥10 | Founder statistic > Dominant model: 1.66 +CYP19 > (TTTA) ≥10 | Founder statistic > Additive model: 1.13 +CYP19 > P | Nonfounder statistic > Recessive model: 0.11 +CYP19 > P | Nonfounder statistic > Dominant model: 0.10 +CYP19 > P | Nonfounder statistic > Additive model: 0.38 +CYP19 > P | Founder statistic > Recessive model: 0.37 +CYP19 > P | Founder statistic > Dominant model: 0.05 +CYP19 > P | Founder statistic > Additive model: 0.13 +CYP19 > (TTTA) 11 | Estimated allele frequency (%): 28.78 +CYP19 > (TTTA) 11 | Nonfounder statistic > Recessive model: - 1.09 +CYP19 > (TTTA) 11 | Nonfounder statistic > Dominant model: 1.83 +CYP19 > (TTTA) 11 | Nonfounder statistic > Additive model: 0.97 +CYP19 > (TTTA) 11 | Founder statistic > Recessive model: - 1.50 +CYP19 > (TTTA) 11 | Founder statistic > Dominant model: 1.96 +CYP19 > (TTTA) 11 | Founder statistic > Additive model: 0.89 +CYP19 > P | Nonfounder statistic > Recessive model: 0.14 +CYP19 > P | Nonfounder statistic > Dominant model: 0.03 +CYP19 > P | Nonfounder statistic > Additive model: 0.17 +CYP19 > P | Founder statistic > Recessive model: 0.07 +CYP19 > P | Founder statistic > Dominant model: 0.03 +CYP19 > P | Founder statistic > Additive model: 0.19 \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt index 3c6b95c..09122b0 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-81395.out.txt @@ -19,11 +19,10 @@ VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > OR ( VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > P: - VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients ( n = 110): 79 VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 30 (37) -VAT -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > Number of patients ( n = 110): 55 -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 35 (63) -VAT related to multidrug-resistant bacteria > Yes | Univariate analysis > P: 0.001 -VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > OR (95% CI): 3.5 (1.5–8.3) -VAT related to multidrug-resistant bacteria > Yes | Multivariate analysis > P: 0.004 -VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients ( n = 110): 55 -VAT related to multidrug-resistant bacteria > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 17 (30) \ No newline at end of file +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > Number of patients ( n = 110): 55 +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 35 (63) +VAT related to multidrug-resistant bacteria > VAT > Yes | Univariate analysis > P: 0.001 +VAT related to multidrug-resistant bacteria > VAT > Yes | Multivariate analysis > OR (95% CI): 3.5 (1.5–8.3) +VAT related to multidrug-resistant bacteria > VAT > Yes | Multivariate analysis > P: 0.004 +VAT related to multidrug-resistant bacteria > VAT > No | Univariate analysis > Number of patients ( n = 110): 55 +VAT related to multidrug-resistant bacteria > VAT > No | Univariate analysis > Number of patients with MV duration ≥ 14 days (%): 17 (30) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt index e4f0444..36caf83 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-83651.out.txt @@ -37,8 +37,7 @@ Parameter | Population average > Estimate: Infusion (RSE %) Parameter | Population average > (RSE%) 1: Oral (RSE %) Parameter | Interindividual variability > Estimate %: Subcutaneous (RSE %) Parameter | Interindividual variability > (RSE%): IIV 3 (RSE %) -Residual error 2 -Proportional | Population average > Estimate: 0.191 (8.2) -Proportional | Population average > (RSE%) 1: 0.232(9.8) -Proportional | Interindividual variability > Estimate %: 0.162 (8.8) -Proportional | Interindividual variability > (RSE%): 24 (28) \ No newline at end of file +Residual error 2 > Proportional | Population average > Estimate: 0.191 (8.2) +Residual error 2 > Proportional | Population average > (RSE%) 1: 0.232(9.8) +Residual error 2 > Proportional | Interindividual variability > Estimate %: 0.162 (8.8) +Residual error 2 > Proportional | Interindividual variability > (RSE%): 24 (28) \ No newline at end of file diff --git a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt index 4838bfa..8989838 100644 --- a/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt +++ b/benchmarks/gold/rules/realworld/pubtabnet/pubtabnet-87275.out.txt @@ -1,44 +1,40 @@ -Age at reference (years) -< 35 | Cases ( n = 506) > n: 62 -< 35 | Cases ( n = 506) > %: 12.3 -< 35 | Controls ( n = 459) > n: 80 -< 35 | Controls ( n = 459) > %: 17.4 -35+ | Cases ( n = 506) > n: 444 -35+ | Cases ( n = 506) > %: 87.7 -35+ | Controls ( n = 459) > n: 379 -35+ | Controls ( n = 459) > %: 82.6 -Race -White | Cases ( n = 506) > n: 450 -White | Cases ( n = 506) > %: 88.9 -White | Controls ( n = 459) > n: 412 -White | Controls ( n = 459) > %: 89.8 -Nonwhite | Cases ( n = 506) > n: 56 -Nonwhite | Cases ( n = 506) > %: 11.1 -Nonwhite | Controls ( n = 459) > n: 47 -Nonwhite | Controls ( n = 459) > %: 10.2 -Family history -None | Cases ( n = 506) > n: 280 -None | Cases ( n = 506) > %: 56.7 -None | Controls ( n = 459) > n: 294 -None | Controls ( n = 459) > %: 66.1 -First degree | Cases ( n = 506) > n: 94 -First degree | Cases ( n = 506) > %: 19.0 -First degree | Controls ( n = 459) > n: 36 -First degree | Controls ( n = 459) > %: 8.1 -Second degree | Cases ( n = 506) > n: 120 -Second degree | Cases ( n = 506) > %: 24.3 -Second degree | Controls ( n = 459) > n: 115 -Second degree | Controls ( n = 459) > %: 25.8 -Unknown | Cases ( n = 506) > n: 12 -Unknown | Controls ( n = 459) > n: 14 -Menopausal status -Premenopausal | Cases ( n = 506) > n: 445 -Premenopausal | Cases ( n = 506) > %: 88.3 -Premenopausal | Controls ( n = 459) > n: 392 -Premenopausal | Controls ( n = 459) > %: 85.8 -Postmenopausal | Cases ( n = 506) > n: 59 -Postmenopausal | Cases ( n = 506) > %: 11.7 -Postmenopausal | Controls ( n = 459) > n: 65 -Postmenopausal | Controls ( n = 459) > %: 14.2 -Unknown | Cases ( n = 506) > n: 2 -Unknown | Controls ( n = 459) > n: 2 \ No newline at end of file +Age at reference (years) > < 35 | Cases ( n = 506) > n: 62 +Age at reference (years) > < 35 | Cases ( n = 506) > %: 12.3 +Age at reference (years) > < 35 | Controls ( n = 459) > n: 80 +Age at reference (years) > < 35 | Controls ( n = 459) > %: 17.4 +Age at reference (years) > 35+ | Cases ( n = 506) > n: 444 +Age at reference (years) > 35+ | Cases ( n = 506) > %: 87.7 +Age at reference (years) > 35+ | Controls ( n = 459) > n: 379 +Age at reference (years) > 35+ | Controls ( n = 459) > %: 82.6 +Race > White | Cases ( n = 506) > n: 450 +Race > White | Cases ( n = 506) > %: 88.9 +Race > White | Controls ( n = 459) > n: 412 +Race > White | Controls ( n = 459) > %: 89.8 +Race > Nonwhite | Cases ( n = 506) > n: 56 +Race > Nonwhite | Cases ( n = 506) > %: 11.1 +Race > Nonwhite | Controls ( n = 459) > n: 47 +Race > Nonwhite | Controls ( n = 459) > %: 10.2 +Family history > None | Cases ( n = 506) > n: 280 +Family history > None | Cases ( n = 506) > %: 56.7 +Family history > None | Controls ( n = 459) > n: 294 +Family history > None | Controls ( n = 459) > %: 66.1 +Family history > First degree | Cases ( n = 506) > n: 94 +Family history > First degree | Cases ( n = 506) > %: 19.0 +Family history > First degree | Controls ( n = 459) > n: 36 +Family history > First degree | Controls ( n = 459) > %: 8.1 +Family history > Second degree | Cases ( n = 506) > n: 120 +Family history > Second degree | Cases ( n = 506) > %: 24.3 +Family history > Second degree | Controls ( n = 459) > n: 115 +Family history > Second degree | Controls ( n = 459) > %: 25.8 +Family history > Unknown | Cases ( n = 506) > n: 12 +Family history > Unknown | Controls ( n = 459) > n: 14 +Menopausal status > Premenopausal | Cases ( n = 506) > n: 445 +Menopausal status > Premenopausal | Cases ( n = 506) > %: 88.3 +Menopausal status > Premenopausal | Controls ( n = 459) > n: 392 +Menopausal status > Premenopausal | Controls ( n = 459) > %: 85.8 +Menopausal status > Postmenopausal | Cases ( n = 506) > n: 59 +Menopausal status > Postmenopausal | Cases ( n = 506) > %: 11.7 +Menopausal status > Postmenopausal | Controls ( n = 459) > n: 65 +Menopausal status > Postmenopausal | Controls ( n = 459) > %: 14.2 +Menopausal status > Unknown | Cases ( n = 506) > n: 2 +Menopausal status > Unknown | Controls ( n = 459) > n: 2 \ No newline at end of file diff --git a/src/table2rules/_core.py b/src/table2rules/_core.py index 0a450b5..48889a9 100644 --- a/src/table2rules/_core.py +++ b/src/table2rules/_core.py @@ -211,6 +211,11 @@ def _build_rules(grid) -> List[LogicRule]: for row_idx in range(len(grid)): if row_idx in rows_with_value: continue + # A label-only row promoted to a row-group ancestor (scope="rowgroup") + # is threaded into the value lines beneath it — emitting it here too + # would duplicate it as an orphan label. + if any(grid[row_idx][c].get("scope") == "rowgroup" for c in range(n_cols)): + continue # Anchor the rule at the row's data column so it satisfies the quality # gate's "rules originate from " invariant. A row with no at # all is a true full-width divider — already handled as a @@ -319,6 +324,148 @@ def _next_band_below(after_row: int, min_colspan: int) -> int: grid[r][cc]["scope"] = "rowgroup" +def _mark_label_only_rowgroups(grid) -> None: + """Promote *label-only rows* to ```` so the maze threads + them into each value line's row path, the row-side counterpart of the + full-width band handled by :func:`_mark_rowgroup_bands`. + + A label-only row is a body row whose value (````) columns are all empty + while a leading label column carries text — the ``Label | Value`` form + pervasive in financial/insurance schedules (``9. Trip Cancellation | (empty)`` + above its value rows). Unlike a full-width band the label cell does *not* + span the value region; the other columns are simply empty, so + ``is_full_width_note`` geometry never sees it. Without this pass the row is + emitted as an orphaned ``is_label`` rule and the values beneath it lose their + group identity. + + Detection is geometric, not flag-based: a row with no value-bearing ```` + but exactly one non-empty body ```` label source cell. (Row-label + columns are already promoted to ```` upstream — Signal A/B/C + in grid_parser and simple_repair — so "no non-empty ````" means "no + value".) + + The single-label-cell requirement is what separates a group header from a + data row whose *designated* value columns merely happen to be empty. A genuine + group header carries one title ("9. Trip Cancellation", possibly spanning the + first N>1 columns via one ``colspan`` cell). A data row whose value columns + are blank ("Average: | 80.2 | 10.7 | 3.3", or a summary row under a header + that over-promoted numeric columns to row labels) spreads several distinct + values across its label cells — threading those as a group path would invent + a breadcrumb and misattribute it to the rows below. Such rows stay on the + ``is_label`` preservation path, unchanged. + + Stacking and extent (no content-aware level inference): + + * A maximal run of *consecutive* label-only rows forms one header stack. Its + members are threaded as nested ancestors in row order — a title followed by + a description (``10. Travel Delay`` then ``If the departure…``) both land in + the path, title first. + * A stack's extent runs from just below the stack down to the row before the + next stack OR the next full-width band, whichever comes first — so a group + never leaks into the next line-item or across a section divider. + * A stack is promoted only when its extent holds a real value row (parity + with the full-width-note guard): a trailing label that groups nothing is + left for the ``is_label`` preservation path, never stranded as an + empty-extent rowgroup. + + The stored ``rowgroup_extent_end`` is what the maze honors for these bands; + full-width bands keep their colspan-bounded extent. The two compose: a + section band (wider) and a label-only group (narrower) nest consistently. + """ + if not grid or not grid[0]: + return + n_rows = len(grid) + n_cols = len(grid[0]) + + def _is_body_row(r: int) -> bool: + return not any( + grid[r][c].get("is_thead") or grid[r][c].get("is_header_row") for c in range(n_cols) + ) + + def _has_value(r: int) -> bool: + return any( + grid[r][c]["type"] == "td" and (grid[r][c].get("text") or "").strip() + for c in range(n_cols) + ) + + def _label_cols(r: int) -> List[int]: + cols: List[int] = [] + for c in range(n_cols): + cell = grid[r][c] + if cell.get("is_thead") or cell.get("is_header_row"): + continue + if cell["type"] != "th": + continue + if cell.get("is_span_copy"): + # A span copy of a label cell originating in this same row is + # part of a multi-column label (label spans the first N>1 + # columns); promote it too. A span copy reaching down from a + # row above is not a label of this row. + origin = cell.get("origin", (r, c)) + if origin[0] != r: + continue + if not (grid[origin[0]][origin[1]].get("text") or "").strip(): + continue + elif not (cell.get("text") or "").strip(): + continue + cols.append(c) + return cols + + def _single_label_origin(r: int) -> bool: + # A group header is exactly one label source cell (a title, possibly + # colspan'd). More than one distinct non-empty label cell means a data + # row, not a divider — do not thread it. + origins = set() + for c in _label_cols(r): + cell = grid[r][c] + origins.add(cell.get("origin", (r, c)) if cell.get("is_span_copy") else (r, c)) + return len(origins) == 1 + + # A row already carrying a rowgroup cell (a full-width band promoted above, + # or a source scope="rowgroup") is a boundary, not a label-only candidate. + band_rows = { + r for r in range(n_rows) for c in range(n_cols) if grid[r][c].get("scope") == "rowgroup" + } + + is_label_row = [ + _is_body_row(r) + and r not in band_rows + and not _has_value(r) + and bool(_label_cols(r)) + and _single_label_origin(r) + for r in range(n_rows) + ] + + r = 0 + while r < n_rows: + if not is_label_row[r]: + r += 1 + continue + # Gather the maximal consecutive run of label-only rows. + s_start = r + while r + 1 < n_rows and is_label_row[r + 1]: + r += 1 + s_end = r + r += 1 # advance past the stack for the outer loop + + # Extent: down to the row before the next boundary (next label stack or + # full-width band). Bounded by a value row's presence. + extent_end = n_rows - 1 + for rr in range(s_end + 1, n_rows): + if is_label_row[rr] or rr in band_rows: + extent_end = rr - 1 + break + has_data_row = any(_has_value(rr) for rr in range(s_end + 1, extent_end + 1)) + if not has_data_row: + continue + + for rr in range(s_start, s_end + 1): + for c in _label_cols(rr): + grid[rr][c]["type"] = "th" + grid[rr][c]["scope"] = "rowgroup" + grid[rr][c]["rowgroup_extent_end"] = extent_end + + def _process_table_with_gate(table_html: str) -> Tuple[List[LogicRule], GateResult]: """Runs the full pipeline and returns rules plus the gate verdict. @@ -337,6 +484,7 @@ def _process_table_with_gate(table_html: str) -> Tuple[List[LogicRule], GateResu return [], GateResult(ok=False, score=0.0, reasons=["empty_grid"]) _mark_rowgroup_bands(grid) + _mark_label_only_rowgroups(grid) rules = clean_rules(_build_rules(grid)) gate = assess_confidence(grid, rules) if not gate.ok: diff --git a/src/table2rules/maze_pathfinder.py b/src/table2rules/maze_pathfinder.py index 87e335e..0e974c2 100644 --- a/src/table2rules/maze_pathfinder.py +++ b/src/table2rules/maze_pathfinder.py @@ -172,7 +172,14 @@ def find_headers_for_cell( origin_row, origin_col = origin my_colspan = origin_cell.get("colspan", 1) origin_rowspan = origin_cell.get("rowspan", 1) - if origin_rowspan > 1: + stored_extent = origin_cell.get("rowgroup_extent_end") + if stored_extent is not None: + # Label-only bands carry an explicit extent (the run of value + # rows they group, bounded by the next stack or section band), + # because their colspan=1 label cannot encode nesting depth the + # way a full-width band's width does. + extent_end = stored_extent + elif origin_rowspan > 1: extent_end = origin_row + origin_rowspan - 1 else: extent_end = len(grid) - 1 diff --git a/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md b/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md new file mode 100644 index 0000000..7acca26 --- /dev/null +++ b/tests/fixtures/matrix/label-only-rowgroup-vs-data-row.md @@ -0,0 +1,20 @@ + + + + + + + + + + + +
AB
Region X
AsiaJapan1020
AsiaKorea3040
Totaln=4
diff --git a/tests/fixtures/matrix/label-only-rowgroup.md b/tests/fixtures/matrix/label-only-rowgroup.md new file mode 100644 index 0000000..a0e224b --- /dev/null +++ b/tests/fixtures/matrix/label-only-rowgroup.md @@ -0,0 +1,27 @@ + + + + + + + + + + + + + + + +
BenefitMaximum limit (S$)
Value PlanEconomy Plan
9. Trip Cancellation
If the trip is cancelled5,00010,000
10. Travel Delay
If the departure is delayed
1. Adult insured person100150
2. Child insured person5075
11. Trip Postponement
From 1421338e709cd2f8bba000d009389af105435aa8 Mon Sep 17 00:00:00 2001 From: maish Date: Sun, 14 Jun 2026 19:29:56 +0800 Subject: [PATCH 2/2] chore: release 0.6.1 Co-Authored-By: Claude Opus 4.8 (1M context) --- CHANGELOG.md | 2 ++ pyproject.toml | 2 +- 2 files changed, 3 insertions(+), 1 deletion(-) diff --git a/CHANGELOG.md b/CHANGELOG.md index 5cae9ed..f14a86e 100644 --- a/CHANGELOG.md +++ b/CHANGELOG.md @@ -5,6 +5,8 @@ All notable changes to `table2rules` are documented here. Dates are in ## [Unreleased] +## [0.6.1] — 2026-06-14 + ### Fixed - **Label-only rows are now threaded as row-group headers.** 0.6.0's row-group diff --git a/pyproject.toml b/pyproject.toml index 10750b3..908a154 100644 --- a/pyproject.toml +++ b/pyproject.toml @@ -4,7 +4,7 @@ build-backend = "setuptools.build_meta" [project] name = "table2rules" -version = "0.6.0" +version = "0.6.1" description = "Convert HTML tables to flat, LLM-friendly rules using spatial pathfinding." readme = "README.md" license = "MIT"